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Nano-sized particles formed from amphiphilic block copolymers have shown 
great advantages as delivery agents for anti-cancer therapy, such as improving 
localization in tumor tissues via the enhanced permeability and retention (EPR) effect 
from the hyperpermeable angiogenic vasculature surrounding tumors. Self-assembled 
cationic polymer nanoparticles with well-defined core/shell structure are promising 
carriers for synergistic codelivery of small molecule drugs and nucleic acids/proteins 
against cancer. These particles can encapsulate hydrophobic drugs in the core and bind to 
biomolecules such as nucleic acids or proteins on the shell. In my research, cationic 
core/shell nanoparticles self-assembled from a biodegradable amphiphilic copolymer 
poly{N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido ethyl) methyl 
bis(ethylene) ammonium bromide] sebacate}P(MDS-co-CES) have been fabricated and 
used for the codelivery of various anti-cancer drugs and therapeutic proteins for improved 
cancer therapy.  
The first part of this thesis focuses on the evaluation of these cationic 
nanoparticles as carriers for the delivery of therapeutic proteins. Studies have been 
performed to determine the in vitro cytotoxicity and delivery efficiency of a model 
therapeutic protein, Lectin-A (MW: 30.7 kDa) through adsorption of the protein on the 
cationic surface of the P(MDS-co-CES) nanoparticles. The results show that the 
nanoparticles deliver Lectin-A much more efficiently compared to the commercially-
available protein carrier, BioPorter.  
The core/shell structure of these nanoparticles allows the physical entrapment of 
hydrophobic drugs in the core. Hence, further studies have been performed by using 
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P(MDS-co-CES) nanoparticles to codeliver another therapeutic protein with a similar 
molecular weight, i.e. recombinant human tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL, MW: 20 kDa), together with an anticancer drug doxorubicin 
(Dox) simultaneously. TRAIL is a promising anticancer agent as it is selectively toxic to 
cancer cells and exerts limited toxicity to normal tissues when introduced systemically in 
vivo. Cellular response towards the P(MDS-co-CES) nanoparticle/TRAIL nanocomplexes 
has been investigated in both wild type and TRAIL-resistant SW480 cells (a human colon 
adenocarcinoma cell line). Cytotoxicity studies have shown that the co-delivery system 
synergistically enhances cytotoxic and anti-proliferative effects in both wild type and 
TRAIL-resistant SW480 cells. Receptor-blocking studies have demonstrated that the 
cellular uptake of Dox-loaded P(MDS-co-CES) nanoparticle/TRAIL complexes occurs 
through  specific interactions between the death receptors on the cells and TRAIL present 
on the nanoparticle surface. Importantly, Dox-loaded nanoparticle/TRAIL 
nanocomplexes are toxic towards the cancer cells, but they do not exhibit significant 
cytotoxicity against non-cancerous cells (i.e. WI38, a human lung fibroblast cell line). In 
a separate study, the codelivery of TRAIL with another anti-cancer drug, paclitaxel (Pac), 
using P(MDS-co-CES) nanoparticles  also induced synergistic anti-cancer effects on 
various human breast cancer cell lines with different TRAIL-sensitivity. The cytotoxicity 
of the codelivery system is significantly higher compared to free Pac+TRAIL 
combination in two out of the three cell lines tested. 
The versatility of the P(MDS-co-CES) nanoparticles to codeliver larger 
therapeutic proteins together with anticancer drugs is also investigated. The combination 
of a therapeutic antibody, Herceptin (MW: 145 kDa) and Pac is used to treat human 
ix 
breast cancer cells with overexpression of human epidermal growth factor receptor-2 
(HER2/neu). Physical characterization shows that the Pac-loaded nanoparticle/herceptin 
nanocomplexes remain stable under physiologically-simulating conditions with sizes at 
around 200 nm. Anticancer effects of this co-delivery system have been investigated in 
human breast cancer cell lines with varying degrees of HER2/neu expression. Targeting 
ability of this co-delivery system is demonstrated through confocal imaging, which shows 
significantly higher cellular uptake in HER2-overexpressing BT474 cells as compared to 
HER2-negative HEK293 cells. 
Animal studies were first carried out by investigating the differences in tissue 
biodistribution between intravenous vs. intratumoral injections of nanocarriers through in 
vivo imaging experiments. The latter method shows better tumour accumulation without 
distribution into major tissue organs. Finally, tumor efficacy studies are performed using 
the Pac and Herceptin codelivery system to treat female athymic mice that bear BT474 
tumor xenografts. Mice that are treated with Pac-loaded nanoparticle/herceptin 
nanocomplexes experience significantly slower tumor growth compared to those treated 
with Pac-loaded nanoparticle alone. Lesser tumor growth difference was observed 
between the codelivery system and herceptin delivered using drug-free nanoparticles. 
In all, P(MDS-co-CES) nanoparticles has demonstrated excellent properties as 
codelivery carriers of multiple therapeutics to cancer cells. Despite the inadequate in vivo 
success of the P(MDS-co-CES) nanoparticles, the research presented here contributes to 
the realization and development of protein-and-drug codelivery in a single therapeutic 
system. Huge potential can be seen in such polymeric carriers to play an increasingly 
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TR (F) cells. 
 
Figure 5.7 Viability of parental SW480 cells in the presence or absence of pan-
caspase inhibitor ZVAD-FMK pretreatment (50 µM) prior to 48 hour 
incubation with nanocomplexes. P(MDS-co-CES) and TRAIL 
concentrations were fixed at 5 mg/l and 10 nM respectively. Dox 
loading level: 8.6%. Cell culture was performed in serum-containing 
medium. The error bars represent the mean ± S.D. (n=3). Statistical 
significance in differences was evaluated by Student's t-Test. P≤0.05 
was considered statistically significant. 
 
Figure 5.8  Viability of WI38 cells after 48 hours incubation with various 
formulations. Cell culture was performed in serum-containing medium. 
P(MDS-co-CES) (5 mg/l) and TRAIL (10 nM) were used. Dox loading 
level: 8.6%. Free Dox concentration: 0.43 mg/l (Equivalent Dox 
concentration in 5 mg/l of Dox-loaded nanoparticles). The standard 
deviation is shown by error bars that represent the mean ± S.D. (n=3).  
 
Figure 5.9 Colony formation at Day 9 and 13 in parental SW480 and TRAIL-
resistant SW480-TR cell lines respectively subsequent to 48 hours 
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treatment with (1) control, (2) blank nanoparticles, (3) TRAIL, (4) blank 
nanoparticle/TRAIL complexes, (5) Dox-loaded nanoparticles, (6) Dox-
loaded nanoparticle/TRAIL complexes. Colonies were stained with 
0.5% w/v crystal violet. Cell culture was performed in serum-containing 
medium. TRAIL: 10 nM; P(MDS-co-CES): 1 and 3 mg/l for SW480 
and SW480-TR respectively. Dox loading level: 8.6%. The error bars 
represent the mean ± S.D. (n=3). Statistical significance in differences 
was evaluated by Newman–Keuls Multiple Comparison Test after 
analysis of variance (ANOVA). P≤0.05 was considered statistically 
significant. (B) Images of SW480 colony taken at Day 9 subsequent to 
48 hours treatment with (1) control, (2) blank nanoparticles, (3) TRAIL, 
(4) nanoparticle/TRAIL complexes, (5) Dox-loaded nanoparticles and 
(6) Dox-loaded nanoparticle/TRAIL complexes. P(MDS-co-CES) and 
TRAIL were fixed at 1 mg/l and 10 nM respectively. Dox loading level 
= 8.6%. Colonies were stained with 0.5% w/v crystal violet. 
 
Figure 6.1  Size and zeta potential properties of paclitaxel (Pac)-loaded P(MDS-co-
CES) nanoparticle/Herceptin complexes. Experiments were carried out 
in triplicates. The standard deviation is presented in error bars. 
 
Figure 6.2  Native protein gel assay of paclitaxel-loaded P(MDS-co-CES) 
nanoparticle/Herceptin complexes. Lane 1 – Herceptin (4 μg) alone, 
Lane 8 – paclitaxel-loaded P(MDS-co-CES) nanoparticles (200 μg) 
alone, Lanes 2 to 7 – nanoparticle to antibody mass ratios:  0.1, 0.5, 1, 5, 
10 and 50 respectively.  
Figure 6.3  Release profiles of paclitaxel (Pac) from P(MDS-co-CES) micellar 
nanoparticles with and without Herceptin in PBS (pH 7.4) at 37°C. Each 
condition was tested in triplicates. The standard deviation is presented in 
error bars. 
 
Figure 6.4 Stability of paclitaxel-loaded P(MDS-co-CES) nanoparticle/Herceptin 
complexes in PBS containing 10% FBS incubated at 37oC. Each 
condition was tested in triplicates. The standard deviation is presented in 
error bars. 
 
Figure 6.5 Cellular distribution of (A) fluorescence-labeled Herceptin, and (B) 
nanoparticle/Herceptin complexes in comparison with (C) 
BioPorter/Herceptin complexes. Nuclei were stained blue with DAPI, 
and cellular distribution of Alexa Fluor 647-Herceptin is shown as red 
fluorescence in the cytosol or purple fluorescence in the nucleus. Alexa 
Fluor 647-Herceptin: 200 nM; P(MDS-co-CES) nanoparticles: 40 ppm. 
 
Figure 6.6  Viability of BT474 cells after being incubated with P(MDS-co-CES) 
nanoparticles, BioPorter, BioPorter/Herceptin and P(MDS-co-CES) 
nanoparticle/Herceptin complexes at Herceptin concentrations of 200 
and 2000 nM. Concentrations of P(MDS-co-CES) and BioPorter are at 
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40 ppm and 16 ppm respectively. Each condition was tested in eight 
replicates. The standard deviation is shown by error bars. 
 
Figure 6.7  Viability of MCF7, T47D and BT474 cells after being treated with 
different formulations. Cells were treated once with (1) blank 
nanoparticles, (2) paclitaxel-loaded nanoparticles, (3 and 6) Herceptin at 
200 and 2000 nM, (4 and 7) blank nanoparticle/Herceptin complexes at 
200 and 2000 nM Herceptin and (5 and 8) paclitaxel-loaded 
nanoparticle/Herceptin complexes at 200 and 2000 nM Herceptin 
respectively. P(MDS-co-CES) concentrations were fixed at 20 ppm for 
MCF7 and T47D cells and 40 ppm for BT474 cells respectively. Cell 
culture was performed in serum-containing medium. Each condition 
was tested in eight replicates. The standard deviation is shown by error 
bars. Paclitaxel concentration: 3.35 µM for both T47D and MCF7 and 
6.7 µM for BT474. 
 
Figure 6.8 Viability of MCF7, T47D and BT474 cells after being treated with 
different formulations. Twice-repeated daily treatment of (1) blank 
nanoparticles, (2 and 5) Herceptin at 200 and 2000 nM, (3 and 6) blank 
nanoparticle/Herceptin complexes at 200 and 2000 nM Herceptin 
respectively. Cells in (4 and 7) were pretreated with (3 and 6) for 24 
hours prior to treatment with paclitaxel-loaded nanoparticle/Herceptin 
complexes at 200 and 2000 nM Herceptin respectively. P(MDS-co-
CES) concentrations were fixed at 20 ppm for MCF7 and T47D cells 
and 40 ppm for BT474 cells respectively. Cell culture was performed in 
serum-containing medium. Each condition was tested in eight replicates. 
The standard deviation is shown by error bars. Paclitaxel concentration: 
3.35 µM for both T47D and MCF7 and 6.7 µM for BT474. 
 
Figure 6.9 Confocal images of cellular internalization of P(MDS-co-CES) 
nanoparticle/Herceptin nanocomplexes in (A) HER2 overexpressing 
BT474 cells and (B) HER2-negative HEK293 cells at 10 minutes, 30 
minutes and 2 hours. Nuclei were stained blue with DAPI, and cellular 
distribution of Alexa Fluor 647-Herceptin and FITC-loaded P(MDS-co-
CES) nanoparticles are shown as red and green fluorescence 
respectively. Yellow regions represent the co-localization of Herceptin 
and P(MDS-co-CES) nanoparticles in cells. In both cell lines, Alexa 
Fluor 647-Herceptin (200 nM) and 40 ppm of P(MDS-co-CES) 
nanoparticles were used.  
 
Figure 6.10  Viability of HER2-negative HEK293 and HER2 overexpressing BT474 
cells after being treated with different formulations for 48 hours. 
P(MDS-co-CES) concentrations were fixed at 40 ppm for both cell 
lines. Cell culture was performed in serum-containing medium. Each 
condition was tested in eight replicates. The standard deviation is shown 
by error bars. 
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Figure 7.1 (A) In vivo biodistribution of P(MDS-co-CES) nanoparticles with 
different injection methods (tail-vein vs. intratumoral). (B) Distribution 
of P(MDS-co-CES) nanoparticles in different tissues 7 days post-
injection. (Top row, starting from left: heart, lungs and tumor. Bottom 
row: spleen, liver and kidneys) 
 
Figure 7.2 Changes in relative tumor size (%) with time. Statistical significance in 
tumor size differences at the end of treatment was evaluated by Tukey 
Test after analysis of variance (ANOVA). *P≤0.05 was considered 
statistically significant. 
 
Figure 7.3 Distibution of nanocomplexes within BT474 tumor tissue 4 hr after 
intratumoral injection. Nuclei were stained blue with DAPI, and cellular 
distribution of Alexa Fluor 647-Herceptin and FITC-loaded P(MDS-co-
CES) nanoparticles are shown as red and green fluorescence 
respectively. Yellow regions represent the co-localization of Herceptin 
and P(MDS-co-CES) nanoparticles in cells.  
 
Figure A1 (A) 1H NMR and (B) FT-IR spectra of PMDS. 
 
Figure A2 (A) 1H NMR and (B) FT-IR spectra of Be-chol. 
 
Figure A3 (A) 1H NMR and (B) FT-IR spectra of P(MDS-co-CES). 
 
Figure A4 A typical TEM image of micelles prepared using P(MDS-co- CES) in 











Caspase Cysteine-dependent aspartate-specific protease 
DCM Dichloride methane 
DISC Death-inducing signalling complex 
DMAc Dimethylacetamide 
DMEM Dulbecco's Modified Eagle's Medium 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
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FACS Fluorescence-activated cell sorter 
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CHAPTER 1  
LITERATURE REVIEW 
 
1.1 Brief Background 
Cancer treatment through chemotherapy began as early as the 1940s with the first 
discovery of nitrogen mustard [1] and folic acid antagonist drugs [2] as anti-cancer 
agents. Since then, the developments made in cancer therapy have been expanding with 
tremendous improvements in the understanding of cancer biology and pharmacology, as 
well as the utilization of this knowledge to improve clinical strategies. One of the most 
important breakthroughs in cancer treatment occurred in the mid 50s, when the use of 
combination therapy was first demonstrated by Emil Frei, Emil Freireich and James 
Holland. They found that the combination of Purinethol (mercaptopurine), Oncovin 
(vincristine sulfate), methotrexate, and prednisone— which together were referred to as 
the POMP regimen — could induce long-term remissions in children with acute 
lymphoblastic leukemia [3]. As research on combination therapy progresses, the clinical 
benefits of employing such treatment regimes become evident as the appropriate 
permutation of combined drugs on cancer cells is able to give rise to augmented effects 
with reduction of dose-related side effects of individual agents.  
 As the understanding of oncogenic mechanisms deepens, alongside with the 
development of recombinant technologies, the use of biopharmaceuticals came into light 
as an alternative to small-molecule drugs for cancer treatment. Biopharmaceutical drugs 
refer to a wide range of medicinal products created by biotechnology processes and these 
include nucleic acids (DNA, RNA or antisense oligonucleotides) and recombinant 
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therapeutic proteins. Over the past several decades, extensive efforts have been placed 
into exploring the different varieties of these biopharmaceuticals as a cure for cancer. By 
far, protein therapeutics has been the most successful class of biopharmaceutical drugs 
for cancer therapy with approximately one quarter of all biotechnology products in 
development being monoclonal antibodies, and some have already been approved by the 
U.S.A. F.D.A. for the treatment of cancer [4]. 
 The application of anti-cancer agents in clinical settings is often met with many 
difficulties. For small-molecule drugs, common impedence include poor solubility as 
most of such drugs are often hydrophobic in nature; damage to surrounding tissue upon 
extravastion of the drugs; lack of selectivity for target tissues and poor biodistribution 
resulting in dose-limiting side-effects; rapid plasma clearance and degradation in vivo and 
the latter two problems are prevalent with use of protein therapeutics. 
 To circumvent the problems associated with conventional (“free”) drugs, the use 
of drug delivery systems (with diameters around 200 nm or less) has been extensively 
explored to help improve the pharmacokinetics and biodistribution of the associated 
therapeutic agents [5]. These systems include liposomes and other lipid-based carriers 
such as lipid emulsions, and lipid-drug complexes; also included are micelles, polymer-
drug conjugates and immunoconjugates. The potential of using drug delivery systems for 
cancer treatment have been demonstrated as early as 1974 for liposomes [6], and 1980 for 
polymeric nanoparticles [7]. Till this date, several drug delivery systems have moved into 
clinical application. Examples include liposomal doxorubicin (Myocet) which has shown 
less cardiotoxicity than doxorubicin for the treatment of metastatic breast cancer [8], and 
PEG-L-asparaginase [9, 10] with significantly longer plasma half life than the 
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unpegylated enzyme (357 hr vs. 20 hr)  for acute lymphoblastic leukemia treatment. 
However, despite the advancements that drug delivery systems have made in improving 
cancer treatment, it is also important to realize that there are still concerns associated with 
its use.  In spite of the reports on evasion of multi-drug resistance by drug delivery 
systems [11, 12], the possibility cannot be ruled out for the emergence of drug resistant 
variants during prolonged treatment. In a study reported by Panyam et al., treatment of 
multidrug resistant (MDR) cells showed that cytotoxicity of nanoparticle-encapsulated 
Paclitaxel (Pac) can only be restored under the influence of P-glycoprotein (P-gp) 
inhibitor, verapamil, and  sustained inhibition of P-gp is required for sustained 
therapeutic efficacy of the encapsulated drug [13].  
Another approach to reduce the chances of developing MDR that is better 
accomodated for clinical application is by combining different drugs with synergisitic or 
additive therapeutic effects that are non-cross resistant with one another. However, some 
of the main drawbacks include multiple administrations and uncertainty in the 
distribution of the different drugs to various body tissues. This leaves us room for 
improving drug formulations for better therapeutic efficacies and clinical convenience. In 
particular, it is exceedingly attractive to use nanoparticulate delivery systems for 
combinational therapy as these vehicles are able to co-deliver multiple drugs 
simultaneously in a single administration. One of the earlier studies involving co-delivery 
systems was conducted by Janoff et al. [14] where different small molecule anti-cancer 
drugs (irinotecan/floxuridine, cytarabine/daunorubicin, and cisplatin/daunorubicin) were 
co-delivered using liposomal systems and showed synergisitic therapeutic effects in mice 
models [15].  With structural versatility of nanoparticulate delivery vehicles, the 
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therapeutic agents that can be loaded into the carriers are not limited to only small 
molecule drugs, macromolecules such as nucleic acids and proteins can also be 
codelivered together using these vehicles.  
 
1.2 Combinational Therapy 
1.2.1 Introduction to combination therapy 
The era of combination therapy began in mid 1950s, in the National Cancer 
Institute (NCI), when three physician-scientists, Holland, Frei and Freireich, proposed a 
revolutionary alternative approach to single drug therapy—by using combinations of 
multiple drugs to eliminate cancer cells before they developed resistance. Several years 
later, this group of researchers reported successful clinical studies which showed that the 
POMP regimen can treat pediatric patients with acute lymphoblastic leukemia and lower 
the chances of cancer relapse.  This approach was also taken on by another group of 
researchers from the same institute, Vincent DeVita, George Canellos, who showed that 
the combination of nitrogen mustard, vincristine, procarbazine and prednisone — 
together referred to as the MOPP regimen — could provide a cure against both 
Hodgkin’s lymphoma and non-Hodgkin’s lymphoma [16]. These two successful 
combination regimens have since been actively used in clinics and has become the 
standard of care for patients with such cancers.  
Following these landmark discoveries, new drugs and potent combinations for 
cancer treatment have been discovered, including taxanes, campthothecin, platinum-
based agents, nitrosoureas and anthracyclines [17]. In scenarios where single agents are 
unable to produce satisfactory results in patients with advanced cancer, their use in 
combination are usually considered. In clinical settings, when several drugs have been 
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demonstrated to be therapeutic against a particular type of cancer, combining them 
becomes almost intuitive for clinicians. Table 1.1 shows some of the various 
combinations of small molecule drugs and antibodies that have been used in clinical 
studies.  
Table 1.1 Examples of clinical studies conducted using various combinations of anti-cancer agents. 
Treatment Cancer type 




Cetuximab 1.5 6.9 
Cetuximab/Irinotecan 
Colorectal 
4.1 8.6 (p =0.48) 
[18] 
     
Docetaxel 4.2 11.5 
Capecitabine/Docetaxel 
Breast 6.1 14.5 (p = 0.126) [19] 
     
Irinotecan (I)/Fluourouracil 





8.8 17.9 (p =0.008) 
[20] 
     
Docetaxel 6.1 22.7 
Trastuzumab/Docetaxel 
Breast 11.7 31.2 (p = 0.0325) [21] 
     
Cyclophosphamide, 
Vincristine, and Prednisone 
(CVP) 




35 30 (89% of the patients) 
[22] 
     
Paclitaxel (Pac) 22.2 









Strong emphasis is placed on the importance of selection of drugs for combination 
purpose. This is because, even though some drugs are potent when used individually, 
administrating them together does not guarantee enhancement in therapeutic efficacies. 
For instance, the combined use of two of the commonly used anti-cancer drugs, paclitaxel 
(Pac) and doxorubicin (Dox) did not increase the overall survival of patients compared to 
when the drugs were administered alone [23].  
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In most cases, the empirical approach is usually employed to test the effectiveness 
of different drug combinations on patients. This has been justified by the lack of methods 
to identify the sensitivity of tumors to individual agents or to a combination of agents 
[24]. In the recent decade, with the increasing knowledge regarding the complexity of 
cancer biology and the existence of multiple targets in the same or different interactive 
pathways in cancer cells, combinations of molecularly targeted agents have been 
investigated. However, due the specificity of such agents, focusing on a single target 
would usually give rise to modest clinical effects except during rare circumstances in 
which the cancer development is dominated by the abnormality or defect of a single gene 
[25]. Furthermore, due to the adaptability and variations in oncogenic pathways, ‘cross-
talk’ between different pathways can occur to signal survival requirements of the cancer 
cells, leading to the activation of other molecular targets [26, 27]. Hence, the combination 
of therapeutic agents targeting a combination of various pathways may give rise to 
greater anti-cancer effects compared to monotherapy using single agents. Given the vast 
number of possible combinations of agents that can be used, the opportunities to develop 
effective combinations for improving therapeutic efficacy is attractive and abundant.  
 
1.2.2 Rational for combining drugs 
1.2.2.1 To evade drug resistance 
In cancer therapy, the combination of drugs with different modes of biological 
action has been used in order to evade the development of drug resistance. When single 
agents are used to treat cancer, the repeated exposure of cancer cells to drugs can result in 
the development of clinical resistance.  Drugs that are used as monotherapy are usually 
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those that target specific proteins involved in cancer development. These drugs can also 
lose their effects in advanced stages of cancer as the some cells acquire independence 
from such proteins [28]. There is a wide range of mechanisms through which cancer cells 
can acquire drug-resistance, including the mutation or overexpression of the molecular 
target, inactivation of the drug, or elimination of the drug from the cells [29]. For 
instance, tumors may become refractory to monotherapeutic anti-angiogenic drugs which 
targets only one angiogenic protein (e.g. VEGF) [30]. Another example is that in mice 
models that have been engineered with controllable oncogenes, the tumors that initially 
relied on the oncogene eventually lose this dependency as they develop [31]. 
There are two main aspects of the problem: firstly, the re-proliferation of cancer 
cells between therapy cycles and the development of resistant cells with each cycle, 
resulting in lower number of cells being eliminated. Another major issue with 
monotherapy is that when cancer cells develop resistance to some drugs of a particular 
class, the resistance has likelihood to be extended to the entire class of similar drugs. To 
evade the occurrence of multi-drug resistance, drug combinations are often used. The 
motion behind such practice is based on the postulation that the probability of cancer 
cells developing resistance to a combination of non-cross-resistant drugs varies as the 
product of the probabilities of resistance to each of the individual drug [24].  Thus, by 
lowering the chances of developing multi-drug resistance through the use of drug 
combinations, therapeutic regimens can be continued for longer period of time without 
losing the drug efficacy.  
 
1.2.2.2 To enhance anti-cancer activity 
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Clinical prediction of drug efficacy and toxicity from theoretical knowledge or 
preclinical studies is often difficult and imprecise. As the efficacies of anti-cancer agents, 
particularly for small molecule-drugs, vary with the dosage used, clinicians usually 
administer drugs at levels at or close to the maximum tolerated dose (MTD) (Box 1.1) to 
achieve optimal therapeutic effects with tolerable side-effects. Therefore, there is a 
limitation as to the amount of single agents that can be used for treatment. The 
therapeutic window of any given drug refers to the range of dose of a drug or of its 
concentration in a bodily system that provides safe and effective therapy. The differences 
in therapeutic windows of different drugs are related to their functions, as in whether they 
inhibit the essential of non-essential functions of the human body. With reference to this 
context, inhibitors of essential functions will affect the survival of at least one vital cell 
type in the body.  As a result, such drugs may be more potent but are likely to have 
narrow therapeutic windows. On the contrary, drugs that inhibit non-essential functions 
would likely be well tolerated, but their efficacy may be lower unless the appropriate 
cancer types are targeted [28]. To achieve enhanced therapeutic efficacy while 
maintaining side-effects at manageable levels, clinicians often combine two or more 
drugs in the treatment. This approach is useful only if the combination maintains or 
widens the therapeutic window and also, if the modulatory effects of one drug on another 
occur at a dose that is much lower than the MTD of either drug [32]. For instance, in a 
phase 3 clinical trial, when paclitaxel and bevacizumab were combined at levels below 
the MTDs, progression-free survival was significantly increased as compared to Pac 
alone, from 5.9 to 11.8 months [33]. 
________________________________________________________________________
Box 1.1 Studies that lead to the concept of maximum tolerate dose (MTD) 
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In 1955, the National Cancer Chemotherapy Service Center (NCCSC) was set up at the National Cancer 
Institute (NCI) in the U.S.A. to promote cancer drug discovery. The NCCSC established the necessary tests 
and indicators for the discovery, development, toxicology and clinical evaluation of candidate drugs. Later 
in the 1960s, Frank Schabel and Howard Skipper at the Southern Research Institute added on to the NCI’s 
efforts by developing in vivo assays for analyzing toxicity of anti-cancer agents [34, 35]. In their studies, 
they demonstrated that anti-cancer agents display fractional killing effect on tumor cells that is dependent 
on the dose of agents used. In addition, they were also the first to propose that high dose of anti-cancer 
agents should be used to cure patients in order to prevent the likelihood of drug resistance development. 
This concept led to the current clinical practice of administering drugs at dosages close to or at the 
maximum tolerated dose (MTD).  
 
 
1.2.3 Types of drug combinations and mechanisms 
When two or more anti-cancer agents are combined, the resultant therapeutic 
effects may vary over a wider range compared to the summed effects of the individual 
agents. Drug combinations may produce effects that are pharmacodynamically 
synergistic, additive or antagonistic if the effect is larger, equal to, or lower than the 
summed effects of the single drugs [36]. The addition of drug to another can modulate the 
therapeutic activities of the partner drug by affecting the pharmacokinetics of the drugs in 
terms of absorption, distribution, metabolism and excretion. 
Researchers and clinicians aim to discover drug combinations that produce 
synergistic therapeutic effects, where the ‘whole’ is greater than sum of the action of its 
parts [37]. Synergistic and potentiative combinations will allow favorable outcomes 
including enhanced therapeutic effectiveness; reduced drug dosages (hence related-side 
effects) at equal or higher level of efficacy; and/or decreased or postponed acquirement 
of drug resistance [38, 39]. The use of non-synergistic combinations is not favored 
clinically and these have been mostly replaced by single agents [40]. 
 
1.2.3.1 Pharmacodynamically synergistic combinations 
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There are mainly three groups of synergistic drug combinations that work based 
on different pharmacodynamic mechanisms: firstly, anti-counteractive actions of drugs 
that decrease the molecular pathway’s counteractive behaviour to repel a drug’s 
therapeutic effects; secondly, complementary actions of drugs that involves a positive 
modulation of a target or process by approaching the pathway at different points; thirdly, 
facilitating actions whereby one drug can help in enhancing the activity of another drug 
[40]. Table 1.2 shows some examples of synergistic drug combinations. 
 
Table 1.2 Examples of pharmacodynamically synergistic drug combinations. 







Cellular damage by chemotherapy can 
result in the conversion of EGFR ligands 
from growth factors into survival factors 
for EGFR-expressing cancer cells. 
Blockage of EGFR mitogenic signaling 
by ZD-1839 in combination with 
cytotoxic drugs could irreversibly damage 








Pac results in transient mitotic arrest with 
activation of cdc-2 kinase. After which, 
the cells exit mitosis with a reduction in 
cdc-2 kinase activity and MPM-2 
labeling. Flavopiridol accelerates the 
mitotic exit when administered after pac 
treatment by inhibiting cdc-2 kinase and 
in association with a more rapid decrease 
in MPM-2 labeling. 
[42] 
    
Cetuximab Gefitinib or Erlotinib 
Distinct classes of EGFR inhibitors, 
providing greater inhibition of the EGFR 
signalling and great down-regulation of p-
MAPK and p-AKT expression. 
[43] 
Angiostatin Endostatin 
Synergisitic inhibition of endothelial cell 




Both antibodies target HER2 receptors. 
Pertuzumab sterically blocks HER-2 
dimerization with other HER receptors 
and blocks ligand-activated signaling 
from HER-2/EGFR and HER-2/HER-3 
heterodimers. 
[45] 
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Angiotensin II Chemotherapeutic drugs 
Tumor blood flow increases in 
angiotensin II-induced hypertensive state 
but maintains constant in normal blood 
vessels. Hence, delivery of drugs to 






Trifluoperazine is an inhibitor of 
calmodulin and can alter membrane 
permeability. Treatment with it can 
significantly increase adriamycin 





1.2.3.2 Pharmacodynamically additive combinations 
 Additive combinations often have similar activity or overlapping effects on 
different targets of the same signaling pathways, and as a result they regulate the same 
molecular target in an equivalent manner. Otherwise, they can have interactions that 
directly or indirectly affect the same site of the same target. For example, additive drug 
interactions were observed in human colon cancer cell lines after treatment with 17-
allylamino-17-demethoxygeldanamycin (17-AAG) and oxaliplatin. 17-AAG inhibits the 
activity of transcription factor NF-κB through the abrogation of upstream components of 
the NF-κB pathway, and that this results in a shift of the balance from cell survival to cell 
death in response to oxaliplatin treatment. 
 
1.2.3.3 Pharmacodynamically potentiative combinations 
Another type of drug combination which provides the enhancement of therapeutic 
efficacy is one that potentiates the partner drug’s effects through positive regulation of 
drug transport or permeation, distribution or localization and metabolism. Improvements 
of the transport of drug into target cells or organelles occur via the disruption of transport 
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barrier, delay of barrier recovery, or prevention of drug efflux. The distribution or 
localization of drugs to target tissues is improved by inhibiting metabolic processes that 
convert drugs into excretory products. Positive modulation of metabolism occurs via the 
stimulation of conversion of drugs into active forms, or inhibit the conversion of drugs 
into inactive forms [40]. One example is co-administration of a P-glycoprotein inhibitor, 
cyclosporin A, with Pac. As a single agent, orally administered Pac has poor 
bioavailability because of its high affinity for the multidrug transporter P-glycoprotein, 
which is present in abundant levels in the gastrointestinal tract. The combined 
formulation significantly increases the oral bioavailability and systemic exposure of 
orally administered Pac [49]. 
 
1.2.3.4 Combinations that lower therapeutic efficacy 
Some drugs work against each other and such pharmacodynamically antagonistic 
drug combinations are unsuitable to be used in clinical applications. Antagonistic 
mechanisms include interference of drug actions at the same target, or indirectly by 
disrupting related pathways that regulate the same target. One example of antagonistic 
drug combination is Pac and flavopiridol, with actions closely related in the cell cycle 
process. Pac induces apoptosis during mitosis, whereas pretreatment of cells with 
flavopiridol inactivates the cdc-2 kinase, which prevents the mitotic arrest of Pac from 
occurring in the context of a properly activated cdc-2 kinase. Therefore, the treatment 
sequence of flavopiridol followed by Pac becomes inactive [42]. 
Another type of drug combination that lowers therapeutic efficacy is one which is 
pharmacokinetically reductive. Such combinations of drugs result in negative modulation 
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of drug transport, permeation, distribution or localization, and metabolism. For instance, 
cisplatin, by itself results in DNA inter- and intra- strand adduction. When another drug, 
procainamide hydrochloride is added, it results in the formation of less toxic cisplatin-
procainamide complex. Thus, this reduces cisplatin-induced hepatotoxicity by the 
inactivation of cisplatin or its highly toxic metabolites and rearrangement to a different 
subcellular distribution of platinum [40]. 
 
1.2.4 Methods for analyzing drug interactions  
To study the overall therapeutic effects of drug combinations, various methods 
have been developed and explored. One of the commonly used and preferred methods is 
the isobolographic analysis, which was first introduced by Loewe in 1953, where 
additivity was predicted between ethyl alcohol and chloral hydrate [50, 51]. This method 
has been employed in my work for the analysis of effects of various drug combinations. 
The isobologram method evaluates the effect of interaction of two drugs at a 
specified effect level, such as half of the maximal inhibition and the concentration at 
which it occurs is defined as the IC50. Using graphical analysis, the concentrations 
required to produce the given effect (for example, IC50) are determined for each of the 
individual drugs, A (ICx, A) and B (ICx, B). These points, (ICx, A, 0) and (0, ICx, B), are then 
plotted on the x and y axes of a two-coordinate plot. A line is drawn to connect these two 
points and this is defined as the line of additivity. After which, treatment is then 
performed by using the drugs in combination with varying concentrations used. The 
concentrations of A and B in the combination that provide the same effect, denoted as 
(CA, x, CB, x), are placed in the same plot. Effect of the drug interaction is determined 
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according to the position of the points (CA, x, CB, x) with respect to the line of additivity. 
Synergy, additivity, or antagonism is represented when the point is located below, on, or 
above the line, respectively [52, 53]. This isobologram method evaluates drug interaction 
at chosen therapeutic effect levels and provides a more comprehensive analysis of the 
drug interaction at the corresponding concentrations. 
The Loewe model is based on the assumption that there is no self interaction of 
each individual drug. It also takes into account of the non-linear display of drug 
concentration-effect relationship such as the commonly observed sigmoidal curve. This 
will provide an advantage for evaluating drugs demonstrating such a relationship. This 
model also assumes that two drugs act through a similar mechanism, and the effect of 
each drug and the drug combination are related through equipotent dose ratios. 
Comparatively, another model – the Bliss independence model, assumes that the drugs 
act through independent mechanisms and combined effect of two drugs equals to the 
multiplication product of the effects of individual drugs. This assumption place a limit on 
the capacity for analysis as it is only applicable for drugs that exhibits linear dose-
dependent effect but not for those with nonlinear relationships [54, 55]. 
 Because of the application versatility of the Loewe additivity model, many other 
methods have been developed based on it. These include the interaction index 
calculation, the median effect method, and several three-dimensional surface-response 
models [52, 56]. The surface response methods involve more complex and rigorous 
calculations and thus, have not gained wide usage.  
 
1.2.5 Issues and strategies for combination therapy 
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1.2.5.1 Practical issues for consideration 
 
 Drug combinations can have a wide range of effects that are different from that of 
single agents and it is often difficult to predict the sensitivity of tumors to the different 
combinations. In clinical settings, the empirical approach is often employed to study drug 
interactions and therapeutic efficacies of different combinations of drugs. To design 
effective clinical trials for drug combinations, several issues have to be carefully 
considered. Firstly, substantial preclinical and clinical data showing therapeutic potential 
of the combination must be obtained prior to planning the trial. Secondly, as the 
prevalence of different cancers may vary with different populations [57], the selection of 
population to be studied is important to ensure good relevance to the disease. Thirdly, 
since anti-cancer agents are being developed by many different pharmaceutical 
companies, intellectual property issues may arise with successful drug combinations [24].  
 
1.2.5.2 Mechanistic considerations 
 
 The main priority for development of drug combinations is to allow enhanced 
therapeutic efficacy while maintaining acceptable pharmacology and non-specific 
toxicity. As such, knowledge on the mechanisms of action and resistance development to 
single agents and interaction mechanisms of the drug combinations should be well 
explored. There should also be strong evidence of therapeutic enhancement (either 
synergistic, potentiative or additive) from preclinical studies. An important point to 
consider is that in some cases, monotherapy using single agents may not produce anti-
cancer effect at desired therapeutic levels, but may result in substantial enhancement of 
therapeutic effects when used in combinations with other drugs. For instance, LY303511 
(LY30) is an inactive analog of LY294002 (LY29), a widely used inhibitor of the 
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phosphatidylinositide-3-kinase (PI3K)/Akt survival pathway, and when LY30 is 
combined with tumor necrosis factor-related apoptosis inducing ligand (TRAIL), the 
combination is able to induce significant increment of cell death [58]. 
 Selection of drugs used for combinations may be conducted in such a way 
whereby the therapeutic activity of the first agent can be enhanced by the second agent. 
This is often decided based a number of strategies. Firstly, in combination, the second 
agent chosen is able to affect the targeted molecule of the first agent more effectively; 
and/or it is able to affect additional targets or interfere with related pathways; and/or it 
can be used as a counteractive agent against cellular process that arises during multi-drug 
resistance development. For instance, the downregulation of genes that serves as anti-
apoptotic or protective factor such as HER2, interleukin10, Bcl-2 [59-61] and restoration 
of tumor suppressor p53 functions [62] by either gene therapy or small molecule drugs 
can increase cancer cells sensitivity to conventional chemotherapeutic agents. Another 
example is the combination of interferon (IFN) with chemotherapeutic drugs. IFNs have 
weak cytotoxicity but are able to inhibit cell cycle progression, which mainly occurs as S 
phase accumulation. The cell cycle inhibition has been implicated in the antitumor effect 
of combinations of IFNs and chemotherapeutic drugs such as cisplatin and Pac [63, 64]. 
In anti-angiogenic therapy, treatment with angiogenesis inhibitor (TNP-470) together 
with an anti-cancer prodrug, cyclophosphamide, can enable the eradication of drug-
resistant tumors [65].  
  Therapeutic effectiveness of single or combined drugs is usually achieved through 
the modulation of multiple molecular targets rather than single targets. Investigations of 
drug effects on the molecular interactions within cells are commonly performed using the 
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empirical approach. Besides this, the integration of network biology and computational 
technologies can provide the alternate means to conceptualize and analyze the entire 
regulation and signaling networks of different normal and cancer cells. The 
understanding of network system of gene expression profiles and interaction between 
different genes and proteins in oncogenesis can be improved by network models such as 
the Boolean genetic network. Boolean networks represent a simplification of the actual 
complicated cell system in which each gene is considered to be a binary variable and can 
either be active = ‘on’ or  inactive = ‘off ’ through regulation by other genes as 
represented by logical or Boolean functions. The information obtained will enable the 
identification of oncogenic pathways of specific cancers or their subtypes, and provide 
guidance to the use of specific molecular targeted agents as well as appropriate drug 
combinations for specific patients [38, 66]. 
 
1.2.5.3 Strategies for determining regimens 
 
The strategies for designing combination regimens is based on the following 
principles: firstly, the drugs should be preferably targeted against the cancer cells over 
normal cells; secondly, as the therapeutic efficacies of the drugs is likely to be correlated 
with the dosage and duration of drug administration, the drugs should be used at or close 
to their maximal tolerated dose (MTD); thirdly, optimal combinations utilize agents with 
different mechanisms of action; and lastly, drug combinations should be selected to 
minimize any overlapping toxicities of the individual agents [64].  
When drug combinations have been carefully evaluated using the above 
guidelines, other related practical parameters have to be considered as well. When single 
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agents are used, clinicians often have to use doses that are close to the MTD. This is 
because the destruction of cells by drugs follows the first order kinetics and only a fixed 
fraction of cells can be killed with a given dose. The implication of the fractional killing 
effect is that to completely eradicate a population of cancer cells, it is necessary either to 
increase the dose of drug within the MTD, or to initiate the treatment when the initial 
cancer cell number is small enough. Since the opportunity to treat early stages of cancer 
is uncommon, clinicians are often left with the option to increase the dose of single 
agents used, which tends increase dose-related side effects and limits the possible dosage.  
As such, the use of drug combination can help evade such problems by reducing the dose 
of individual agents used [67]. 
Besides the dose used, one of the important factors that can greatly interfere with 
the success of the treatment is the dose scheduling of the drugs involved.  Appropriate 
scheduling of drug exposure enables optimal interaction of chemotherapeutic agents. An 
example of such is the combinations of melphalan, BCNU (1,3 bis(2-chloroethyl)-1-
nitrosourea), or cisplatin with topotecan, which were found to have highest effectiveness 
when cells were exposed to the alkylating agent or platinating agent prior to topotecan 
treatment [68].  
Another important factor is the dose intensities used during treatment. 
Therapeutic drugs may be given at different frequencies and this can give rise to different 
efficacies of treatment. For instance, in a retrospective clinical study, association between 
relapse-free survival and dose intensity was observed in clinical trials involving 
cyclophosphamide, methotrexate, and fluorouracil-containing adjuvant chemotherapy of 
stage II breast cancer [69]. In another study, female patients with stage II breast cancer 
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treated with combinations of cyclophosphamide, doxorubicin, and 5-fluorouracil also 
showed therapeutic dependencies on the frequencies of dosages [70]. 
 
 
1.2.6 Reasons for failure of some regimens 
  
Due to the vast number of mechanisms by which different agents can interact, the 
therapeutic outcomes of combination regimens are usually complex and unpredictable. In 
some cases, therapeutic benefits may not result from certain combination regimens. There 
are several possible reasons that can result in the failure of combination therapy. Firstly, 
the nature of the effects the agents have on the cells, either individually or in 
combination, may not lead to augmentative interactions. These drugs may have 
overlapping activities on the same molecular target or signaling pathways and as a result, 
they would not have addition clinical gain when combined in the same regimen. 
Secondly, some combinations may result in antagonistic or reductive biological effects, 
which may even give rise to reduced effectiveness, as compared the single agent. Thirdly, 
the expressed level or biological functionality of molecular target may be low in the 
cancer cells. If the intended target is absent or there are other irrelevant pathways that can 
provide alternative signaling to maintain essential functions in the cancer cells, the effect 
of the combination regimen will decreased significantly. Fourthly, even with combination 
regimen, drug resistance can also develop in cancer cells after repeated administration. 
For instance, the cancer cells may acquire alterations in drug metabolism and transport, 
resulting in lower drug levels in the cells. As a result, the therapeutic efficacy of the 
agents will be become significantly reduced [24]. 
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1.3 Protein Therapeutics  
Early development of cancer therapeutics had been based on drugs that can inhibit 
cancer cell growth through blockage of cellular events essential for proliferation. For 
instance, in 1963, researchers at Eli Lily discovered Vinca alkaloids as a new class of 
oncolytic agents as it can stop the proliferation of cancer cells during their original 
screening for anti-diabetic agents [71]. Several years later, further research then showed 
that the anti-cancer activity of the Vinca alkaloids is attributed to their ability to inhibit 
microtubule polymerization, and thereby blocking mitosis from occurring [72]. Likewise, 
such early anti-cancer agents are usually small molecules, which are able to block cancer 
cell proliferation by modifying DNA structure and impairing DNA accurate replication or 
other cellular events such as nucleotide biosynthesis. In all, the screening process to 
identify potential anti-cancer agents has been mostly carried out using an empirical 
approach up till now. This is because the anti-cancer efficacy of candidate agents during 
in vitro tests and animal tumor models may not accurately reflect the complexities of 
human cancer. Hence, it is often difficult to recognize the reasons behind the success and 
failure of different candidate agents and the varying degrees of sensitivity of cancer cell 
types to different drugs.  
In the last few decades, with the widening application of molecular biology, target 
identification in cancer became important and high through-put screening of potential 
oncogenes could be performed. Till now, many genes have already been extensively 
explored and some found to affect oncogenesis and cancer cell proliferation. With 
regards to target selection, some of the key areas that are being studied include genes and 
gene products affecting apoptosis induction, cell-cycle regulation, signal transduction and 
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tumor angiogenesis [73]. Through molecular biology techniques, gene candidates can be 
cloned and expressed into recombinant proteins with therapeutic functions. The vast 
number of proteins with therapeutic potential opened up a wide area for research and 
advancement. Various cloning and expression approaches in different host systems have 
also been developed. Currently, there is more than 130 different protein or peptide 
therapeutics approved by the US Food and Drug Administration (FDA) for clinical 
applications. Some examples are given in Table 1.3.  In commercial perspective, it has 
been predicted that the global market value for therapeutic proteins will grow from 
34,000 million USD to 52,000 million USD and oncology-related proteins will be the 
second most important revenue generator with an increasing market share of 14% in 2004 
to 18% in 2010 [74]. 
 
Table 1.3 Examples of U.S. F.D.A. approved protein or peptide-based therapeutics [75, 76]. 
Generic Name Company Type of therapeutic Indication of first FDA approval 
Year of first 
FDA 
approval 
Rituximab Genentech mAB Non-Hodgkin's lymphoma 1997 
Trastuzumab Genentech mAB Breast cancer 1998 
Denileukin diftitox Seragen rDNA Cutaneous T-cell lymphoma 1999 
Gemtuzumab 
ozogamicin Wyeth mAB Acute myeloid leukemia 2000 
Ibritumomab 
tiuxetan BiogenIDEC mAB Non-Hodgkin's lymphoma 2002 
Abarelix depot Praecis Synthetic peptide Prostate cancer 2003 
Tositumomab-I131 Corixa Seattle mAB Follicular lymphoma 2003 
Bevacizumab Genentech mAB Colorectal cancer 2004 
Cetuximab Imclone Systems mAB Colorectal cancer 2004 
Panitumumab Amgen mAB Colorectal cancer 2006 
 
1.3.1 Recombinant proteins 
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 The success of protein therapeutics in disease treatment has been first recognized 
in 1922, when the collaborative efforts of 4 researchers - Frederick Banting, Charles Best, 
John J.R. Macleod, and James Collip, demonstrated that insulin, purified from bovine and 
porcine pancreas, was able to replace the biological activities of the protein hormone in 
patients suffering from diabetes mellitus type I (DM-I) [77]. Despite the clinical benefits, 
the extraction of the therapeutic protein from animal sources meant that the availability of 
such treatment may be limited and expensive, and immunogenicity would be a potential 
complication. Subsequently, with breakthroughs in genetic research and expression 
engineering, production of recombinant human insulin from Escherichia coli became 
possible. US FDA approval was then given in 1982 and large-scale production of 
recombinant insulin enabled widespread inexpensive DM-I treatment. More recently, 
some research groups have succeeded in deriving human insulin from transgenic plants 
with the anticipation that this technique will be able to reduce production costs [78, 79]. 
 In view of the huge clinical potential of protein therapeutics, various systems have 
been developed for recombinant protein production. These include bacteria, yeast, insect 
cells, mammalian culture, and transgenic plants and animals [80-86]. Selection of 
production method is dependent on the cost or the post-translation modifications required 
for protein functions. For many proteins, it can be difficult to manufacture in recombinant 
form or expressed in microbial systems. For instance, the commonly used bacterial 
systems for protein production cannot perform glycosylation reactions while yeasts, 
baculovirus and transgenic plants produce glycosylated proteins that are different from 
the human version and are unsuitable for clinical use. Deviations in glycosylation 
patterns can lead to enormous differences in biological activity, serum half-life and 
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immunogenicity of the recombinant proteins when administered into the body [87].   To 
improve the physiochemical and biological properties of recombinant proteins, extensive 
research has been put into devising strategies to modify targets and oligosaccharides on 
particular therapeutic protein to produce glycoforms with enhanced therapeutic activities 
[88]. Another approach adopted to improve the pharmacokinetics of recombinant proteins 
is through pegylation – which is the process by which polyethylene glycol (PEG) chains 
are attached to protein and peptide agents. By conjugating to PEG, this will increase the 
molecular mass of the protein drugs and shield them from proteolytic enzymes. For 
instance, Pegaspargase (Oncaspar), an FDA approved recombinant protein, used 
clinically in combination with chemotherapy for the treatment of acute lymphocytic 
leukaemia contains the pegylated enzyme L-asparaginase. Without pegylation, the 
enzyme causes allergic reactions and has a short half life of 20 hr. Comparatively, with 
pegylation, its half life can be extended to 357 hours with lower immunogenicity 
problems [89].  
 
1.3.2 Rationale for using protein therapeutics 
 There are many reasons behind the extensive research efforts put into developing 
protein therapeutics, most of which are based on the advantages they have over small-
molecules drugs and gene therapy. First, as compared to the large number of protein 
therapeutics currently used for disease treatment, no human gene therapy product has yet 
been approved by U.S. F.D.A. as a standard-of-care in clinics and this technology is also 
currently unavailable for most diseases. On the contrary, in genetic conditions where 
there are alterations or mutations of particular genes, protein therapeutics can provide 
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effective replacement treatment without involving gene therapy. Second, as the effects of 
proteins are short-lived compared to genetic therapeutics, the risk of any adverse long 
term consequences would be much lower. Third, some molecular targets exhibits 
biphasic, U-shaped dose-related efficacy and these targets are unsuitable for gene therapy 
because of the difficulties in controlling and predicting the in vivo expression of the gene. 
For instance, Folkman et al. initially discovered in one of their studies that gene therapy 
of endostatin produced an excessively high level of the protein such that the anti-
angiogenic effect was heavily reduced [90, 91]. Fourth, while protein therapeutics can be 
produced on cost-effective scale and administrated in vivo through straightforward 
intravenous (IV) infusion with low risk of immunogenicity [87], gene therapy can have 
various pros and cons depending on the methods used. While in vivo gene transfer is 
more cost-saving, it is not patient-specific and immune response can be evoked against 
the delivery vectors. In the ex vivo approach, cells have to removed from the patient for 
transfection, and although this method offers higher transfection efficiency, it is largely 
patient-specific due to cell immunogenicity, and in turn, this technique is also more 
costly because of the cell manipulation procedures [92]. Fifth, proteins are highly specific 
in terms of target interactions and biological functions and these properties are difficult 
for simple chemical entities to mimic. Sixth, as a result of the specificity of proteins, 
there is a lesser likelihood for protein therapeutics to disrupt normal physiological 
processes and cause unwanted side effects. Seventh, protein production strategies have 
matured through many decades of development and scale-up optimization studies, and 
this has allowed protein therapeutics to be produced in a cost-effective manner. With the 
large number of various systems available, the optimal production method can be made 
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according to the cost as well as modifications of the protein required for its therapeutic 
functions. Eighth, past records revealed that protein therapeutics development is also 
more advantageous in both approval time and success probabilities. For instance, it has 
been reported that the probabilities for successful transition from clinical evaluation to 
U.S. F.D.A. approval were higher for monoclonal antibodies compared to small molecule 
drugs ( Figure 1.1) [75]. In another study, it was found that the clinical development and 
approval time was ~30 months faster for anti-neoplastic protein therapeutics compared to 
small molecule drugs approved in 1980-2001 [93]. Last, as proteins are unique in their 
biological functions, companies will be able to obtain patent protections for protein 
therapeutics they develop. The last three points illustrates the commercial advantages 
proteins have over small molecule drugs that have made the development of protein 





Figure 1.1 Probabilities of clinical phase transition for cancer therapeutics [75]. 
 
1.3.3 Challenges for protein therapy 
 Despite proteins having great potential to be used as therapeutic agents; they also 
have several limitations that will hinder their widespread usage in clinics. First, proteins 
typically have low stability and short in vivo half-lives, and their clinical application 
require either infusions or frequent repeated injections [94]. Such treatment methods are 
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unfavorable because of its invasiveness to human body and increased chances for other 
complications (e.g. treatment cost, patients’ compliance and pathogenic infections). 
Second, another problem resulting from protein instability is the risk of administrating 
degraded protein as it could lead to undesirable side effects or loss of therapeutic 
effectiveness [95]. Third, while oral delivery has been proposed as an alternative method 
to administer protein therapeutics, a lot of improvement is necessary to increase the oral 
bioavailability of the proteins before the benefits of such systems can be realized. One of 
the main obstacles is that most proteins are hydrophilic with large molecule size and this 
prevents their partition into epithelial cell membranes and absorption via transcellular 
passive diffusion. Another problem is the inherent susceptibility of proteins to pre-
systemic enzymatic degradation in the gastrointestinal tract [96]. To tackle these 
problems, many improvement strategies have been developed and these are further 
discussed in Box. 1.2. Fourth, immunogenicity against therapeutic proteins also poses a 
major challenge for its clinical application. Immune response can arise as anti-therapeutic 
protein antibodies (anti-drug antibodies) can development during treatment. These 
antibodies can either neutralize or reduce the therapeutic efficacies of the protein drug or 
in a worse scenario; it may cross-react with autologous proteins and lead to adverse side 
effects [97]. In most cases, immune responses are generated against proteins generated 
from non-human origin. Fortunately, the severity of this problem has been lowered 
through the development of humanized antibodies and also the production of fully human 
antibodies using transgenic animals or phage display technologies [87].  For example, 
Herceptin is a recombinant monoclonal antibody used to treat breast cancer patients with 
tumors that over-expressed HER2 receptors. This antibody was developed from a murine 
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monoclonal antibody that was later humanized to minimize the immunogenicity 
associated with the non-human therapeutic protein [98]. Fifth, the selection of production 
system for the protein also faces several issues. The system must be able to produce the 
protein with the correct post-translation modification needed for its biological functions. 
The convenience and cost involved for protein purification and storage must also be 
considered. In terms of storage, the system should also be assessed for protein 
misfolding, aggregation and instability. On top of these, the system must also generate 
sufficient quantity of the protein in a cost-effective manner to allow widespread clinical 
use [99-101].    
 
Box. 1.2 Challenges faced in oral delivery of protein therapeutics. 
The most convenient route for administering therapeutic agents into patients is via oral delivery. However, 
the attempts that have been made to deliver proteins and peptides drugs have not been widely successful. 
One of the reasons is their solubility characteristics and large molecular size. Most of these proteins are 
hydrophilic and are unable to get absorbed through passive transcellular diffusion. The paracellular route is 
also not available for protein absorption as the dimensions of the paracellular space of the human intestinal 
epithelium is < 10Ǻ [102], and is therefore restricted only to small hydrophilic molecules (100-200 Da) 
[103]. Furthermore, proteins are vulnerable to hydrolysis and modification at the acidic gastric pH levels 
and proteloytic degradation in the gastrointestinal tract [104].  
To increase the oral bioavailability of the therapeutic proteins, many strategies have been developed. One 
of such is the inclusion of additives in the drug formulations to enhance permeation of the proteins through 
the epithelium or inhibit proteases in the gastrointestinal (GI) tract. For instance, additives which modulates 
tight-junction permeability such as Zonula Occludens toxin [105] and Pz-peptide [106] have been shown to 
enhance protein absorption. However, there are also risks associated with this approach as the alteration of 
the tight junctions will not only enhance transport of the protein drug, but may also potentially increase the 
absorption of unwanted toxins/bacteria/immunogens present in the GI tract [107]. Another method that has 
been extensively researched upon is protein encapsulation technology in particulate carriers to minimize 
exposure of the protein to proteolytic enzymes. Till this date, polymeric drug delivery systems based on 
hydrogels, nanoparticles, microspheres, and lipid-based drug delivery systems (e.g. liposomes and 
microemulsions) have been developed for oral protein delivery [96]. In some reports, the potential of 
acrylic-based polymers and chitosan nanoparticles for oral protein delivery have been shown by several 
research groups [108-110]. In the GI tract, the proteolytic activity is highest in the stomach and duodenum, 
and is sharply reduced in the ileum and colon. Systems involving protein encapsulation with thick enteric 
coatings that delay the release of the drug until the drug reaches the ileum and colon has been devised. In 
addition, to target drug absorption in the large intestine, encapsulation of proteins with polymeric materials 
that can be specifically degraded by the human colonic microflora has been proposed [111]. However, the 
major disadvantage of these systems  is the delay and reduction in time period for drug absorption, as well 
as the lack of control over absorption time due to the variability in intestinal motility and gastric emptying 
[103]. Other methods to improve oral bioavailability include structural modification of the proteins. For 
example, to increase the cellular uptake of the proteins, ligands such as vitamin B12 receptors [112] and 
29 
dipeptide that can be recognized by a peptide-influx transporter [113] have been chemically conjugated to 
the proteins for receptor-mediated endocytosis.  
__________________________________________________________________ 
1.3.4 Current technologies in protein drug delivery  
Over the past few decades, with the increasing identification of more therapeutic 
targets and developments made in the field of biotechnology, more protein and peptide 
pharmaceuticals have become commercially available. However, most of these drugs 
encounter difficulties in moving on to eventual clinical application as many obstacles still 
exist with regards to their delivery in a convenient, stable and cost-effective manner. The 
rising demand for improved methods for the delivery of protein agents has fuelled the 
development of numerous protein delivery systems. Selection and optimization of protein 
delivery systems involve several key issues. In particular, the system should allow a 
sufficiently high bioavailability after administration. The bioavailability of the 
therapeutic protein is dependent on the efficiency of the system as well as the properties 
of the delivery route. If only a small percentage of the protein is delivered to the 
circulation after administration, this would render the system ineffective as the significant 
loss of protein will lead to higher manufacturing and treatment cost. In addition, the 
delivery method may involve formulations/additives or routes of administration that 
could alter the pharmacology and/or toxicity of the protein and this may difficult to 
predict using preclinical animal models. Hence, thorough preclinical and clinical 
investigations would be required for the development of new delivery methods. 
By far, the most convenient route for systemic delivery of most drugs is through 
the oral route. However, research efforts put into developing such systems for protein 
delivery have not been met with significant success due to the inherent properties of 
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proteins that results in low oral bioavailability (Box. 1.2).  Parenteral delivery of protein 
drugs have been the most common method for systemic delivery due to the ease of 
administration and lower cost compared to other delivery methods [95]. It also allows the 
rapid onset and distribution of the proteins which is beneficial for maintaining protein 
activity.  Furthermore, when compared to oral delivery systems, parenteral delivery 
provides an advantage through the evasion of gastrointestinal first-pass effect.  
As preclinical studies and clinical trials are usually performed using parenteral 
delivery methods, the development of injectable formulations or devices tend to have a 
higher likelihood to succeed compared to alternative forms of delivery. Different 
strategies have been proposed to improve on parenteral delivery methods with regards to 
the enhancement of protein stability and therapeutic efficacy. These strategies can be 
broadly divided into 3 main classes: structural modification of protein, sustained-release 
formulations and modulation to delivery devices/systems. There is a large number of 
ways in which proteins can be modified; first, proteins may be pegylated to increase 
protein solubility and stability and also to reduce proteolysis and immunogenicity. 
However, pegylation can cause a decrease in the in vitro activity of proteins, but 
generally this negative effect can usually be offset in in vivo systems by the increase in 
circulation half-life of the protein. Pegylation may also reduce the binding affinity of 
therapeutic proteins to their cellular targets and alter the bioactivity of the proteins [89]. 
Modification of proteins through glycoengineering methods can also improve the protein 
folding, transport to specific tissues and binding affinity to receptors/targets [114]. 
Conjugation of proteins to other macromolecules such as serum albumin can help to 
increase protein stability in vivo. An example is Albuferon in which interferon alpha is 
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genetically fused to albumin. In primate studies, the rate of clearance of Albuferon was 
approximately 140-fold slower and the half-life 18-fold longer, than for interferon alpha 
[115]. Last, stimuli-sensitive polymers may be used to entrap or bind therapeutic proteins 
to increase their stability during delivery and release them in a regulated fashion. Many 
studies involving glucose-responsive polymers for insulin delivery has been carried out 
(Figure 1.2) [116, 117]. Insulin is first added to polymers with glucose-binding moieties 
for the formation of nanogel/microgels. After administration, when blood glucose level 
rises, insulin will be subjected to competitive binding with glucose molecules and release 




Figure 1.2 Self-Assembly of the glucose-responsive microgel and glucose-sensitive release of 
insulin [116]. 
 
Besides modifying protein structures and drug formulations, alterations can also 
be made to parenteral delivery device. To increase the ease of injections, a variety of 
devices such as prefilled syringes [118], pen devices [119, 120] and needle-free injectors 
[121] have been developed. With the exception of needle-free injectors, the 
pharmacology, toxicity and bioavailability of the proteins are likely to be the same for 
these systems as all of them involve direct injection into the body. As for needle-free 
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injectors, a high-velocity jet is typically used to deliver drugs across the skin into the 
subcutaneous or intramuscular region. These injectors have been used to deliver several 
therapeutic proteins such as insulin [122], growth hormones [122, 123] and 
erythropoietin [124]. One of the main concerns regarding their use is the shear force 
generated, which may be detrimental to protein integrity. Studies involving in vitro 
models have also shown significant variability in jet penetration in relation to the 
mechanical properties of the skin. Other issues include topical irritation, occasional pain 
and bleeding that is associated with the depth of penetration of the jet [121]. 
Another technique that has been extensively explored for delivering drugs into the 
systemic circulation is transdermal delivery. Delivering drugs through the skin is 
favorable as it can help to evade the gastrointestinal first-pass effect and is also more 
psychologically appealing to patients compared to the conventional injection/infusions 
using the hypodermic needle. A major product used for transdermal delivery is the 
transdermal therapeutic system (TTS), popularly known as patches. Despite the ease of 
application, the variety of drugs that can be administered using conventional TTS is 
highly limited. The main obstacle is that a large majority of drugs is unable to permeate 
skin at therapeutic rates due to the barrier imposed by stratum corneum layer of the skin. 
Drugs that can delivered using TTS should have low molecular mass (<500 Da), high 
lipophilicity and high therapeutic activity at a low dose. Therefore, this method is 
unsuitable for delivery of proteins.  
Improvements to transdermal delivery methods have been focused on increasing 
skin permeability via temporary disruption to the structural integrity of stratum corneum. 
Several approaches has been studied, ranging from chemical enhancers [125] to physical 
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methods such as iontophoresis and electroporation [126, 127] and pressure waves 
generated by acoustic systems [128]. The extent of disruptions generated by these 
methods is believed to be nanosized, which allows the transport of small drugs and, in 
some cases, macromolecules, but not sufficiently large to cause damage of clinical 
significance. Iontophoresis involves the application of a low electrical current (~500 
μA/cm2) to the skin, allowing drugs to permeate through a combination of mechanisms: 
electrophoretic driving force, electro-osmotic driving force and transient increase in skin 
permeability. On the other hand, electroporation involves the use of short high-energy 
pulses to disrupt local areas of skin. Transport of drugs through skin has been shown to 
increase by several orders of magnitude with electroporation, with partial reversibility 
within seconds and full reversibility within minutes to hours. Large molecules of several 
thousand kDa can be successfully delivered using this technique [129].  More recently, 
ultrasound has been also used to deliver high molecular mass drugs such as insulin, 
erythropoietin and interferon [128]. This occurs mainly through the generation of 
cavitational events which causes the disruption of stratum corneum [130].  
An alternative approach to the above methods involves creating larger transport 
pathways using arrays of microscopic needles. One of the main advantages of using 
microneedles for transdermal delivery is due to the anatomy of the stratum corneum. As 
this layer of the skin does contain nerves, the administration of drugs in this manner is 
unlikely to cause pain. Both in vitro and in vivo studies have shown that the 
administration of drugs using microneedles into skin can significantly increase 
permeability of small molecule drugs, proteins and nanoparticles [131, 132].  As yet, 
development in transdermal delivery systems has not been extended to treatment of 
34 
cancer. For cancer therapy, this mode of delivery is mostly used for long-term cancer 
pain management by replacing frequent dosing of pain-relievers with transdermal patches 
for sustained release of the drug [133, 134].   
Another non-invasive approach for protein delivery that has also been explored is 
pulmonary delivery. Over decades, the lungs have been recognized as a potential entry-
site for proteins and macromolecular drugs. This is because of the many favorable 
characteristics of the lungs to be used as a drug delivery site. These include low intrinsic 
proteolytic activity, large alveolar absorption area ( about 100 m2), extensive vasculature, 
thin layer alveolar epithelium (0.1–0.2Ǻ) and short distance of air–blood exchange 
passage (15 µm) [135]. There are three commonly used pharmaceutical aerosols: jet or 
ultrasonic nebulizers, metered dose inhalers (MDIs) and dry powder inhalers (DPIs) 
[136]. Most studies on the pulmonary delivery of proteins are in favor of the use of DPIs 
because of the lower risk of protein instability compared to using MDIs and nebulizers. 
Dry-powder insulin inhalers have been used successfully to treat both type I and II 
diabetic patients and provided patients with greater treatment satisfaction than the control 
groups [137, 138]. Interesting, for cancer therapy, nebulization has been used to fabricate 
Aviscumine (recombinant mistletoe lectin) in a pulmonary delivery formulation. This 
protein has been successfully formulated for parenteral injections/infusions and current 
research is directed towards delivering it using alternative, non-invasive delivery systems. 
However, in one of the recent studies reported by Steckel et al., neubulization 
significantly affected protein stability and only 50% of the protein activity was retained 
after the process [139].  
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Besides protein instability, other challenges also exist for the development of 
pulmonary delivery systems. First, the efficiency of pulmonary delivery is inversely 
related to the molecular size of the proteins and the absorption of the macromolecules 
from the lungs into the bloodstream is usually low [140]. Side-effects may arise due to 
the pulmonary therapy. The administration of particulate matters to lungs could 
potentially affect lung function after prolonged duration and patients may also suffer 
from cough related to the therapy. Predictability of therapeutic efficacy from preclinical 
studies is also difficult as the bioavailability of proteins delivered through the pulmonary 
route in humans may differ greatly from animal models [141]. And furthermore, since the 
actual dosage of drug given using inhalers may not be precise, pulmonary delivery would 
be limited to drugs that have broad therapeutic windows. For anti-cancer therapy, studies 
on treatment with common small-molecule anti-cancer drugs have been carried out in 
hope of achieving region-specific delivery to lung tumors. However, such systems often 
met with problems associated with intra-arterial perfusion of organs, such as achieving a 
uniform distribution of the drug throughout the target tissue. Penetrability of the drugs in 
the tumor tissue also varies according to the physical and chemical characteristics of the 
drugs used as well as the tumor cell types [142].  
Box. 1.3 Commonly used pharmaceutical aerosols. 
Nebulizers deliver drugs in the form of inhalable fine mist. Compressed gas or ultrasound may be used to 
convert liquid to aerosol droplets in the respirable size range. Nebulizers are frequently used to deliver 
relatively large volumes of drug solutions and suspensions that cannot be easily formulated into MDI or 
DPI. One of the key concerns for its use in protein delivery is the production of heat during the generation 
of aerosol droplets that may be detrimental to the protein integrity [136]. 
 
MDIs contain therapeutic drugs that are contained in a propellant system, which contains liquefied gas in a 
pressurised container sealed with a metering valve. The drug is delivered as an aerosol spray in a metered 
dose. MDIs are typically inexpensive, portable, low cost and provide reproducible dose of the drug [143]. 
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However, high velocity of the spray may result in significant loss of the drug through impact with 
oropharyngeal areas. 
 
DPIs deliver drugs as clouds of dry and fine particulates. DPIs are inexpensive, portable, propellant-free 
and show enhanced stability of proteins as a due to storage in moisture-free state. Thus, they may be more 





Amongst the various non-invasive modes of delivery, oral formulations of anti-
cancer drugs have been most successful in clinical application. Many emerging oral 
pharmaceuticals are new formulations of drugs developed from those typically given 
through parenteral methods. Currently, some of the most widely used drugs delivered 
through the oral route are 6-mercaptopurine, methotrexate and busulphan in patients with 
leukaemia and lymphoma. Oral formulation of topotecan has shown similar therapeutic 
efficacy to parenteral administrations in small cell lung cancer and has better toxicity 
profile with less neutropenia [145, 146]. Despite the benefits that oral chemotherapy 
provides, such as ease of application and reduced cost, conventional infusion/injections 
still dominates over oral delivery. One of the main reasons is that these drugs are usually 
low-priced ‘generic drugs’ that have not been a high sales priority for the major 
pharmaceutical companies. Another reason could be the perception that both clinicians 
and drug developers generally have whereby chemotherapy is more effective when given 
through the parenteral route [147].  
 
1.3.5 Proteins used in the studies (i.e. Lectin-A, TRAIL and Herceptin)  
Various proteins have been used in this thesis at different phases to evaluate the 
protein delivery capabilities of P(MDS-co-CES) carriers. At the beginning, the focus has 
been placed on the accessing the prospect of using these nanoparticles as carriers for the 
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delivery of proteins. A model cytotoxic protein, Lectin-A (MW: 30.7 kDa) is selected as 
its main cytotoxic action is via the inactivation of ribosome in the cytosol, which in turn 
disrupts the cellular translation during protein biosynthesis [148-150]. Lectin-A, by itself, 
is unable to enter cells without assistance from delivery carriers but will induce 
significant cytotoxicity when it gets delivered into the cytosol. Therefore, in vitro 
cytotoxicity resulting from Lectin-A chain delivery is used as an indicator of the protein 
delivery efficiency of the nanoparticles.  
In the later phase, the study was then moved on to the codelivery of another 
therapeutic protein, i.e. recombinant human tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL, MW: 20 kDa), together with an anticancer drug. TRAIL is 
selected as a promising anticancer protein as it is selectively toxic to cancer cells and 
only exerts limited toxicity to normal tissues in vivo. The core/shell structure of the 
P(MDS-co-CES) micelles allows the physical entrapment of hydrophobic drugs in the 
core and also the binding to proteins on the surface of the micelles.  
With the codelivery system in place, it became desirable to enhance the 
therapeutic index of the nanocarriers through means of active targeting. A therapeutic 
antibody, Herceptin (MW: 145 kDa), targeted against human epidermal growth factor 
receptor-2, is codelivered with an anticancer drug, paclitaxel. Herceptin is selected for its 
specificity towards the HER-overexpressing cells and also for its availability as a FDA –
approved therapeutic mAB. The binding of Herceptin onto the surface of the drug-loaded 
carriers can confer HER2-receptor specificity to the delivery system and sensitize the 
HER2+ cancer cells to anticancer drug treatment.  
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1.4 Nanoparticulate drug delivery systems 
One of the main challenges in the development of anti-cancer drug formulations is 
the delivery of the drugs with sufficiently high bioavailability so as to achieve the 
therapeutic intention [5]. As many anti-cancer agents are hydrophobic, clinical 
administration of these drugs typically require dissolution using organic solvents. For 
instance, clinical application of paclitaxel (Pac) has been mostly hindered by its 
tremendously low aqueous solubility (0.3 µg/ml in water) [151]. This restricts its 
administration to a formulation comprising of 50:50 mixture of Cremophor EL 
(polyethoxylated castor oil):absolute ethanol. However, hypersensitivity reactions such as 
rashes and flushing occur in 41-44% of patients and also potentially-fatal reactions in 1.5-
3%, even in those with cortisteriods premedication [152-154]. To reduce the dependence 
on this formulation, attempts have been made to modify the chemical structural of the 
drugs to increase their solubility, but limited success has been achieved [155-157].  
Besides poor solubility, other challenges include the lack of target selectivity and 
poor biodistribution of small molecule drugs, whereby the anti-cancer agents are 
distributed non-specifically in the body and affect both cancerous and normal cells. This 
leads to dose-limiting side effects and lowers the dose-achievable in the cancer tissue. 
Small molecule drugs are also subjected to rapid plasma clearance and degradation in 
vivo, which will jeopardize the effectiveness of the therapy.  
Over the past few decades, the development of drug delivery systems has been 
extensively explored as carriers of anti-cancer agents to help improve the 
pharmacokinetics and biodistribution. In relation to the context of my investigation, I will 
discuss the use of nanoparticles, as drug delivery systems. These nanosized carriers can 
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be made using a variety of materials including polymers (polymeric nanoparticles, 
micelles, or dendrimers), lipids (liposomes), viruses (viral nanoparticles), and 
organometallic compound (nanotubes). The key features of these nanoparticles and some 
examples are given in Table 1.4.  
Table 1.4 Types and examples of nanoparticles for delivery of therapeutics agents. 
Type of 
Nanoparticles Key features Examples Ref. 
a) Amphiphilic, self-assemble into 
nanoparticles 
Doxorubicin-loaded PEG-aspartic 
acid micelles (NK911) 
[158] 
b) Capacity to encapsulate 
hydrophobic drugs 
Pac-loaded PEG-PLA micelles 
(Genexol-PM) 
[159, 160] 
c) Versatility in structural 
manipulation for drug loading and 
release  
Doxorubicin-loaded PEG-PLGA 




d) Surface modification possible, 
e.g. PEGylation, targeting moieties 
  
 e) Relatively easy preparation      
    
Polymer-drug 
conjugates 
a) Water soluble HPMA copolymer–Doxorubicin 
(PK1) 
[162] 
 b) Versatility in structural 





 c) Possibility to include 
bioresponsive elements 
Polyglutamate–Pac (XYOTAX) [164] 
    
Dendrimers a) Water soluble Methotrexate-loaded PAMAM 
dendrimers 
[165] 
 b) Uniform and monodisperse 5-fluorouracil-loaded 
Folate−PEG−PAMAM dendrimers 
[166] 
 c) High stability due to covalent 
bonds 
  
 d) High density of functional groups   
    
Liposomes a) Biocompatible Liposomal Doxorubicin  (Myocet) [167] 
 b) Typically low toxicity PEG–Liposomal Doxorubicin (Doxil) [168] 
 c) Surface modification possible, 
e.g. PEGylation, targeting moieties 




    
Viral 
nanoparticles 
a) High specificity Viral capsid–DNA aptamer  [171] 
 b) Biocompatible Folate-PEG-Cowpea mosaic virus for 
DNA delivery 
[172] 
 c) Efficient cellular uptake and 
release of cargo 
  





    
Carbon 
nanotubes 
a) Water soluble and biocompatible 
through chemical modification 




 b) Capacity to encapsulate drugs in hollow inner space 
SWNT–Pac conjugate [174] 
   Doxorubicin-loaded SWNTs [175] 
 
1.4.1 Rationale of using nanoparticles 
The use of nanoparticles as drug delivery systems offers several advantages as 
compared to using conventional free drugs. First, they serve as reservoirs to deliver 
hydrophobic anti-cancer drugs without organic solvents. Second, there is enormous 
flexibility in tuning the drug loading content and release rates by modifying the chemical 
nature of the nanoparticles. Third, functionalization of the carriers can carried out for the 
attachment of bioresponsive elements or targeting moieties. Fourth, nanoparticles can 
help to improve the pharmacokinetics of the drugs and reduce clearance. Furthermore, 
nanoparticles can have better tissue specificity than free drugs as they can accumulate 
within tumors by both passive and active targeting. When conventional anti-cancer agents 
are administered into the body, they are distributed nonspecifically in the body and they 
affect both cancerous and normal cells. The lack of target-specificity is a major barrier 
that limits the dose achievable within the tumor, and this result in suboptimal treatment 
with undesirable side effects. In other scenarios, efforts made in attempt to improve 
selectivity through the development of molecular targeted therapy [38].  However, the 
gradual lose of therapeutic effectiveness of such targeted agents is inevitable during 
clinical treatment due to the emergence of multi-drug resistance (MDR) [176, 177]. 
Nanoparticles have been reported to overcome MDR, as they enter cells via endocytosis, 
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thereby bypassing the recognition of P-glycoprotein efflux system  one of the main 
contributors of drug resistance [178]. 
 
1.4.2 Size and surface characteristics 
One of the major reasons to develop nanoparticles as drug delivery carriers is to 
achieve longevity in blood circulation. Extended plasma half-life and delay in clearance 
will enable the therapeutic agent to be released from the carriers in a sustainable fashion 
without being eliminated and this will in turn; increase the chances of interaction with its 
therapeutic target. After administration into the bloodstream, opsonization (binding of 
serum proteins onto particles to identify as being foreign to the bodily system) of 
nanoparticles occurs and the particles become internalized by the macrophages of the 
RES (consisting mainly of liver, spleen, lungs and bone marrow). This results in a 
significant loss of nanoparticles from the circulation and is dependent on their size and 
surface characteristics. Small size and/or hydrophilic surfaces are necessary to reduce 
opsonization and elimination. The fate of injected nanoparticles can be controlled by 
adjusting their size and surface characteristics. 
Size: The size of nanoparticles should lie within an optimal range whereby they 
should be sufficiently small enough to escape capture by the RES and also large enough 
to prevent renal clearance (~ 5.5 nm [179]) as well as leakage back into the blood vessels 
after entry into the tumor tissue. By modifying the chemical structure of the carriers (e.g. 
hydrophobic/hydrophilic composition, block lengths), the size of the nanoparticles can be 
adjusted.   
Surface characteristics: The half-life and clearance of the nanoparticles are also 
strongly influenced by the surface characteristics of the nanoparticles. It has been 
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established in  the early seventies that particles with hydrophilic surfaces tend to remain 
the circulation longer than those that are more hydrophobic [180]. To increase the 
hydrophilicity of the nanoparticles, hydrophilic groups such as PEG can either be 
chemically added or physically adsorbed onto the nanoparticle surface [181, 182].  
 
1.4.3 Drug loading 
Another important attribute of a successful drug delivery system is to have a high 
drug loading capacity. This will allow more drugs to be delivered per administration and 
thereby, lowering the number of administrations and amount of nanocarriers required. In 
general, small molecule drugs can be loaded into nanoparticles via two different ways  
either by chemical conjugation of the drugs to the carriers or by physical entrapment of 
the drugs into the carriers through non-covalent interactions. The incorporation of the 
drug can be carried out during the process of nanoparticle fabrication or after the 
nanoparticles have been fabricated by immersing them in the drug solutions. 
 In terms of chemical conjugation of anti-cancer agents with nanocarriers, it is 
necessary to have functional groups that are accessible for the reactions to occur. For 
drugs that do not have functional groups available, derivative compounds and chemical 
linkers can be used. Careful selection of appropriate linkers is necessary for the creation 
of polymeric prodrugs remain inert during circulation but allows the drugs to be released 
when the targeted sites are reached. For instance, acid labile linkers such cis-aconityl, 
hydrazone and acetal have been widely used for conjugation of doxorubicin to polymers 
such as N-(2-hydroxypropyl)–methacrylamide copolymer (HPMA) [183], while ester 
linkages has been utilized in poly-(L)-glutamic acid-Pac conjugates (CT-2103) [184].   
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As for physical entrapment of drugs, the drug loading capacity in polymeric 
micellar nanoparticles via is dependent on various factors, such as the interaction 
between the polymer and drug and the length of repeating units in the polymer. 
Increasing the length of polymers tend to increase the association between the carrier and 
the drug [185] but may affect the aggregation behaviour of micelles. These results 
indicate that there is a need to optimize the length of polymer used for the drug 
entrapment. Other factors include the proportion of the core and shell-forming blocks in 
the copolymer, as well as the compatibility between the micellar core and the solubilizate 
(in this case, drug) [186, 187], assessed by the Flory–Huggins interaction parameter (χsp):  
χsp=(δs−δp)2Vs/RT  
where δs and δp are the Scatchard–Hildebrand solubility parameter of the solubilizate and 
the core-forming polymer, respectively, Vs is the molar volume of the solubilizate, R is 
the gas constant and T the Kelvin temperature. Higher compatibility is indicated by lower 
χsp values. However, the Flory–Huggins interaction parameter is based on the regular 
solution theory and is unable to take into account the specific interactions between drugs 
and polymers. Furthermore, since polymers contain several different components, it is 
difficult to obtain of the Hildebrand–Scatchard solubility parameter of each component. 
 
1.4.4 Drug release 
Controlled drug release is an important feature for the development of useful drug 
delivery system. Nanocarriers should provide protection of its therapeutic load against 
leakage and degradation in circulation while enabling a sufficiently high local drug 
bioavailability in the target tissue. The release kinetics is dependent on several factors: 
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the rate of dissociation between the drug and the nanoparticles, breakdown of the 
linkages (in the case of polymer-drug conjugates), diffusion through the nanoparticle core 
and corona, and degradation/erosion of the carriers. Most drugs exhibit two-phase-release 
profiles, of which the drug is released at a relatively rapid rate in the early phase followed 
by a gradual and sustained release in the later phase. For some nanoparticle systems, 
there may be an initial burst release of drugs due to the dissociation of drug molecules 
that are weakly bound to the nanoparticle surface or corona. Following this, the drug 
release kinetics is mostly determined by the rate of diffusion across the nanoparticle 
barrier layer.  
The rate of drug release is greatly influenced by both the physical and chemical 
properties of the carriers. Several reports have shown that nanoparticles comprising of 
higher molecular weight polymers with larger particle size generally can impede drug 
diffusion across the nanoparticle barrier and lower the rate of drug release. Interactions 
between the drugs and hydrophobic segments of the carrier may also affect drug release 
rates [188]. For example, Oh et al. reported the release of doxorubicin from poly(γ-
benzyl-(L)-glutamate)/poly(ethylene oxide) (PBLG/PEO) polymeric nanoparticles with 
constant PEO length was dependent on the  hydrophobic PBLG content. Significantly 
slower drug release and lesser cumulative release was observed over 24 hrs for the 
polymer with 60 mole% PBLB compared to those with 40 and 12.5 mole% [189]. 
 
1.4.5 Passive targeting  
Nanoparticles typically have size ranging from 5 to 200 nm. The lower bound is 
based on the sieving coefficients for the glomerular capillary wall, which gives an 
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estimate for the threshold for renal elimination to be ~5 nm (diameter) [190]. The upper 
bound of particle size is mostly dependent on the microvascular permeability in tumors 
(~ 400 to 600 nm) [191]. Particles within the appropriate size range can preferentially 
target and accumulate in the tumor sites through the “Enhanced Permeation and 
Retention (EPR)” effect. This passive targeting phenomenon was first reported by Maeda 
et al. [192], who attributed it to two factors: the disorganized and leaky tumor vasculature 
which leads to hyperpermeability to macromolecules, alongside with poor lymphatic 
drainage in the tumor tissue to prevent escape of these macromolecules after entry. In 
greater detail, as fast-growing tumor cells reach a size of 2-3 mm, angiogenesis is 
induced to accommodate the increasing demand for oxygen and nutrients. 
Neovascularization or rerouting of existing blood vessels near the tumor tissue occurs to 
supply the tumor needs. As a result of the imbalance of angiogenic regulators such as 
growth factors and matrix metalloproteinases, tumor blood vessels are structurally and 
functionally abnormal. In contrast to normal blood vessels, tumor vessels are highly 
disorganized, defective or leaky with gap sizes varying from 100 nm to 2 µm [193, 194] 
as the endothelial cells are poorly aligned with large fenestrations [195].  This enables 
nanoparticles to escape easily from the blood stream and accumulate inside tumor tissue, 
while re-entry back into the bloodstream is prevented by the defective lymphatic drainage 
in the tumor [196]. With the appropriate drug carriers, the EPR effect can bring about 10 
to 100 times higher tumor concentration of the therapeutic drug than that resulting from 
free drug administration [197]. 
Passive targeting can also be achieved by making use of certain properties of the 
nanoparticles, such as cationicity. Positively-charged liposomes have been shown to have 
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higher distribution into tumors as a result of the electrostatic interaction with negatively-
charged phospholipid headgroups expressed at relatively higher levels on tumor 
endothelial cells than normal endothelial cells [198-200]. 
 
1.4.6 Active targeting  
Besides passive targeting, chemotherapeutic agents can also be delivered to tumor 
cells through an active approach. The surface of nanoparticles can be functionalized and 
attached with ligands that can specifically recognize receptors expressed on the tumor 
cells. There are some criteria that need to be fulfilled in order to achieve effective active 
targeting of nanoparticles. First, the selected antigens and receptors surface should be 
expressed abundantly on tumor cells with little or no expression on normal cells. Second, 
the expression should be homogeneously expressed on all cells of the targeted tumor 
[201]. Last, there should not be any release of cell-surface antigens and receptors into the 
blood circulation. For instance, folate [202, 203], lectin/carbohydrate moieties and 
antibody/antibody-fragments are some of the types of ligands used for active targeting 
(Box. 1.4). 
 The binding of ligands to their cellular antigens/receptors will trigger 
internalization of the conjugates via receptor-mediated endocytosis. This mode of cellular 
entry is target-selective and useful for overcoming MDR by escaping recognition by 
efflux pump proteins on the cell surface [204].  However, in endocytotic processes, the 
recycling of endosomes back to the cell membrane may impede the efficient transport of 
the drug-loaded nanocarriers to the cytoplasm [205]. To prevent this, the release of drugs 
can be improved by disrupting the endosomal vesicles through the incorporation of 
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proton-buffering groups into the carrier structures. Subsequently, the endosomes be will 
destabilized via the ‘proton-sponge effect’ in the acidic microenvironment of the vesicles 
[206, 207], resulting in the release of the therapeutic drugs into the cytoplasm.  
 
Box. 1.4 Affinity groups for active targeting. 
Interactions between lectins and carbohydrate enable active targeting via the addition of carbohydrate 
moieties to nanoparticles that recognize specific lectins on the cells (direct lectin targeting) or the 
incorporation of lectins into nanoparticles that recognize cell surface carbohydrates (reverse lectin 
targeting). For instance, the interaction between galactose and the asialoglycoprotein receptor expressed at 
high levels in hepatocytes has been exploited in several liver cancer targeting systems [208, 209]. 
Transferrin, a glycoprotein that recognizes Transferrin receptors that are overexpressed in several cancer 
cell types,  have also been incorporated into nanoparticle systems to deliver anti-cancer agents [210, 211]. 
However, the main challenge in these systems is that the interaction between carbohydrates and lectins is 
directed to entire organs. Therefore, the therapeutic agents will not only localize at the tumor sites but the 
normal tissues in the organ as well [212], and serious considerations have to be made to minimize damage 
to neighbouring tissues.  
 
Interactions between antibody/antibody fragments and their complementary cellular receptors allow 
targeted delivery of the nanoparticles to the cancer tissue.  Once the ligand-receptor interactions are 
achieved, the nanoparticles will be internalized by the cells via receptor-mediated endocytosis. These 
interactions can have positive effects on therapeutic activities either by enhancing the tumor localization or 
cellular uptake of these nanoparticles [213]. Besides targeting anti-cancer drugs to cancer cells, some 
antibodies (e.g. Herceptin [214, 215] also have inherent therapeutic properties which can bring about 
additive or synergistic interactions when delivered together to the cells. Currently, antibody fragments are 
more commonly used as targeting moieties for conjugation to nanosized drug carriers as they are smaller in 
size than antibodies. Furthermore, they do not contain the Fc effector region that could generate undesirable 
interaction with normal cells, and can lead to premature elimination through phagocytosis [216].  
 
Angiogenesis-associated targeting is useful in developing targeted drug delivery systems to tumors. The 
advantages of targeting tumor blood vessels have been described by Kumar et al, In brief, first, the 
endothelial cells of angiogenic vessels are less likely to acquire phenotypic changes and drug resistance. 
Second, the physiological barriers that exist for drug delivery into tumors can be evaded by targeting the 
blood vessels. Third, the destruction of the tumor vasculature will greatly reduce the oxygen and nutrients 
supply to the tumor cells, hence, impeding the growth of the tumor. Last, such systems can be used 
unanimously for most tumors [217].  
______________________________________________________________________________________ 
 
1.4.7 Augmentation of drug delivery 
Structural and physiological disparities exist between tumor and normal tissues, 
and these differences have been explored to improve the therapeutic efficacy of drug 
delivery systems. For instance, compounds that affect blood vessels constriction/dilation 
can be added to nanocarriers to enhance vascular permeability and improve 
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biodistribution of drugs into tumor via the EPR effect. Vascular density in tumor tissues 
is typically higher than normal tissues and unlike normal blood vessels; tumor blood 
vessels do not have a smooth-muscle layer to regulate blood pressure and flow. When 
vasoconstrictor such as angiotensin-II (AT-II) is used to induce hypertension in normal 
blood vessels, the smooth-muscle layer constricts to maintain constant blood flow volume 
at higher blood pressure and flow rate. On the contrary, in AT-II-induced hypertension, 
tumor blood vessels cannot regulate the blood flow volume due to the lack of the smooth-
muscle layer. As a result, the blood flow volume will increase as the blood pressure 
increases. In a report by Suzuki et al., tumor blood flow volume can increase 2–6 times 
by infusing tumor-bearing rats with AT-II [47]. The higher amount of blood volume 
reaching the tumor can bring about greater distribution and accumulation of drugs in the 
tumor tissue. At the same time, AT-II will induce constriction of normal blood vessels 
and tightening of  endothelial gaps junctions which will then limit the extravasation of 
nanoparticles, leading to significantly lower amount of drug reaching healthy tissues 
[196].  
Besides vasoconstriction, other means of modulating tumor blood vessels has also 
been explored. As such, vasodilators have been used to enhance vascular permeability by 
increasing the size of endothelial gaps of vessels. For instance, Bradykinin (BK), which is 
an endogenous vasodilator involved in tumor angiogenesis [218] and is upregulated in 
many tumors, can be degraded by angiotensin-converting enzyme (ACE). Therefore, the 
use of ACE inhibitors will increase the local concentration of BK in the tumor and 
enhance the delivery of nanocarriers to the tumor tissues [196].  
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1.4.8 Protein and peptide delivery using nanoparticles 
 As discussed earlier in section 1.3, there are many advantages of using proteins 
and peptides as therapeutics. Amongst which, the most attractive factors include the high 
specificity of target interactions and reduced risk of interference to normal physiological 
processes. Furthermore, the advancements in protein expression technology have made 
these compounds available on a larger and more economic scale than in the past. 
However, research progress in protein has far outpaced the ability to deliver these 
compounds effectively using delivery systems. Currently, the use of proteins/peptides for 
medical treatment has been mostly limited by their susceptibility to degradation and short 
plasma half-life. In this pursuit, the nanosized delivery systems have been explored for 
improving the stability of proteins against enzymatic degradation and thus, prolonging 
the lifespan of these therapeutic agents in circulation. 
 
1.4.8.1 Protein loading into nanoparticles 
For the preparation of protein-loaded nanoparticles, it is necessary to ensure that the 
therapeutic protein remains stable and subsequent dissociation from the nanoparticles is 
unhindered. Based on the preparation method chosen, the therapeutic agent can be 
entrapped in the polymer matrix, encapsulated in a hydrophobic core of micelles or 
adsorbed onto the particle surface. The methods that have been explored for protein 
loading include emulsification solvent evaporation [219], emulsion polymerization [220], 
nanoprecipitation [221] and salting out techniques [222]. As organic solvents are used in 
all the above procedures, a major challenge faced is the inevitable detrimental effects 
they will have on the stability and activity of the loaded protein. For instance, the w/o/w 
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double emulsion method has been widely used for encapsulating protein drugs into both 
nano- and microparticles. However, this technique not only requires the use of organic 
solvents, extended shearing/stirring rates and/or sonication [223-225] is also required for 
the fabrication of the particles. Subjecting proteins to such harsh conditions will 
inevitably lead to considerable loss in protein activity. In addition, it has also been 
reported that that such methods are also more suitable for loading compounds with 
hydrophobic nature to reduce drug leakage towards the outer aqueous medium [221]. In a 
study conducted by Barichello et. al., they observed that the encapsulation efficiency 
reduces with drug hydrophilicity and insulin, which is insoluble in organic solvents, was 
found be bound to the PLGA nanoparticles mostly via surface adsorption rather than 
encapsulation within the carriers [226].  
 Protein adsorption to nanoparticles can occur via electrostatic interactions, van 
der Waals forces and hydrogen bonding [227]. To enhance binding, nanoparticles with 
surface charges may be used. When proteins are added to charged nanoparticles, both the 
pH and ionic strength of the incubation medium can greatly affect the interaction and 
strength of association between the proteins and its carrier. pH influences the zeta 
potential of the both the proteins and nanoparticles and therefore, the charge 
neutralization and redistribution between the polymeric surface and protein molecule. 
Changes in ionic strength of the medium will affect the shielding effect on surfaces 
charges and the electrostatic interactions between the counter ions of the nanoparticles 
and protein [227]. Depending on the ionic strength and nature of the proteins, 
hydrophobicity of the polymeric carriers may also act as a governing parameter for 
protein binding. In a report by Bayraktar et al., they have suggested that the facial 
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specificity in binding of cytochrome c to carboxylate-functionalized nanoparticles is 
related to the balance between electrostatic association as well as hydrophobic 
interactions [228]. 
 In some cases, binding between proteins and nanocarriers may not occur due to 
insufficient non-coulombic interactions or electrostatic repulsion between like-charges on 
the two entities. For such systems, chemical means can be used to manipulate the charge 
moieties to enable binding. For instance, Kataoka et al. [229] have reported the use of 
citraconic anhydride to convert positively-charged primary amines of polymeric 
nanoparticles to citraconic amides.  The presence of carboxylate groups on the amides 
will confer negative charges to the nanoparticle and will allow binding with basic 
proteins.  
 
1.4.8.2 Amphiphilic polymers used in protein/drug delivery systems 
 Research efforts made in the development of protein drug delivery have been 
mostly driven by the need to increase the bioavailability of therapeutic proteins by 
improving their stability. Various strategies that aim to prevent protein degradation as 
well as enhancing distribution to target sites have been explored. Through recombinant 
techniques, genetic fusions of protein/peptide ligands such as antibody fragments to 
therapeutic proteins [230, 231] have been created to alter the biodistribution of the native 
protein. For instance, in a study conducted by Pardridge and his co-workers, brain 
derived neurotrophic factor (BDNF) was fused to heavy chain of a chimeric monoclonal 
antibody that recognizes human insulin receptors (HIRMAb). The resultant HIRMAb-
BDNF fusion protein had >100-fold longer mean residence time than native BDNF and 
52 
the interaction with HIR also enabled the therapeutic protein to cross the blood brain 
barrier [232]. Similar modification to proteins can also be made through chemical means 
whereby ligands/polymers can be covalently attached to free amine [233] or thiol  [234] 
groups of proteins to produce conjugates with improved stability and tissue localization. 
Proteins-polymer conjugate systems have shown to increase protein stability and this can 
be attributed to enhanced protein surface activity, steric hindrance of protein-protein 
interactions, and increased viscosity limiting protein structural movement.  
 
Biodegradable polymers 
 Besides enhancing protein stability, other properties such as solubility, 
biocompatibility and protein activity can also be adjusted through the chemical 
conjugation with synthetic polymers [235]. For therapeutic applications, there is an 
inclination towards the use of biodegradable polymers as the degradable products can be 
cleared from the body and are more likely to bring about improved patient compliance. 
Such polymers can be degraded by various ways, including hydrolysis (e.g. PLGA), 
solubilization (e.g. pluronics), bulk or surface erosion, or cleavage of labile bonds in the 
bioconjugates. There are several types of cleavable linkages that have been used for the 
formation of biodegradable polymers. In ascending orders of relative hydrolysis rates 
under physiological conditions: 
 
 
Figure 1.3 Labile bonds arranged in order of sensitivity to hydrolysis [235]. 
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Besides the sensitivity of cleavage bonds to hydrolysis, polymer morphology is also 
another influencing factor in the degradability of the polymers.  Hence, the relative rates 
at which polymers degrade cannot be predicted solely from the hydrolytic susceptibility 
of these bonds. 
 
Stimuli-responsive polymers 
 Polymers that exhibit changes in behavior and physical properties have also been 
explored as they can impart stimuli-sensitivity to the delivery systems. In cancer research, 
the common stimuli involved are temperature and pH as differences in these two 
environmental factors exist between normal and tumour tissues. The latter has a slightly 
higher local temperature [236] and lower extracellular pH (6.8–7.2) compared to normal 
tissue (pH ~ 7.4) [237]. Therefore, the incorporation of stimuli-responsive polymers into 
drug delivery systems can assist in the selection of tumour against normal tissue and 
enable better targeting efficiency. For instance, one of the most widely studied thermo-
responsive polymers is poly(N-isopropylacrylamide) (PNIPAM) [238-240], which 
undergoes a exhibit a coil to globule transition at 32 oC, changing from a hydrophilic 
state below this temperature to a hydrophobic state above it. PNIPAM becomes insoluble 
upon heating beyond 32 oC and this temperature is termed as the lower critical solution 
temperature (LCST). Other such polymers include those that contain N,N-
diethylacrylamide (DEAM) [241], methylvinylether (MVE) [242] and N-
vinylcaprolactam (NVCl) [243]. In addition, there are also polymer systems which 
become soluble upon heating, have an upper critical solution temperature (UCST). LCST 
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and UCST systems are not limited to aqueous solvent environment, but importantly, only 
polymers that are soluble in aqueous conditions and have transition temperature in 
physiologically acceptable range (~20–40oC) are of interest for biomedical applications 
[244]. The temperature at which the transition occurs depends on various environmental 
factors such as the presence of surfactants, co-solvents and salt concentration [245]. 
Another way to alter the transition temperature is by changing the 
hydrophilic/hydrophobic balance of the polymer by copolymerization with a second 
monomer. Co-polymerizing with hydrophilic lowers the LCST and vice versa for 
hydrophobic monomers [246, 247]. In the case of drug delivery, increasing the precision 
of drug release can be done by in co-polymerizing both thermo- and pH-responsive 
monomers to create a dual-responsive system. 
 
Physical interaction 
Polymer systems have been widely explored as drug delivery agents and have 
demonstrated great potential as both chemical conjugates [248-251] or as physical 
carriers [252-255], mostly for small molecule drugs. In consideration of the delicate 
nature of proteins, chemical conjugation of polymers to proteins may be less preferential 
as the modification of protein structure may run into risks of changes to folding and in 
turn, the loss of protein specificity and activity.  Instead, polymers may serve well as 
carriers of therapeutic proteins through various modes of physical interaction (as 
mentioned in section 1.4.5.1). This will more likely ensure that the folding structure of 
proteins is preserved and reduce any losses of protein integrity. For example, 
nanoparticles fabricated from polymers such as chitosan [256, 257] and poly(lactide-co-
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glycolide) (PLGA) [258, 259] have been employed in many studies involving protein 
delivery. Such polymeric carriers utilize non-covalent interactions for protein adsorption 
which can prevent alterations to native protein structure. Importantly, they also protect 
the therapeutic proteins from degradation [260] and can also enable tunability of protein 
loading and release properties [256] of the delivery system through modification of 
polymer structures. 
 
Amphiphilic copolymers used for therapeutic codelivery 
 Over the recent years, there has been a growing interest on the use of amphiphilic 
polymers to codeliver multiple therapeutic agents in a single carrier as more researchers 
recognize the appeal of targeting several oncogenic molecules for cooperative therapeutic 
effects.  
My lab was one of the earliest to report the use of polymeric nanoparticles to 
codeliver therapeutic combinations for cancer treatment. A cationic amphiphilic 
copolymer, poly{(N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido 
ethyl) methyl bis(ethylene) ammonium bromide] sebacate} (P(MDS-co-CES)) has been 
synthesized by my previous lab member (Y. Wang) and has been successfully used for 
the codelivery of nucleic acids (DNA and siRNA) and anticancer drugs [261-264]. This 
polymer contains an amine-containing polyester main chain with cholesterol pendant 
groups. The amphiphilic structure enables it to self-assemble to form micelles with a 
core/shell structure. Such structure allows for the physical encapsulation of hydrophobic 
drugs within the core and the binding of hydrophilic biomolecules to the surface of the 
micelles.  
56 
Physical characterization of P(MDS-co-CES) shows that it has a low Critical 
Micelle Concentration (CMC) of ~1.9 mg/L which indicates good particle stability in 
extensive dilute conditions such as the bloodstream. Gel electrophoresis assays have 
shown that these cationic nanoparticles have excellent nucleic acids binding capacity and 
are able to induce high in vitro gene transfection. Animal studies conducted with the 
codelivery of Interleukin-12 gene and Paclitaxel (Pac) using the P(MDS-co-CES) 
nanoparticles displayed significant enhancement in tumor reduction compared to the 
individual therapeutic agents in 4T1-tumor bearing mice.  
In other earlier work on codelivery, in 2007, Bae Y.H. and his co-workers 
reported that the use of branched poly(ε-caprolactone) (PCL) grafted branched 
polyethylenimine (PEI) [265] to form nanoparticles that can encapsulate doxorubicin. 
And at the same time, these nanoparticles can deliver luciferase gene and induce 
luciferase expression on liver cancer cells.  
The codelivery of small molecule drugs has also been reported. In 2009, Panyam 
J. et al. [266] published an article on the codelivery of Paclitaxel and p-glycoprotein 
inhibitor which led to higher cellular accumulation of the anticancer drug and reduction 
in tumor growth. One of the latest developments in 2011 is on the use of dendritic 
polyamines conjugated with β-cyclodextrin to improve the solubility of hydrophobic 
drugs while the cationic amine component binds to Epidermal Growth Factor (EGFR) 
siRNA. This combination was delivered to brain tumor cells which overexpress the 
EGFR receptors and enhancement in cell death was reported [267].  
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1.5 Objectives and scope of the research 
 
The ultimate goal of my study is to develop multifunctional co-delivery system 
from self-assembled polymeric core/shell nanoparticles that can be used ubiquitously for 
the simultaneous delivery of both anti-cancer drug and therapeutic proteins. Initial work 
has been started based on the hypothesis that amphiphilic polymers can enable the 
loading of both hydrophobic drugs and therapeutic proteins in a single nanosized 
therapeutic system and codeliver them together to cancer cells for enhanced anticancer 
effects. Investigations have been carried out progressively to understand various aspects 
of delivery vehicle.  Prior to to my research, the polymer P(MDS-co-CES) has been 
synthesized by my previous lab member, Wang Y., [261-264].  The synthetic chemistry 
and characterization of P(MDS-co-CES) is described in Section 2.2 and Appendix I.  
It is known that physical properties of nanoparticles such as size and charge will 
greatly influence the biocompatibility and biodistribution of the drug delivery systems to 
different organs.  Therefore, at the initial phase, it is important to characterize the 
polymeric nanoparticle according to their particle size and zeta potential. To understand 
the capacity of these micelles to delivery therapeutic agents of different nature (i.e. small 
molecule drugs and proteins– molecular size and hydrophobicity/ hydrophilicity), 
separate assessments have been carried out to evaluation of their protein binding capacity 
as well as hydrophobic drug encapsulation efficiency and release behavior.  
In order for the polymeric nanoparticles to function effectively as delivery 
vehicles, it is essential that they are biocompatible and can remain stable in physiological 
conditions. Size measurements of the nanoparticles are performed in physiologically-
simulating conditions to investigate any changes in physical stability with time. In vitro 
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cell culture studies are conducted to evaluate the cytotoxicity of these micelles and in 
vivo studies in mice model are carried out to assess the dose-related physiological effects. 
Next, a model protein, Lectin-A (MW: 30.7 kDa), is used for the initial study to 
evaluate the delivery efficiency of the nanoparticles. Lectin-A is unable to enter into cells 
without aid from delivery carriers but can induce significant cytotoxic when it is 
delivered intracellularly. Hence, in vitro cytotoxicity induced by Lectin-A delivery can be 
used as an indication of the protein delivery efficiency of the nanoparticles. Comparisons 
are also made against other commercially-available protein delivery agents such as 
BioPorter and ProJect according to the degree of cytotoxicity resulting from the different 
systems.  
Combination therapy with two or more drugs in has been widely reported to show 
great improvements in cancer treatment efficacy and lower risk of multidrug resistance 
development. However, current treatment regimens are typically developed using free 
drugs without delivery carriers and may not be able to bring about the best possible 
therapeutic efficacy. In my study, one of the key aspects is to investigate the possibility 
of using polymeric micelles as co-delivery vehicles of anti-cancer drugs and proteins to 
impede cancer growth. From there, I will move on to delivering another therapeutic 
protein of similar molecular weight, i.e. recombinant human tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL, MW: 20 kDa) and anti-cancer drugs simultaneously. 
The main rationale for using TRAIL is because of its advantageous cytotoxic selectivity 
towards cancer cells with limited toxicity to normal tissues when introduced in vivo [268, 
269]. Different delivery systems consisting of TRAIL-polymeric nanoparticles loaded 







systems is investigated in cancer cells with different degrees of TRAIL-sensitivity.  Dox-
loaded P(MDS-co-CES) nanoparticle/TRAIL complexes is used for treatment against 
both wild type and TRAIL-resistant SW480 cells and cytotoxicity studies is carried out to 
evaluate synergy in therapeutic effects. Comparison is made against free drug 
combinations to evaluate the differences in therapeutic effectiveness. To determine if the 
co-delivery systems exhibit unspecific cytotoxicity against non-cancerous cells, WI38, a 
human lung fibroblast cell line is used as a representative cell line for in vitro cell culture 
studies.  
The final aim of this study is to develop a targeted delivery system that can 
simultaneously deliver both anti-cancer drug and proteins (Fig. 1.4) to cancer tissues. 
This is because targeted delivery of proapoptotic molecules to specific sites is likely to 
enable higher therapeutic effectiveness and lower the risk of damaging normal tissues in 
the body. A therapeutic antibody, Herceptin, was chosen as it can recognize HER2-
receptors that are found to be overexpressed in 30% of human breast cancer patients. The 
binding of Herceptin onto the surface of the drug-loaded micelles will confer HER2-
recognition to the delivery system and can increase sensitivity of the cancer cells to drug 
treatment. Investigations are made to evaluate if the co-delivery of both Herceptin and 





Figure 1.4. Nanocomplexes for codelivery of anti-cancer drug and protein therapeutics. 
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 CHAPTER 2 
MATERIALS AND METHODS 
 
In my work, the possibility of utilizing various therapeutic proteins as 
monotherapy or in combination with different conventional chemotherapeutic drugs in 
nanoparticulate systems was evaluated. Physical characterization of nanocomplexes and 
enhancement of tumor cell death to combinational treatment were evaluated through 
various in vitro assays. The materials and methods used in this study are: 
 
2.1  Materials 
Therapeutic proteins 
· Recombinant lectin A-chain of the heterodimeric lectin from Viscum album 
coloratum (Korean Mistletoe) was kindly provided by A/P Ho Sup Yoon, from 
Nanyang Technological University [270]. 
· Soluble human TRAIL (Mw: 20 kDa) was purchased from BioMol, U.S.A.  
· Herceptin was purchased from Roche, Switzerland.  
 
Chemotherapeutic drugs 
· Paclitaxel was purchased from Sigma, U.S.A.  





Dimethyl sulfoxide (DMSO), dimethylacetamide (DMAC) and dimethyl formamide 
(DMF) were purchased from Sigma-Alrich, U.S.A. 
 
Reagents  
Polystyrene beads were obtained from Dukescientific, U.S.A. Dialysis buffer used 
for nanoparticle fabrication was self-prepared using sodium acetate and acetic acid (ACS 
grade, Merck, U.S.A.). 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT), crystal violet, sodium azide and paraformaldehyde were obtained from Sigma, 
U.S.A. MTT was dissolved in phosphate-buffered saline (PBS, pH 7.4) with a 
concentration of 5 mg/ml, and the solution was filtered with a 0.22 mm filter to remove 
blue formazan crystals prior to use. Propidium iodide and 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate (DiL)was purchased from Invitrogen, U.S.A. 
BioPorter was purchased from Genlantis, U.S.A. and ProJect was purchased from Pierce 
Biotechnology, U.S.A. and both were used according to the manufacturer’s instructions. 
Death receptors blocking antibodies (Anti-DR4 and Anti-DR5) were purchased from 
Enzo Life Sciences, U.S.A. Pan-caspase Inhibitor ZVAD-FMK was purchased from 
Promega, U.S.A. For in vivo studies, 17ß-Estradiol release pellets were obtained from 
Innovative Research of America, U.S.A. 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindotricarbocyanine iodide (DiR) was purchased from  Caliper Lifesciences, 
USA. Unless stated otherwise, all reagents and solvents were of commercial grade, and 
were used as received. 
 
Cell lines  
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The cell lines that were used are human breast cancer MDA-MB-231, MCF7, T47D and 
BT474, human cervical cancer HeLa, human liver carcinoma HepG2, human colorectal 
carcinoma SW480, mouse breast cancer 4T1 cell lines and human lung fibroblast WI38 
and human embryonic kidney HEK293 cells. All cell lines were purchased from ATCC, 
U.S.A.  
 
Cell culture medium  
HepG2, HeLa and HEK293 were cultured in DMEM, MDA-MB-231 and SW480 in 
Leibovitz L-15, T47D, BT474, 4T1 and WI38 in RPMI 1640 and MCF7 in either MEM 
or RPMI 1640. All the culture media were supplemented with 10% fetal calf serum, 100 
U/ml penicillin and 100 μg/ml streptomycin (HyClone, U.S.A.). 
 
2.2 Synthesis of P(MDS-co-CES)  
P(MDS-co-CES) (Figure 2.1A) was obtained by a three-step synthesis [261]. The 
detailed synthetic chemistry of the polymer is given the Appendix I. Briefly, the main 
chain, poly(N-methyldietheneamine sebacate) (PMDS), was first produced by 
condensation polymerization between N-methyldiethanolamine and sebacoyl chloride. 
Excess triethylamine was used to remove hydrochloride and limit protonation of the 
tertiary amine. Next, cholesteryl chloroformate was allowed to react with 2-
bromoethylamine hydrobromide in an amidation reaction. The resulting hydrophobic N-
(2-bromoethyl) carbarmoyl cholesterol was then grafted onto the hydrophilic poly(N-
methyldietheneamine sebacate) main chain through a quaternization reaction to obtain the 
final product.  
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The main chain is a polyester, and the pendant chain contains hydrolytically labile 
urethano groups, rendering this copolymer degradable. The degree of cholesterol grafting 
was about 28.5%. P(MDS-co-CES) had a weight average molecular weight (Mw) of ~ 5.0 
kDa with a polydispersity index of 1.7, as measured by gel permeation chromatography 
[Waters 2690, MA, U.S.A., with a differential refractometer detector (Waters 410, MA, 
U.S.A.); Mobile phase:water of HPLC grade with a flow rate of 1 mL/min; Polystyrene 
standards: molecular weight ranging from 1300 to 30,000]. The nitrogen content was 
determined to be 4.0 % in weight as estimated by elemental analysis using Perkin-Elmer 
Instruments Analyzer 2400. 
 
 
Figure 2.1. Synthesis of cationic amphiphilic polymer P(MDS-co-CES) [262]. 
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2.3 Preparation of P(MDS-co-CES) micellar nanoparticles 
To prepare the cationic micellar nanoparticles, 15.0 mg of P(MDS-co-CES) was 
dissolved in 5.0 ml of DMF, which was placed in a dialysis membrane with a molecular 
weight cut-off (MWCO) of 2000 Da (Spectrum Laboratories, U.S.A.). The dialysis bag 
was then immersed in 500 ml of de-ionized water or 20 mM sodium acetate/acetic acid 
buffer with pH 4.6 at room temperature for 24 hours. The dialysis buffer was replaced 
hourly with fresh buffer solution for the first 8 hours during the 24 hour course. At the 
end of the dialysis process, the resulting micelle solution was then filtered through a 0.22 
μm filter in a sterile environment to remove large aggregates. The micelles were 
characterized with respect to their size and zeta potential using a zetasizer with dynamic 
light scattering capability (scattering angle: 90°) and equipped with a He-Ne laser beam 
at 658 nm (Malvern Instruments Zetasizer Nano ZS, UK).  
 
2.4  Preparation of drug-loaded P(MDS-co-CES) nanoparticles  
Fabrication of drug-loaded P(MDS-co-CES) nanoparticles were carried via the 
dialysis method whereby the chemotherapeutic drugs were physically entrapped into the 
hydrophobic core of the micelles. Details of experimental procedures are as follows. 
 
2.4.1  Preparation of Pac-loaded nanoparticles 
The polymer (15.0 mg) and pac (3.0 mg) were dissolved together in DMF. The 
mixture was placed in a dialysis membrane tube with MWCO of 2000 Da (Spectrum 
Laboratories, U.S.A.). The dialysis bag was then immersed in 500 ml of 20 mM sodium 
acetate/acetic acid buffer with pH 4.6 at 4°C for 2 days. The dialysis buffer was replaced 
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3 times per day with fresh buffer solution during the 2-day course. At the end of the 
dialysis process, the resulting micelle solution was filtered through a 0.45 μm filter in 
order to remove large aggregates, and then freeze-dried. To determine the encapsulation 
efficiency and loading level of drug, the drug-loaded micelles were dissolved in 3 ml of 
chloroform and 9 ml of ether was added to precipitate P(MDS-co-CES). The mixture was 
centrifuged at 4000 rpm for 20 minutes and the supernatant was decanted into a fresh 
vial, and dried. The deposited drug was dissolved in 1.5 ml of mobile phase consisting of 
water: methanol: acetonitrile in the volume ratio of 35: 20: 45. Drug content was 
analyzed using high performance liquid chromatography (HPLC, Waters 996 PDA 
detector, U.S.A.) at 228 nm UV wavelength. The drug encapsulation efficiency was 
calculated based on the ratio of the amount of drug successfully encapsulated into the 
micelles to the amount of drug initially added during the micelle fabrication process.  
 
2.4.2  Preparation of Dox-loaded nanoparticles  
5.0 mg powdered Dox was dissolved in 2.0 mL DMAC and vortexed intensely for 
20 minutes. Triethanolamine (TEA) was added to the solution in a molar ratio of 3:1 
(TEA : Dox) and vortexed intensely for another 20 minutes to allow time for TEA to 
neutralize the acidic Dox preparation. The Dox solution was then added to 10.0 mg of 
P(MDS-co-CES) pre-dissolved in 2.0 mL DMAc and vortexed to mix. The resulting 
solution was transferred to a dialysis bag with molecular weight cut-off (MWCO) of 1 
kDa, (Spectrum Laboratories, U.S.A). The dialysis bag was then immersed in 500 ml of 
deionized water at room temperature for 2 days. The dialysis medium was replaced 3 
times per day with fresh buffer solution during the 2-day course. At the end of the 
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dialysis process, the resulting micelle solution was filtered through a 0.45 μm filter in 
order to remove large aggregates, and then freeze-dried. To determine the encapsulation 
efficiency and loading level of drug, the drug-loaded micelles were dissolved in DMSO 
and absorbance was measured against a standard calibration curve of free Dox dissolved 
in the same solvent at 488 nm wavelength.  
 
2.5  Preparation of P(MDS-co-CES) nanoparticle/protein nanocomplexes  
Therapeutic proteins used in the experiments were kept in an ice bath during the 
experiments to prevent disruption to its structural stability caused by temperature 
changes. The protein was first added to 20 mM sodium acetate/acetic acid buffer at pH 
6.0. P(MDS-co-CES) nanoparticle/protein nanocomplexes were then formed by adding 
the freshly prepared micelle solution to the protein solution in varying mass ratios, and 
mixed gently. The complex solution was left to stand at room temperature for 30 minutes 
before being characterized and introduced into the cancer cells.  
 
2.6  In vitro drug release 
To function effectively as drug delivery systems, drug-loaded nanoparticles must 
be able to provide a sustained and gradual release of their cargo without significant initial 
burst. It is therefore important to first obtain the in vitro release profile of the 
encapsulated drugs from the P(MDS-co-CES) nanoparticles prior to determining its 




2.6.1  In vitro release of Pac 
Release of Pac from the Pac-loaded micellar nanoaprticles and Pac-loaded 
nanoparticle/TRAIL complexes was studied using the dialysis method. Dialysis 
membrane tube with MWCO of 2000 Da (Spectrum Laboratories, U.S.A.) containing 
10.5 mg of the micelles was immersed in 40 ml of the release medium, i.e. PBS (pH 7.4) 
containing 0.1% (v/v) Tween 80 to maintain a sink condition. This was kept shaking on 
an orbital shaker at 120 rpm at 37oC. At designated time intervals, the release medium 
was removed and replaced with fresh medium. The medium that has been removed was 
analyzed for its drug content.  To do this, 10 ml of dichloromethane (DCM) was added 
and mixed with the release medium through 3 minutes of vigorous vortexing. The organic 
layer was left to settle and carefully extracted into a new glass vial. DCM was evaporated 
by air flow. The deposited drug was dissolved in 1.5 ml of mobile phase and Pac content 
was analyzed using HPLC at 228 nm as described in Section 2.4.1.  
 
2.6.2  In vitro release of Dox 
Release of Dox from the Dox-loaded micellar nanoparticles and Dox-loaded 
nanoparticle/TRAIL complexes was studied using the dialysis method. 4 mL of Dox-
loaded micelles was transferred to a dialysis membrane tube with a molecular weight cut-
off (MWCO) of 2 kDa (Spectrum Laboratories, U.S.A.) and dialysed against 20 mL of 
either phosphate buffered saline PBS (pH 7.4) or 20 mM sodium acetate/acetic acid 
buffer (pH 5.6) solution. The set-up was kept shaking on an orbital shaker at 100 rpm at 
37oC. At designated time intervals, the release medium was removed and replaced with 
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fresh medium. The amount of Dox released into the medium was determined from its 
absorbance at 488 nm wavelength.  
 
2.7 Native protein gel shift assay on P(MDS-co-CES) nanoparticle/protein 
nanocomplexes 
 
Complex formation was carried out in sodium acetate/acetic acid buffer (pH 6.0) by 
adding freshly prepared P(MDS-co-CES) nanoparticles solution to protein in varying 
polymer to protein mass ratios between 0.1 to 50. After that, the mixture was left to stand 
at room temperature for 30 minutes before continuing with native polyacrylamide gel 
electrophoresis (PAGE). Samples were loaded into 5% (for Lectin A and Herceptin) and 
12% (for TRAIL) Tris glycine gel and ran at 200V with Tris glycine running buffer 
(BioRad, USA) for 35 minutes. Bromophenol blue tracked the fronts and the gel was 
stained with SYPRO ruby protein gel stain (Invitrogen, U.S.A.). Destaining was carried 
out in water containing 10% methanol and 7% acetic acid, and the stained gel was 
imaged under ultraviolet excitation. 
 
2.8 Stability of P(MDS-co-CES) nanoparticle/protein complexes under        
physiologically-simulating conditions 
 
To determine the stability of nanocomplexes under physiologically-simulating 
conditions, Herceptin was used as the model protein for this study. The P(MDS-co-CES) 
nanoparticle/Herceptin complex suspension was diluted 10 times with PBS (pH 7.4) 
containing 10% (v/v) FBS and incubated at 37oC. Size measurements were taken at 0, 5 
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minutes, 1 hour, 4 hours and 24 hours. The stability of these complexes is demonstrated 
by the absence of aggregates formation and maintenance of particle size within the 
nanometer range. 
 
2.9 Establishment of TRAIL-resistant SW480-TR cell line from parental  
SW480 
 
In cancer therapy, one of the major problems encountered is the development of 
drug resistance. In order to investigate the efficacy of the Dox-loaded P(MDS-co-CES) 
nanoparticle/TRAIL complex against cells that have developed resistance to TRAIL, we 
first establish TRAIL-resistant cells from parental TRAIL-sensitive SW480 cells. To do 
this, the cells were cultured in T75 flasks and exposed to increasing doses of TRAIL (1, 
2, 4, 8, 10 and 20 nM) for 4 weeks. Cell density was maintained at ~75% confluency and 
subcultured as needed. Each dose was repeated at least twice by exposing cells to 
TRAIL-containing medium for 2 to 3 days depending on the amount of cell death 
induced. The TRAIL-containing medium was then replaced with TRAIL-free medium 
and incubated for 1 to 2 days before the next treatment with TRAIL. By the end of 4 
weeks, the resultant TRAIL-resistant cells (designated SW480-TR) were harvested and 
kept frozen. In between experiments, cells were maintained in a complete RPMI 1640 
medium containing 10 nM TRAIL at 37°C. 
 
2.10 Confocal microscopy and flow cytometry studies on intracellular 
distribution of nanocomplexes   
 
2.10.1  Preparation of FITC-loaded P(MDS-co-CES) nanoparticles 
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P(MDS-co-CES) nanoparticles was labeled by encapsulating FITC into the 
hydrophobic core of the nanoparticles. The polymer (15.0 mg) and 1.0 mg of fluorescent 
dye were dissolved in DMF. The mixture was placed in a dialysis membrane with a 
molecular weight cut-off of 2000 Da (Spectrum Laboratories, U.S.A.). The dialysis bag 
was then immersed in 500 ml of 20 mM sodium acetate/acetic acid buffer with pH 4.6 at 
4°C for 2 days. The dialysis buffer was replaced 3 times per day with fresh buffer 
solution during the 2-day course. At the end of the dialysis process, the resulting 
nanoparticle solution was filtered through a 0.22 μm filter in sterile environment to 
remove large aggregates.  
 
2.10.2 Preparation of fluorescence-labeled protein 
Lectin A-chain and Herceptin were labeled using Alexa Fluor 647 protein 
labeling kit (Invitrogen, U.S.A.) while TRAIL was labeled using Alexa Fluor 555 protein 
labeling kit (Invitrogen, U.S.A.). In brief, the Alexa Fluor dye with a tetrapfluorophenyl 
(TFP) ester moiety was added to the protein in a molar ratio of 15:1 for lectin A-chain, 
17:1 for TRAIL and 28:1 for Herceptin. The reaction was carried out at room temperature 
for 1 hour. Purification of the fluorescent conjugate was carried out using spin columns 
provided in the labeling kit. The conjugate was then analyzed spectrophotometrically 
using the NanoDrop ND-1000 spectrophometer (NanoDrop Technologies, USA) and the 
degree of labeling was determined to be 1.7, 0.1 and 0.1 moles Alexa Fluor dye per mole 
of Lectin A-chain, TRAIL and Herceptin respectively.  
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2.10.3 Intracellular uptake and distribution of fluorescence-labeled protein, 
P(MDS-co-CES) nanoparticles and their nanocomplexes 
 
Cells were seeded onto borosilicate chambered coverglass (Nunc, USA) and 
cultivated in 500 μl of growth medium. For studies involving Lectin A-chain distribution, 
HeLa cells were seeded at a density of 2 × 105 cells per well. For studies involving 
Herceptin distribution, BT474 and HEK293 cells were also seeded at a density of 2 × 105 
cells per well while for studies involving TRAIL distribution, 5 × 104 MCF7, T47D,  
MDA-MB-23 cells were seeded per well.  After allowing the cells to adhere overnight, 
spent growth medium was removed from each well and replaced with 500 ml of the pre-
prepared complex solution in serum-free or serum-containing medium. After 1 hour of 
incubation at 37oC with the nanocomplexes, the growth medium was removed, washed 
with PBS and fixed with 4% paraformaldehyde. The samples were then imaged at 63× 
magnification using a LSM 510 DUO confocal unit (Carl Zeiss, USA). Each condition 
was performed in triplicates. 
Flow cytometry was performed to study the cellular uptake of fluorescently-
labeled TRAIL into MCF7, T47D and MDA-MB-231 cells. The cells were seeded onto 
12-well plates at a density of 1 × 106 cells per well and allowed to adhere overnight. The 
next day, the spent growth medium was removed from each well and replaced with 1 ml 
of the pre-prepared complex solution in serum-containing medium, and the cells were 
incubated for 3 hours at 37oC.  Cells were then trypsinized, washed and resuspended in 
PBS. Cellular uptake of TRAIL was then analyzed with fluorescence-activated cell 
sorting analysis (FACS) on a Becton Dickinson FACSCalibur flow cytometer using BD 
FACSDiva™ software (BD Biosciences, U.S.A.).  
72 
2.10.4 Confocal microscopy studies on receptor-mediated endocytosis 
Confocal microscopy studies were carried out to evaluate receptor-mediated 
endocytosis of the nanocomplexes by using Dox-loaded nanoparticle/TRAIL complexes 
as a model system. TRAIL was labeled using Alexa Fluor 647 protein labeling kit 
(Invitrogen, U.S.A.). Alexa Fluor 647 dye with a tetrafluorophenyl (TFP) ester moiety 
was added to TRAIL solution in a molar ratio of 15:1 and reacted at room temperature for 
0.5 hour. Purification of the fluorescent conjugate was carried out likewise in Section 
2.10.2. 
Nanocomplexes were fabricated using Dox-loaded nanoparticle and Alexa Fluor 
647-labelled TRAIL. SW480 cells were seeded onto borosilicate chambered coverglass 
(Nunc, U.S.A.) at a density of 5 × 104 cells per well, and cultivated in 500 μl of growth 
medium. The next day, the spent growth medium was removed from each well and 
replaced with blocking antibodies anti-DR4 and anti-DR5 in serum-containing medium. 
After 1 hr, pre-prepared complex solution in serum-containing medium was then added. 
At designated time points, the growth medium was removed. The cells were then washed 
with PBS, fixed with 4 w/w% paraformaldehyde in PBS and imaged at 630× 
magnification using LSM 510 DUO confocal unit (Carl Zeiss, U.S.A.). Each condition 
was performed in triplicates. 
 
2.11 Cell viability studies 
One of the main objectives of this research is to successfully utilize these drug-
loaded nanoparticles/protein complexes to induce cell death in cancer cells, either as 
single agents or enhance cell death when used in combinations. The MTT assay is used as 
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rapid and convenient method to determine the end-point cell viability remaining after 
treatment. However, as MTT assay relies on the conversion of membrane-permeant 
colorless tetrazolium salt into colored formazan crystals by metabolically active 
mitochondria in viable cells, alterations in metabolic activities may not reflect the actual 
number of viable cells present. Common situations that can cause changes to 
mitochondrial functions include overconfluency and/or depletion of culture medium. 
However, since this method is inexpensive and allows quick screening of cell killing 
efficiency and effective drug dosages, MTT assay is still suitable for early rounds of 
investigational studies.    
To evaluate the long-term drug effect and proliferation of the cells treated with 
various formulation, anchorage-dependent clonogenic assay was performed. This assay 
allows the assessment of irreversible cessation of cell growth that occurs after the 
removal of therapeutic agents from the cells [271]. The detailed methods for each assay 
are as follows. 
 
2.11.1  Cytotoxicity study using MTT assay 
Depending on the cancer cell lines used, the cells were seeded onto 96-well plates 
at a density of 1- 1.2 × 104 cells per well, and cultivated in 100 μl of growth medium. The 
plates were then returned to incubator for 24 hours to reach 70%-80% confluency before 
the administration of nanoparticle/lectin A-chain nanocomplexes. When the desired cell 
confluency was reached, the spent growth medium was removed from each well and 
replaced with 100 ml of the pre-prepared complex solution. After 4 hours of incubation 
with the complexes, the culture medium was replaced with fresh ones. The plates were 
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then returned to the incubator and maintained in 5% CO2, at 37°C, for 2 days. Each 
condition was tested in eight replicates. After 2 days of incubation, the culture medium 
was removed, and 20 ml of MTT solution was added with 100 μl of fresh medium. The 
plates were then returned to the incubator and maintained in 5% CO2, at 37°C, for a 
further 3 hours. The growth medium and excess MTT in each well were removed. DMSO 
(200 ml) was added to each well to dissolve the internalised purple formazan crystals. An 
aliquot of 100 ml was taken from each well and transferred to a new 96-well plate. The 
plates were then assayed at 550 nm and reference wavelength of 690 nm using a 
microplate reader (PowerWave X, Bio-tek Instruments, U.S.A.). The absorbance readings 
of the formazan crystals were taken to be those at 550 nm subtracted by those at 690 nm. 
The results were expressed as a percentage of the absorbance of the blank. 
 
2.11.2    Anchorage-dependent (monolayer) clonogenicity assay 
Monolayer colony assay was performed in drug-free media after exposure to 
treatment conditions. In a typical assay, cancer cells were first seeded onto 24-well plates 
at a density of 1-2.5 × 105 cells per well, and cultivated in 1ml of growth medium. The 
plates were then returned to incubators to allow cells to adhere overnight. The spent 
growth medium was removed from each well and replaced with 1ml of the pre-prepared 
nanoparticle/TRAIL complex solution. After 48 hour treatment, cells were trypsinized 
and re-seeded at a density of 1-3 × 103 cells per well in 6-well plates in drug and TRAIL-
free medium. These cells were incubated at 37°C for 11 to 17 days for colony formation. 
Media were replaced with fresh (nanoparticle/ TRAIL-free) media every 3 to 4 days. At 
the end of each assay, cells were stained with 1 ml of 0.5% crystal violet for 1 hour and 
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washed three times with distilled water.  Colonies were counted and imaged using a 
stereomicroscope (Nikon, U.S.A.) at 10×magnification, in five microscopic fields per 
well (one central, four peripheral). All assays was performed in triplicate and done 
independently at least twice. 
 
2.12 Cell cycle analysis 
Chemotherapeutic agents, such as Pac and Dox used in this study are known to 
cause either cell cycle arrest at low dosages or apoptosis at higher dosages. When 
administered together with therapeutic proteins, they typically exert synergism in 
apoptosis induction. To determine the effects of single versus combinational therapy, cell 
cycle analysis was performed. In this assay, cell cycle fractions were determined by 
propidium iodide nuclear staining. Briefly, cells were harvested, washed in PBS, fixed 
with 70% ethanol, and stained with 50 µg/ml propidium iodide in the presence of 200 
µg/ml RNase and 0.1% Triton X-100 for 45 minutes at room temperature. Data were 
collected and analyzed with fluorescence-activated cell sorting analysis (FACS) on a 
Becton Dickinson FACSCalibur flow cytometer using BD FACSDiva™ software (BD 
Biosciences, U.S.A.).  
 
2.13 Biodistribution of P(MDS-co-CES)nanoparticles 
To evaluate the biodistribution of P(MDS-co-CES) nanoparticles, a near-infrared 
fluorophore DiR was loaded into the nanoparticles, likewise in Section 2.10.1. Balb/c 
mice, weighing 20–30 g were injected with 200 µL of a cell suspension containing 1 × 
106 4T1 cells subcutaneously. After 2 weeks, when the tumor reached 4–6 mm in 
diameter, the mice were injected with nanoparticles via either tail vein or intratumoral 
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injection. Non-invasive fluorescent imaging at various times up to 3 days after injection 
was performed using the IVIS 100 (Caliper Life Sciences, U.S.A.). The mice were then 
sacrificed at 72 h after injection to estimate the tissue distribution of nanoparticles. All 
animal handling procedures were conducted in accordance with the approved protocol 
from the Institutional Animal Care and Use Committee (IACUC) at the Biological 
Resource Centre of Singapore. 
 
2.14    In vivo anti-tumor efficacy studies of P(MDS-co-CES)nanoparticles 
Female nude mice, weighing 20–25 g were injected with 200 µL of a cell 
suspension (1:1 with Matrigel) (BD Biosciences, U.S.A.) containing 3 × 106 BT474 cells 
subcutaneously. 1 month after inoculation (when the tumor volume was ~100 mm3), the 
tumor-bearing mice were randomly divided into several groups (six mice per group). In 
the experiment 1, group 1 mice were used as nontreated control, group 2 and 3 mice were 
given intratumoral injection of Herceptin (0.5 mg/kg twice weekly) and blank 
nanoparticles/Herceptin complexes respectively, group 4 and group 5 mice were injected 
with Pac-loaded nanoparticles (8 mg/kg twice weekly) and Pac-loaded nanoparticles/Her 
complexes, all on the same schedule. All animal experiments were conducted in 
accordance with the approved protocol from the Institutional Animal Care and Use 
Committee (IACUC) at the Biological Resource Centre of Singapore. The tumor size was 
measured by calipers in two orthogonal diameters and the volume was calculated as 
L×W2 /2, where L and W are the major and minor diameters respectively. Statistical 
significance in differences was evaluated by Newman-Keuls Method after analysis of 
variance (ANOVA). P≤0.05 was considered statistically significant.  In addition, the 
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toxicities of the different formulations were evaluated by monitoring the survival rates 
over the course of treatment.  
 
2.15 Distribution of nanocomplexes within tumors 
To evaluate the biodistribution of nanocomplexes, FITC-loaded nanoparticles and 
Alexa Fluor 647-Herceptin was fabricated, likewise in Section 2.10. Female nude mice, 
bearing BT474 xenografts were used. The mice were injected with nanoparticles via 
intratumoral injection and sacrificed at 3 h post-injection to estimate the distribution of 
nanocomplexes within the tumors. Tissue sections were taken at 3 positions – close to 
skin, middle and distal to skin, and were imaged at 630× magnification using LSM 510 




INVESTIGATION OF CATIONIC POLYMERIC NANOPARTICLES 





Over the past few decades, recombinant protein therapeutics has emerged as an 
important R&D sector for effective treatment against a broad range of human diseases, 
including cancer, autoimmune diseases and metabolic disorders [74, 272]. However, the 
main obstacle to achieving in vivo efficacy of protein therapy lies in the delivery to 
targeted diseased sites. The first part of my thesis focuses on the evaluation of using 
cationic core/shell nanoparticles as carriers for the delivery of therapeutic proteins. 
Lectin-A chain is selected as the model protein for investigation as it is unable to enter 
into cells without assistance from delivery carriers but can induce significant cytotoxicity 
when it gets delivered into the cytoplasm. Therefore, in vitro cytotoxicity resulting from 
Lectin-A chain delivery can be used as an indicator of the protein delivery efficiency of 
the nanoparticles.  
Lectins from Viscum album coloratum (Korean Mistletoe) are heterodimeric, 
consisting of the A-chain with cytotoxic activity and the B-chain with sugar-binding 
property. They are glycoproteins with rRNA N-glycosidase activity, which inactivates the 
ribosome, leading to the disruption of the translocation steps of cellular translation during 
protein biosynthesis and thus cell death [148-150]. Apoptosis induction may also occur 
through the down-regulation of Bcl-2 and telomerase activity and up-regulation of Bax 
[273]. Reports have shown that this lectin is cytotoxic to Molt4 cells [149, 274], and is 
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able to bring about apoptotic death of U937 cells via activation of caspase cascades 
[275]. The counterpart of A-chain, lectin B, serves to mediate the delivery of cytotoxic 
lectin A-chain by binding to the cell surface and facilitating the subsequent 
internalization of the A-chain via endocytosis [149, 276]. The isolation of these 
biologically active lectins from plant extract and/or its production via recombinant 
methods encompasses difficulties such as extensive purification and scale-up problems.  
A number of methods have been proposed to deliver biologically active proteins 
into cells, among which are physical methods such as microinjection [277, 278] and 
electroporation [129, 279]. These physical methods may be difficult to be applied in vivo 
[280]. The protein transduction domains (PTDs) have been conjugated to various active 
proteins for mediating the cellular uptake of the proteins [281, 282]. Another approach in 
rational drug delivery research that is becoming increasingly popular involves cationic 
lipids and polymers [283, 284]. For example, polyethylenimine (PEI)-conjugated proteins 
are able to enter cells based on ionic charge interactions [285]. The conjugation of 
proteins with PEI must be conducted under mild conditions to prevent proteins from 
denaturation. Moreover, cytotoxicity of PEI especially with high molecular weight also 
limits its in vivo applications. In this study, cationic core/shell nanoparticles were 
fabricated via a self-assemly process using biodegradable, cationic and amphiphilic 
copolymer poly{N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido 
ethyl) methyl bis(ethylene) ammonium bromide] sebacate} P(MDS-co-CES) [261]. 
Lectin A-chain interacted with the cationic nanoparticles to form nano-sized complexes, 
and the lectin A-chain binding ability of the nanoparticles was studied by native gel 
electrophoresis. The particle size and zeta potential of nanoparticle/lectin A-chain 
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complexes were measured and compared to those of lectin A-chain complexed with a 
commercially available cationic lipid-based protein carrier, BioPorter [277, 286]. The 
cellular uptake and distribution of nanoparticle or BioPorter/lectin A-chain complexes 
were studied in HeLa cervical cancer cell line by confocal microscopy. The cytotoxicity 
of lectin A-chain delivered by the nanoparticles was investigated against MDA-MB-231 
human breast cancer cell line, HeLa cell line, HepG2 human hepatocellular liver 
carcinoma cell line and 4T1 mouse breast cancer cell line in comparison with BioPorter. 
Lectin A-chain delivered by the nanoparticles yielded significantly higher anti-cancer 
effectiveness when compared to BioPorter. These nano-sized particles may provide a 
platform for intracellular delivery of biologically active proteins. 
 
3.2 Results and Discussion 
3.2.1 Particle size and zeta potential of nanoparticle, BioPorter and their lectin A-
chain complexes 
 
As shown in Figure 3.1, the blank nanoparticles and BioPorter particles had an 
average size of ~ 140 nm and 334 nm with the zeta potential of ~ +28 mV and +22 mV 
respectively. The size of the nanoparticle/lectin A-chain nanocomplexes decreased but 
their zeta potential increased as increasing mass ratio of polymer to lectin A-chain 
(Figure 3.1A). At the mass ratio of 50 or above, their size and zeta potential remained 
relatively constant at approximately 150 nm and +30 mV respectively, indicating that at 
these mass ratios, lectin A-chain was well condensed and complexed with the 
nanoparticles. The small size and positive zeta potential of the complexes rendered them 
suitable for endocytotic cellular uptake. Complexes formed using commercially available 
cationic lipid-based carrier, BioPorter were also characterized with respect to their size 
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and zeta potential. In Figure 3.1B, BioPorter/lectin A-chain complexes were observed to 
have even larger sizes (>455 nm) and less positive zeta potential (< 20 mV) as compared 
to the blank P(MDS-co-CES) nanoparticles and their lectin A-chain nanocomplexes. 
Particles of such large sizes were likely to be aggregates. It is expected that the resulting 
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Figure 3.1 Size and zeta potential properties of nanoparticle/lectin A-chain nanocomplexes, and their lectin 
A-chain binding ability. (A) P(MDS-co-CES) nanoparticle/lectin A-chain nanocomplexes and (B) 
BioPorter/lectin A-chain complexes; Experiments were carried out in triplicates. The standard deviation is 
presented in error bars.  
 
3.2.2 Lectin A-chain binding of nanoparticles 
The protein binding ability of P(MDS-co-CES) nanoparticles was studied by 
native polyacrylamide gel electrophoresis (PAGE) at varying mass ratios. In native 
PAGE, the mobility of lectin A-chain will depend on both its charge and hydrodynamic 
size. The interaction between P(MDS-co-CES) nanoparticles and lectin A-chain will 
neutralize the protein’s charge and decrease the intensity of protein gel bands.  It was 
observed that electrophoretic mobility of lectin A-chain was increasingly reduced as 
more P(MDS-co-CES) was added for lectin A-chain binding, showing that stronger 
B 
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nanoparticle/lectin A-chain interaction occurred at higher nanoparticle to protein mass 
ratios (Figure 3.2). In turn, this correlates to more effective lectin A-chain delivery and 
apoptosis induction with the use of more P(MDS-co-CES) to deliver the protein.   
To ensure that native PAGE was carried out in an accurate manner, the process 
was repeated with lectin A-chain together with bovine serum albumin (BSA). When BSA 
was used as a model protein, a clear band was observed (data not shown). In contrast, a 
smear band pattern was observed for lectin A-chain possibly due to the hydrogen bonds 
formed between the glycoprotein and polyacrylamide gel matrix.  










Figure 3.2 Native protein gel assay of P(MDS-co-CES) nanoparticle/lectin A nanocomplexes. Lanes 1 – 
lectin A-chain (8 μg) alone, Lane 8 – P(MDS-co-CES) (400 μg) alone, Lanes 2 to 7 – polymer to protein 
mass ratios:  0.1, 0.5, 1, 5, 10 and 50 respectively.  
 
3.2.3 Intracellular uptake and distribution of nanoparticle/lectin A-chain 
complexes 
 
To evaluate the efficiency of intracellular lectin A-chain delivery using P(MDS-
co-CES) nanoparticles, the cellular distribution of protein and nanoparticles was 
investigated in HeLa cells using confocal microscopy in comparison with BioPorter. 
Cellular distribution of Alexa Fluor 647-labelled lectin A-chain shows up as red 
fluorescence in confocal images (Figure 3.3A-C). Low fluorescence present in Figure 
3.3C illustrates that lectin A-chain alone was unable to enter cells efficiently without a 
transport carrier. Comparison between Figure 3.3F and I shows the presence of higher 
1 2 3 4 5 6 7 8 
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amount of lectin A-chain in cells treated with P(MDS-co-CES) nanoparticle/lectin A-
chain nanocomplexes as compared to those treated with BioPorter/lectin A-chain 
complexes. Lectin A-chain delivery and internalization was significantly more efficient 
when delivered using P(MDS-co-CES) nanoparticles as compared to BioPorter. This is 
most likely due to the presence of quaternary ammonium groups in P(MDS-co-CES) 
designed for protein binding and tertiary amine groups for endosomal buffering [287] and 
release of nanocomplexes. Fluorescein isothiocyanate (FITC) was loaded into the 
nanoparticles. Green and yellow regions in Figure 3.3J and K represent the localization of 
the nanoparticles, and the co-localization of lectin A-chain and P(MDS-co-CES) 
nanocomplexes in the cytoplasm after one hour of incubation, illustrating that the 
nanoparticles were able to bring lectin A-chain into the cells together as an associated 
complex. The nanoparticles, lectin A-chain and their nanocomplexes were also observed 
in the nuclei, suggesting that lectin A-chain is not only localized in the cytoplasm but also 
localized in the nucleus. This observation could provide one possible molecular basis of 





   
 
 
   
 
                          
Figure 3.3 Cellular distribution of fluorescent-labeled lectin A-chain, P(MDS-co-CES) nanoparticles and 
their nanocomplexes in comparison with BioPorter/lectin A-chain complexes. Nuclei were stained blue 
with (A, D, G) DAPI, and cellular distribution of Alexa Fluor 647-lectin A-chain (B, E, H) and FITC-
P(MDS-co-CES) nanoparticles (J) are shown as red and green fluorescence respectively. (A-C) Control 
experiments with Alexa Fluor 647-lectin A-chain (5 ppm) only, (D-F) Alexa Fluor 647-lectin A-chain (5 
ppm) with BioPorter and (G-K) Alexa Fluor 647-lectin A-chain (5 ppm) with 50 ppm of P(MDS-co-CES) 
nanoparticles. Yellow regions in (K) represent the co-localization of lectin A-chain and P(MDS-co-CES) 
nanoparticles in cells.  
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3.2.4 Cytotoxicity and IC50 of lectin A-chain 
Intracellular release of lectin A-chain from the nanocomplexes is essential for it to 
function as a biologically active protein. To determine whether lectin A-chain retains its 
cytotoxic property after cellular internalization, cytotoxicity tests were carried out in 
MDA-MB-231, HeLa, HepG2 and 4T1 cancer cells. Cell viability after treatment was 
determined via the 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT) assay. For all cell lines tested, lectin A-chain alone did not exhibit significant 
cytotoxicity since the protein was unable to enter the cells and exert its cytotoxic 
properties without a transport carrier (Figure 3.4). This correlates with the significantly 
lower cellular internalization of lectin A-chain seen in confocal images (Figure 3.2A-C). 
At low P(MDS-co-CES) concentrations in the complexes, the cytotoxicity exhibited was 
insignificant, possibly due to insufficient binding between lectin A-chain and P(MDS-co-
CES) nanoparticles (Figure 3.2). The size and zeta potential results also indicate that the 
nanoparticle/lectin A-chain nanocomplexes were too large for efficient cellular uptake at 
these concentrations (Figure 3.1A). Blank nanoparticles possessed non-selective 
cytotoxicity probably due to electrostatic interactions with negatively charged glycocalyx 
of cell surface [288]. To reduce the effects of the non-selective cytotoxicity, polymer 
concentration for complex preparation was optimized for each cell line, being 20, 50, 40 
and 100 ppm for MDA-MB-231, HeLa, HepG2 and 4T1 respectively, at which cell 










































































































Figure 3.4 Viability of (A) MDA-MB-231, (B) HeLa, (C) HepG2 and (D) 4T1 cells after three days of 
incubation with nanoparticle/lectin A-chain nanocomplexes containing a fixed concentration of lectin A-
chain and P(MDS-co-CES) of varying concentration. Lectin A-chain concentrations were fixed at 1, 10, 10 
and 10 ppm for (A), (B), (C) and (D) respectively. Each condition was tested in eight replicates. The 
standard deviation is presented in error bars.  
 
To determine the IC50 value of lectin A-chain, the viability of each cell line was 
tested at varying lectin A-chain concentrations and the optimized polymer concentration, 
which were 0.2, 0.5, 10 and 50 ppm for MDA-MB-231, HeLa, HepG2 and 4T1 cells 
respectively (Figure 3.5). Differences in IC50 between the various cell lines revealed their 
different degrees of sensitivity to the cytotoxicity of nanoparticle/lectin A-chain 
Lectin A-chain P(MDS-co-CES) nanoparticles 
P(MDS-co-CES) nanoparticle/Lectin A-
chain nanocomplex 
(1 ppm) (1 0 ppm) 
(1 0 ppm) (1 0 ppm) 
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nanocomplexes. MDA-MB-231 cells showed the least tolerance to the cytotoxic effects 
of the complexes, followed by HeLa, HepG2 and 4T1 cells.  
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Figure 3.5 Viability of (A) MDA-MB-231, (B) HeLa, (C) HepG2 and (D) 4T1 cells after three days of 
incubation with nanoparticle/lectin A-chain nanocomplexes containing a varying concentration of lectin A-
chain and a fixed concentration of P(MDS-co-CES). P(MDS-co-CES) concentrations were fixed at 20, 50, 
40 and 100 ppm for (A), (B), (C) and (D) respectively. Each condition was tested in eight replicates. The 
standard deviation is presented in error bars.  
 
The cytotoxicity of nanoparticle/lectin A-chain nanocomplexes was compared to 






BioPorter mediated lower cytotoxic effects of lectin A-chain in the serum-containing cell 
culture medium than in the serum-free medium due to its instability in the presence of 
serum proteins. Comparing the two carriers, cytotoxicity exerted by lectin A-chain 
delivered via P(MDS-co-CES) nanoparticles in the serum-containing medium was 
significantly higher than that attained by BioPorter/lectin A-chain complexes. Under the 
same serum conditions, P(MDS-co-CES) nanoparticle/lectin A-chain resulted in 200 and 
500 times lower IC50 of lectin A-chain in MDA-MB-231 and HeLa cells respectively. 
This may be due to greater cellular uptake, stability and endosomal buffering capacity of 
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Figure 3.6 Comparison studies of P(MDS-co-CES) nanoparticles- and BioPorter-mediated lectin A-chain 
delivery to (A) MDA-MB-231, (B) HeLa, (C) HepG2 and (D) 4T1 cells. P(MDS-co-CES) concentrations 
were fixed at 20, 50, 40 and 100 ppm for (A), (B), (C) and (D) respectively in serum-containing medium. 




In this chapter, the possibility of using cationic micelles fabricated from 
biodegradable, amphiphilic polymers intracellular delivery of proteins was investigated.  
The P(MDS-co-CES) micelles were able to bind to therapeutic glycoprotein, lectin A-
chain, to form nanocomplexes that were small enough (~150nm) and positively-charge 
(+30 mV) for mediating cellular uptake. Intracellular release of the protein from the 
nanocomplexes and preservation of protein activity is shown from the cytotoxicity 
studies as protein is only functional when released into the cytoplasm. When compared to 
commercial delivery agent, BioPorter, the cytotoxicity of lectin A-chain delivered by 
P(MDS-co-CES) nanoparticles was significantly higher even in the serum-containing 
medium. Hence, these nano-sized particles show great potential to serve as an efficient 





INVESTIGATION OF CO-DELIVERY OF                       
THERAPEUTIC PROTEIN AND ANTI-CANCER DRUG USING 
CATIONIC POLYMERIC NANOPARTICLES 
 
4.1 Introduction 
Combination therapy with two or more drugs in has been widely reported to show 
great improvements in cancer treatment efficacy and lower risk of multidrug resistance 
development. However, current treatment regimens are typically developed using free 
drugs without delivery carriers and may not be able to bring about the best possible 
therapeutic efficacy. One of the key aspects of my study is to investigate the possibility of 
using polymeric micelles as co-delivery vehicles for anti-cancer drugs and proteins for 
cancer therapy. For this part of my study, investigation was carried out on the delivery of 
another therapeutic protein of similar molecular weight, i.e. recombinant human tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL, MW: 20 kDa) and anti-cancer 
drugs simultaneously. The cooperative interaction of chemotherapeutic drug and TNF-
related apoptosis inducing ligand (TRAIL) is utilized to achieve synergistic anti-cancer 
effects. TRAIL is an important tumor necrosis factor (TNF)-family protein [269, 289], 
and it can initiate apoptosis through binding with cell death receptors, TRAIL-R1 (DR4) 
and TRAIL-R2 (DR5). Briefly, in TRAIL-induced apoptosis, TRAIL first binds to death 
receptors present on cell surface. Following this, formation of the death-inducing 
signaling complex (DISC) occurs, which leads to a cascade of caspases activation. There 
are three additional receptors that act as ‘decoys’: TRAIL-R3 (DcR1), TRAIL-R4 
(DcR2), and osteoprotegerin (OPG). These receptors can bind to TRAIL, but are unable 
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to provide apoptotic signaling [289, 290]. There are other members present in the TNF 
super family, such as TNFα and Fas ligand (FasL). These TNF family proteins can also 
initiate apoptosis in solid tumor but their clinical applications have mostly been hampered 
by hepatotoxicity [268]. On the contrary, native TRAIL is a particularly promising 
therapeutic member of the TNF-family as its cytotoxic activity is selective to the human 
tumor cells and does not exhibit considerable toxicity in normal cells. Studies on in vitro 
hepatotoxicity have been documented [291, 292] but they involved the use of different 
recombinant versions of TRAIL that contains exogenous tags such as polyhistidine 
(TRAIL-His) or FLAG (TRAIL-FLAG). Tagged versions of TRAIL are different from 
native TRAIL with regards to biochemical properties such as zinc content and trimeric 
structure, and such differences have been linked to the variations in their cellular and 
animal toxicities [293].  
Till this date, preclinical models have demonstrated that TRAIL is able to retard 
the growth of human tumor xenografts in animals, and enhance chemotherapy and 
radiotherapy effects without evoking lethal toxicities [268, 269, 289, 294]. Previous 
reports attributed the ability of TRAIL to selectively kill tumor cells largely to the 
relatively higher expression of decoy receptors on normal cells as compared to tumor 
cells [293, 295] as these receptors compete for TRAIL binding with the death receptors. 
In addition, more recent findings have suggested that the relative expression levels 
between death and decoy receptors do not correlate with TRAIL sensitivity, but other 
factors involve in the death signaling pathway such as death inhibitors (e.g. cellular-FLICE 
inhibitory protein (c-FLIP), Fas-associated phosphatase-1 (FAP-1) and Inhibitor of 
Apoptosis (IAP) proteins) may be responsible for differential susceptibility to TRAIL-
induced cell death [268, 290, 295, 296]. 
92 
 
Although TRAIL is able to induce apoptosis in cancers of diverse origin, 
therapeutic efficacy of TRAIL may not be optimal when the protein is used as a 
monotherapy. However, when it is used in combination with conventional 
chemotherapeutic drugs such as cisplatin, paclitaxel, doxorubicin, 5-fluorouracil, and 
camptothecin, the effectiveness of combination treatment is greatly increased [297-303].  
Sensitivity of cancer cells to combination treatment using TRAIL and 
chemotherapy vary widely and the underlying mechanism is still unclear. Some cancer 
cell lines are susceptible to concurrent treatment, while some cancer cells in preclinical 
studies involving Pac and TRAIL combination treatment require sequential treatment of 
cells with the chemotherapeutic drug followed by TRAIL [301, 303] as neither concurrent 
treatment with both agents nor reversal sequence of drug exposure was able to induce 
comparable levels of apoptosis. In such scenarios, despite the promise for therapeutic 
improvements, the downside to sequential treatment method is apparent. Some of the 
potential problems include inconveniences arising from multiple drug administrations 
and ambiguity in whether co-internalization of the therapeutic drug and TRAIL can occur 
in the same cells. Pac, which is a commonly used drug against solid tumors, is 
administered through a vehicle comprising of Cremophor EL (polyethoxylated castor oil) 
and ethanol due to its low aqueous solubility (less than 2 μg/mL). However, the use of 
such organic solvents is often related with hypersensitivity issues. Thus, the development 
of solvent-free formulations such as nanoparticles becomes extremely beneficial for 
patients with adverse response against such solvents [304-306].   
 Several types of polymeric micelles/nanoparticles have been developed and used 
for the delivery of drugs and macromolecular therapeutics such as DNA, siRNA and 
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proteins [261, 307-314]. Recently, our group reported cationic micelles self-assembled 
from a biodegradable amphiphilic copolymer P(MDS-co-CES) [261], and used them for 
efficient in vitro and in vivo co-delivery of drug and gene. In the earlier study, 
nanocomplexes were successfully fabricated by loading an anti-cancer glycoprotein, 
lectin A, onto the surface of the micelles. These cationic nanoparticles have been shown 
to significantly enhance the cellular uptake of the protein and its cytotoxicity against 
several types of cancer cell lines [313]. 
For this study, cationic P(MDS-co-CES) micelles were used to co-deliver Pac and 
TRAIL simultaneously. Pac was loaded into the core of the micelles by physical 
encapsulation and TRAIL was then absorbed onto the surface of these micelles. 
Simultaneous delivery of Pac and TRAIL using the nanoparticles would facilitate clinical 
usage by reducing the number of administrations and concurrently delivering both Pac 
and TRAIL to the same cells. In addition, the dosage of Pac and TRAIL can be 
conveniently manipulated by adjusting the initial loading level via this co-delivery 
approach. Physical properties of the nanoparticle/TRAIL and Pac-loaded 
nanoparticle/TRAIL complexes were characterized with regards to particle size, zeta 
potential, and drug loading as well as release capacities. Cellular localization and uptake 
of fluorescently-labeled TRAIL delivered using P(MDS-co-CES) nanoparticles was 
studied via confocal microscopy and flow cytometry. Co-delivery of Pac and TRAIL 
using the micellar nanoparticles was also demonstrated to exert significant enhanced 
cytotoxic and anti-proliferative effects in three human breast cancer cell lines with 





4.2 Results and Discussion 
4.2.1 Characterization of Pac-loaded nanoparticles and Pac-loaded 
nanoparticle/TRAIL complexes  
 
 
Cationic Pac-loaded P(MDS-co-CES) nanoparticles have an average size of 181 
nm and zeta potential of about 82 mV (Figure 5.1). Compared to blank P(MDS-co-CES) 
nanoparticles (84 nm), the physical entrapment of Pac in the hydrophobic core of 
micelles results in an increase in micellular volume. Formation of nanocomplexes 
between P(MDS-co-CES) nanoparticles and TRAIL shields some of the cationicity of the 
nanoparticles. We observe that as more TRAIL is added for complexation, there is a 
general increase in size and decrease in zeta potential of the complexes. From zeta 
potential measurements, TRAIL shows a weak positive charge in 20 mM sodium 
acetate/acetic acid buffer (pH 6.0) (4 mV). Hence, binding between TRAIL and 
nanoparticles would most likely be occurring through hydrogen bonding, hydrophobic 
interaction and van der Waals forces at different regions of TRAIL and P(MDS-co-CES).  
The overall positive charge of P(MDS-co-CES) nanoparticle/TRAIL complexes may 
improve their interaction with negatively-charged cell membranes and increase cellular 
uptake of the complexes [315, 316]. Moreover, the adsorption of TRAIL molecules on 
particle surface could also increase the probability of TRAIL molecules interacting with 
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Figure 4.1 Size and zeta potential properties of Pac-loaded P(MDS-co-CES) nanoparticle/TRAIL 
complexes. Experiments were carried out in triplicates. The standard deviation is presented in error bars. 
Polymer concentration was fixed at 50 µg/mL. All condition was tested in triplicates.  
 
4.2.2 Native protein gel shift assay on TRAIL binding efficiency of P(MDS-co-
CES)  nanoparticles  
 
Increase in size and reduction in zeta potential of Pac-loaded nanoparticles after 
complexation with TRAIL (Section 4.2.1) illustrates that Pac-loaded nanoparticles are 
able to bind TRAIL and package the protein to form stable nanocomplexes. Native (non-
denaturing) protein gel shift assay was performed to ensure that TRAIL remains in its 
native confirmation and is not denatured during the complexation process. From this 
assay, we are also able to compare the ability of P(MDS-co-CES) nanoparticles to bind 
TRAIL at different mass ratios. Pac-loaded nanoparticle/TRAIL complexes were 
prepared with different mass ratios of nanoparticles to TRAIL, and the resulting mixture 
was then applied to a native polyacrylamide gel. From Figure 4.2, we observe that with 
increasing nanoparticles to TRAIL mass ratio from 1 to 20 (Lanes 2 to 5), the 
electrophoretic mobility of TRAIL is also increasingly reduced. The complete retardation 
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of TRAIL mobility is achieved at mass ratio of 20. Distinct/non-smeared protein bands 
on the gel also indicate that TRAIL remains in their native confirmation after 






Figure 4.2 Native protein gel assay of Pac-loaded P(MDS-co-CES) nanoparticle/TRAIL complexes. Lane 
1 – TRAIL (2 μg) alone, Lane 6 – Pac-loaded P(MDS-co-CES) nanoparticles (40 μg) alone, Lanes 2 to 5 – 
nanoparticle to protein mass ratios:  1, 5, 10 and 20 respectively. 
 
4.2.3 Drug loading and in vitro release 
Encapsulation efficiency and loading level of Pac in P(MDS-co-CES) micellar 
nanoparticles was determined to be 58.3 % and 14.7 % respectively. The release profile 
of Pac from P(MDS-co-CES) nanoparticles with or without TRAIL was monitored over 
191 hours at 37oC (Figure 5.3). Most of the drug molecules are released within the first 
72 hours of incubation. After that, release of drug from the micelles tapers and eventually 
comes to a gradual stop (71.6% and 60.9%, in the absence and presence of TRAIL 
respectively). The release rate and extent of Pac release are slightly reduced by the 
presence of TRAIL on the surface of nanoparticles. 






























Figure 4.3 Release profiles of Pac from P(MDS-co-CES) micellar nanoparticles with and without TRAIL 
in PBS (pH 7.4) at 37°C. Each condition was tested in triplicates. The standard deviation is presented in 
error bars. 
 
4.2.4 Cellular trafficking of P(MDS-co-CES) nanoparticle/TRAIL complexes  
Cellular localization of double-labeled nanoparticle/TRAIL complexes was 
studied in all three cell lines, MCF7, T47D, MDA-MB-231 via confocal microscopy. In 
particular, cellular trafficking of the nanocomplexes was monitored in MDA-MB-231 
over a 3 hour period. Nuclei were stained blue with DAPI, and cellular distribution of 
Alexa Fluor 555-TRAIL and FITC-loaded P(MDS-co-CES) nanoparticles are shown as 
red and green fluorescence respectively. From Figure 4.4, we see that at 5 minutes post-
exposure, nanocomplexes form a thin fluorescent lining with small fluorescent clumps 
(see arrows) along the cell surface membrane. At 30 minutes post-exposure, clumps of 
fluorescence appear within cytoplasm. And at 1 hour post-exposure clumps of 
fluorescence become larger and increase in number. Strong co-localization of Alexa 
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Fluor 555-TRAIL and FITC-loaded P(MDS-co-CES) nanoparticles, represented by 
yellow regions, indicates that TRAIL is delivered to the cells with nanoparticles 
simultaneously. Some Alexa Fluor 555-TRAIL continues to be present on cell surface 
probably due to interaction of TRAIL (dissociated from the nanoparticles) with 
death/TRAIL receptors (see arrows). At 3 hour post-exposure, endocytosis of the 
nanocomplexes becomes more extensive and the reduction of co-localization (red and 
green fluorescence appear at different parts of the cells) demonstrates that TRAIL 
molecules have dissociated from the P(MDS-co-CES)  nanoparticles.  
 
                        
 
                        
 
 
Figure 4.4 Cellular trafficking and distribution of doubled-labeled P(MDS-co-CES) nanoparticle/TRAIL 
nanocomplexes in MDA-MB-231 cells, at 5 minutes, 30 minutes, 1 hour and 3 hours respectively. Nuclei 
were stained blue with DAPI, and cellular distribution of Alexa Fluor 555-TRAIL and FITC-loaded 
P(MDS-co-CES) nanoparticle appears as red and green fluorescence respectively. 1 mg/l of Alexa Fluor 




4.2.5 Cellular delivery of TRAIL using P(MDS-co-CES) nanoparticles 
To provide a clearer understanding of the TRAIL delivery capabilities of P(MDS-
co-CES), fluorescently-labeled TRAIL was delivered using P(MDS-co-CES) 
nanoparticles and the cells were analysed using flow cytometry. From Table 4.1, we 
observe that the amount of TRAIL delivered to all three cell lines using P(MDS-co-CES) 
nanoparticles is significantly higher compared to TRAIL alone. Furthermore, in all three 
cell lines, P(MDS-co-CES) nanoparticles carrying Pac resulted in higher cellular 
association and internalization of TRAIL as compared to blank nanoparticles. This 
indicates that the release of Pac from nanoparticles most likely enhances the expression 
of death receptors on the cells as previously reported, and this has resulted in greater 
interaction between TRAIL and the cells.  
 
Table 4.1 Uptake of Alexa Fluor 555-TRAIL into MCF7, T47D and MDA-MB-231 cells at 3 hours after 
TRAIL delivery using the nanoparticles. The values shown represent the mean ± S.D. (n=3). 
Treatments MCF7 T47D MDA-MB-231 
Control 0.3 ± 0.0 0.2 ± 0.1 0.2 ± 0.1 
TRAIL alone 1 ± 0.2 0.2 ± 0.1 1.3 ± 0.2 
TRAIL with blank P(MDS-co-CES) 16.3 ± 0.5 8.5 ± 0.6 66.8 ± 2.0 
TRAIL with Pac-loaded P(MDS-co-
CES) 20.2 ± 0.8 14.2 ± 0.6 74.6 ± 2.6 
 
 
4.2.6 Sensitization of cancer cells to TRAIL and synergistic cytotoxic effect 
achieved by simultaneous delivery of Pac and TRAIL using P(MDS-co-CES) 
nanoparticles 
 
Enhancement of cytotoxicity and apoptosis induction of Pac-loaded 
nanoparticle/TRAIL complexes is studied. For TRAIL delivery, prior cytotoxicity 
experiments have been performed to optimize P(MDS-co-CES) concentrations to enable 
efficient binding with TRAIL without significant non-specific cytotoxicity from the 
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cationic polymer. Concentration of P(MDS-co-CES) is determined by allowing the 
maximum possible amount of polymer to be used while maintaining the cell viability to 
be greater than 85%, which is 10 mg/l.  
TRAIL shows certain cytotoxicity towards MDA-MB-231 cells, and cell viability 
was ~ 80% after 48 hours of incubation with 10 nM TRAIL. However, it does not induce 
significant cytotoxicity against MCF7 and T47D (cell viability: ~92% for MCF7 and 
~98% for T47D at 10 nM TRAIL). This is most likely to do with the different sensitivity 
of the cells to TRAIL as MDA-MB-231 has been known to be TRAIL-sensitive while 
MCF7 and T47D are semi-sensitive to TRAIL [301, 302]. Delivery of TRAIL using 
blank P(MDS-co-CES) nanoparticles resulted in an increase in cytotoxicity compared to 
TRAIL alone especially for semi-sensitive MCF7 and T47D (Table 4.2). This is probably 
due to the increase in TRAIL binding and internalization into the cells mediated by the 
delivery using the nanocarriers (Table 4.1). 
From Figure 4.5A-C, when Pac is incorporated into the micelles and co-delivered 
with TRAIL simultaneously, cytotoxicity is significantly enhanced for all three cell lines 
tested. This event is observed especially after 48 hours of incubation and we attribute this 
to the gradual release of Pac within the cells and low initial amount of released Pac 
during the first 24 hours of incubation. Indeed, co-delivery of Pac sensitizes the cells to 
TRAIL. For example, in MDA-MB-231 cells, cell viability is significantly reduced by 
approximately one-fold after being treated with Pac-loaded nanoparticle/TRAIL 
complexes (TRAIL: 10 nM; Pac: 1.67 µM) to 42% as compared to 78% with TRAIL or 
91% with Pac-loaded nanoparticles alone, demonstrating significant synergistic effect in 
suppressing cell survival. This finding is in agreement with that reported by Singh TR et 
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al [301]. They observed an enhancement of cytotoxic effect when these three cell lines 
were pretreated with free Pac followed by TRAIL. To confirm synergism, the dose-
response interactions at the IC50 level were analyzed by the isobologram method. 
Synergy between the two compounds is shown as the drug combination dose falls to the 
left of the line of additivity. Synergistic cytotoxic effects from the co-delivery of Pac and 
TRAIL was seen in all three cell lines (representative isobologram in Figure 4.5D). With 
this increase in therapeutic efficacy, the amount of Pac and TRAIL needed to induce the 
same level of cytotoxicity is successfully reduced and this serves to reduce the adverse 
side effects of the therapeutic agent. Importantly, the co-delivery approach is more 
advantageous when compared to the free Pac and TRAIL formulation for future clinical 


















































































































Figure 4.5 Viability of (A) MCF7, (B) T47D and (C) MDA-MB-231 cells after 24 and 48 hours incubation 
with (1) blank nanoparticles, (2) TRAIL, (3) blank nanoparticle/TRAIL complexes, (4) Pac-loaded 
nanoparticles (5) Pac-loaded nanoparticle/TRAIL complexes. Cell culture was performed in serum-
containing medium. P(MDS-co-CES) (10 mg/l), TRAIL (10 nM) and Pac (1.67 µM) were used. The 
standard deviation is shown by error bars that represent the mean ± S.D. (n=4). Statistical significance in 
differences was evaluated by Newman–Keuls Multiple Comparison Test after analysis of variance 
(ANOVA). P≤0.05 was considered statistically significant. (D) An isobologram analysis representing the 
synergy between the two drugs at combination dose of Pac-loaded nanoparticles (10 mg/l) and TRAIL (10 
nM) in MCF7. 
 
 
Cytotoxicity was further compared against treatment with the combination of free 
Pac and TRAIL (Table 4.2). Unlike the co-delivery formulation using the nanoparticles, 
the free Pac + TRAIL formulation does not induce any enhancement in cytotoxicity in 
MCF7 and T47D cells as compared to free Pac. However, in MDA-MB-231 cells, 
significant enhancement of cytotoxicity is observed after treatment with the free Pac + 







nanoparticles. Although the mechanisms are not clear, we hypothesize that this may be 
due to the different sensitivity of cells to TRAIL, i.e. MDA-MB-231: TRAIL-sensitive 
and MCF7/T47D: semi-sensitive [301, 302].  An important point to note is that, the co-
delivery of Pac and TRAIL using the nanoparticles is significantly more effective in 
suppressing the survival of MCF7 and T47D (Table 4.2) compared to free Pac + TRAIL 
formulation. 
 
Table 4.2 Viability (%) MCF7, T47D and MDA-MB-231 cells after 48 hours incubation with free 
Paclitaxel (Pac) and Pac-loaded nanoparticles in the presence or absence of TRAIL. P(MDS-co-CES) 
concentration was fixed at 10 mg/l for all cell lines. Cell culture was performed in serum-containing 
medium. The values shown represent the mean ± S.D. (n=3) 
Treatments MCF7 T47D 
MDA-MB-
231 
Free Pac (1.7µM) 80.7 ± 3.0 77.2 ± 5.4 77.9 ± 3.1 
TRAIL (10nM) 91.8 ± 7.8 98.0 ± 5.5 79.6 ± 1.5 
Free Pac (1.7µM) + TRAIL (10nM) 76.2 ± 3.5 72.8 ± 4.5 41.2 ± 1.5 
Blank P(MDS-co-CES) + TRAIL (10nM) 74.7 ± 4.3  79.1 ± 3.1 73.5 ± 2.7 
Pac-loaded P(MDS-co-CES) (1.7µM) 69.1 ± 6.3 82.4 ± 4.3 90.7 ± 8.3 
Pac-loaded P(MDS-co-CES) (1.7µM) + TRAIL 
(10nM) 51.3 ± 2.3 56.6 ± 3.5 42.1 ± 3.2 
 
 
Apoptotic signaling by TRAIL involves prior binding to cell surface death 
receptors (DR4 and DR5), followed by DISC formation at cell membrane rafts. In this 
study, although nanoparticle/TRAIL complexes are internalized after binding to cells 
(Figure 4.4), proapoptotic functions of TRAIL and synergism with pac are not affected. 
This is in agreement with a study conducted by Kohlhaas and her co-workers [317], 
where cellular internalization of TRAIL occurs within a similar time (~ 30 min for 
complete endocytosis). In addition, although cellular entry of TRAIL has not been shown 
to be required for cell death signaling, it occurs naturally subsequent to receptor binding. 
Thus, cell death signaling occurs rapidly after the binding of nanoparticle/TRAIL 
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complexes to cells and internalization of the nanocomplexes therefore is not likely to 
interfere with mechanistic action of TRAIL.  
 
4.2.7 Cell cycle and caspase-dependent apoptosis studies  
Through cell cycle analysis (Figure 4.6) in MCF7 and MDA-MB-231 cells, we 
have demonstrated that pac, when released from micelles, is able to induce cell cycle 
arrest at the G2/M phase. After 48 hours of exposure to Pac-loaded nanoparticles, 67.3% 
and 42.5% of MCF7 and MDA-MB-231 cells were arrested in G2/M phase respectively. 
In view of this hallmark cellular response to Pac, it is clear that the drug released from 
micelles remains active in inducing mitotic arrest. However, although mitotic arrest is 
often associated with growth delay, it is often not representative of cell death occurrences 
[318]. With the co-delivery of Pac and TRAIL, we observe a significant increase in the 
subG1 population in both cell lines, which indicates an increase in apoptotic activity 



































Figure 4.6 Cell cycle analysis of (A) MCF7 and (B) MDA-MB-231 cells after 48 hours incubation with (1) 
medium alone, (2) blank nanoparticles, (3) TRAIL, (4) blank nanoparticle/TRAIL complexes, (5) Pac-
loaded nanoparticles (6) Pac-loaded nanoparticle/TRAIL complexes. P(MDS-co-CES), TRAIL and Pac 
concentrations were fixed at 10 mg/l, 10 nM and 1.67 µM for both cell lines. Cell culture was performed in 




To determine if the observed apoptotic activity occurs through caspase-dependent 
mechanisms, all 3 cell lines were treated with nanoparticles, in the presence or absence of 
the pan-caspase inhibitor, ZVAD-FMK. Cell viability assay reveals that ZVAD-FMK 
inhibits cell death resulting from Pac-loaded nanoparticles, TRAIL and Pac-loaded 
nanoparticle/TRAIL complexes, indicating that the cytotoxic activity is based on caspase-




















































































Figure 4.7 Viability of (A) MCF7, (B) T47D and (C) MDA-MB-231 cells in the presence or absence of 
pan-caspase inhibitor ZVAD-FMK (20µM) pretreatment prior to 48 hour incubation with (1) blank 
nanoparticles, (2) TRAIL, (3) nanoparticle/TRAIL complexes, (4) Pac-loaded nanoparticles and (5) Pac-
loaded nanoparticle/TRAIL complexes. P(MDS-co-CES), TRAIL and Pac concentrations were fixed at 10 
mg/l, 10 nM and 1.67 µM respectively, for all cell lines. Cell culture was performed in serum-containing 
medium. The error bars represent the mean ± S.D. (n=4). Statistical significance in differences was 








4.2.8 Specificity in cytotoxicity towards cancerous cells 
To examine any nonspecific cytotoxicity which the nanocomplexes may have on 
non-cancerous cells, WI38 was chosen as a representative model cell line. Upon exposure 
to various treatments that have been applied to the cancer cells, we observe that there is 
no considerable cytotoxicity to WI38 (Figure 4.8), and the cell viability still exceeds 80% 
after 48 hours of exposure to Pac-loaded nanoparticle/TRAIL complexes while the 
viability of MDA-MB-231 human breast cancer cells is reduced to only 42% after the 
same treatment. This shows that the nanocomplexes have selective killing effects towards 
cancer cells and not the non-cancerous cells. Similarly, treatment of WI38 with the 
combination of free Pac and TRAIL does not induce significant cytotoxicity. This is most 























Figure 4.8 Viability of WI38 cells after 48 hours incubation with (1) blank nanoparticles, (2) TRAIL, (3) 
blank nanoparticle/TRAIL complexes, (4) Pac-loaded nanoparticles, (5) free Pac, (6) free Pac + TRAIL, (7) 
Pac-loaded nanoparticle/TRAIL complexes. Cell culture was performed in serum-containing medium. 
P(MDS-co-CES) (10 mg/l), TRAIL (10 nM) and Pac (1.67 µM) were used. The standard deviation is 
shown by error bars that represent the mean ± S.D. (n=3). Statistical significance in differences was 
evaluated by Newman–Keuls Multiple Comparison Test after analysis of variance (ANOVA). P≤0.05 was 
considered statistically significant.   
 
 
4.2.9 Long-term survival and proliferation assays 
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From anchorage-dependent clonogenic assay (Figure 4.9A and B), we are able to 
determine the long-term drug effect and proliferation of the cells treated with various 
formulations. Pre-exposure of MCF7 and MDA-MB-231 cells to Pac-loaded 
nanoparticles or Pac-loaded nanoparticle/TRAIL complexes significantly impair 
subsequent survival and clonogenicity, and cell death continues even after the drugs are 
removed. In particular, most of the cells treated with the co-delivery system are 
mitotically arrested or enter into senescence [271]. With prolonged culture, these 
senescent cells eventually die, leaving very few cells capable of anchorage and survival. 
In view that Pac-loaded nanoparticle/TRAIL complexes result in significantly higher 
cytototoxicity within a short culture period (48 hours) and higher impediment to long-
term proliferation as compared to TRAIL and Pac-loaded nanoparticles, we have 
established that this co-delivery system displays excellent effectiveness in inducing rapid 





































Figure 4.9 (A) Colony formation at Day 17 and 11 in MCF7 and MDA-MB-231 cell lines respectively 
subsequent to 48 hours treatment with (1) control, (2) blank nanoparticles, (3) TRAIL, (4) blank 
nanoparticle/TRAIL complexes (5) Pac-loaded nanoparticles (6) Pac-loaded nanoparticle/TRAIL 
complexes. Colonies were stained with 0.5% w/v crystal violet. Cell culture was performed in serum-
containing medium. P(MDS-co-CES) (10 mg/l), TRAIL (10 nM) and Pac (1.67 µM) were used. The error 
bars represent the mean ± S.D. (n=3). Statistical significance in differences was evaluated by Newman–
Keuls Multiple Comparison Test after analysis of variance (ANOVA). P≤0.05 was considered statistically 
significant. (B) Images of MCF7 colony taken at Day 17 subsequent to 48 hours treatment with (1) control, 
(2) blank nanoparticles, (3) TRAIL, (4) nanoparticle/TRAIL complexes, (5) Pac-loaded nanoparticles and 
(6) Pac-loaded nanoparticle/TRAIL complexes. P(MDS-co-CES), TRAIL and Pac concentrations were 




                                          
In this study, cationic micellar nanoparticles self-assembled from a biodegradable 
amphiphilic copolymer P(MDS-co-CES) are used to deliver human tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) and pac simultaneously. The co-
delivery of Pac sensitizes human breast cancer cells to TRAIL and achieves synergistic 
anti-cancer activities. Polyplexes formed between Pac-loaded nanoparticles and TRAIL 
1 2 3 




are stable with size at ~180 nm and a zeta potential at ~75 mV. P(MDS-co-CES) 
nanoparticles function effectively as a carrier for delivery of TRAIL to cells. Anticancer 
effects and apoptotic pathway mechanisms of this drug-and-protein co-delivery system 
are investigated in various human breast cancer cell lines with different TRAIL-
sensitivity. The co-delivery of Pac and TRAIL using P(MDS-co-CES) nanoparticles 
induces cell death and deters long-term proliferation of the cells with limited toxicity in 
non-cancerous cells. Another notable advantage is the synergistic anticancer effects 
offered by the simultaneous delivery of Pac and TRAIL in nanoparticle system as 
compared to free drug and protein administration. Thereby, we establish that this co-
delivery system represents a comprehensive and effectual approach towards 





SYNERGISTIC ANTI-CANCER EFFECTS IN                                  
TRAIL-RESISTANT CANCER CELLS BY THE                                 
CO-DELIVERY OF TRAIL AND DOXORUBICN USING         
CATIONIC POLYMERIC NANOPARTICLES 
 
5.1 Introduction 
Colorectal cancer is the third most common cause of cancer-related death 
throughout the world [57] and for many years, it has served as a prototypic model for 
research on the role of epigenetic mutations in tumorigenesis [319, 320]. Interventional 
approaches of the disease are often met with obstacles such as either intrinsic resistance 
to chemotherapeutic drugs, or the acquirement of drug resistance in those who responded 
positively during the initial phase of treatment. Like most other human cancers, the 
development of drug resistance poses a major concern for the eventual failure of 
chemotherapy. In recent times, most of the cancer treatment approaches involve the use 
of multiple therapeutic agents as the use of single agent in cancer chemotherapy is largely 
limited by dose-dependent toxicity and development of drug resistance after repeated 
administrations. To formulate potent drug combinations, it is therefore important to 
identify and deliver therapeutic molecules that can overcome cellular resistance 
mechanisms. 
Proapoptotic proteins belonging to the tumor necrosis factor (TNF) family of 
death ligands, including TNF, Fas ligand (FasL) and TNF related apoptosis-inducing 
ligand (TRAIL) [321, 322] can be used to overcome resistance to conventional 
chemotherapeutic drugs. In addition, unlike many conventional anti-cancer agents, 
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TRAIL can induce apoptosis independent of the p53 tumor suppressor gene status of 
cancer cells, which is mutated in >50% of human cancers [323]. 
However, similar to many other chemotherapeutics, resistance to the treatment 
can eventually develop with repeated administrations of TRAIL. Many studies have 
shown that the development of resistance to TRAIL may be the result of changes in the 
expression levels of the various protein factors involved in the apoptotic signaling [324, 
325]. As a result, the use of TRAIL as a monotherapy may be futile as an ultimate cure 
for these cancers. Various attempts have been made to treat patients with TRAIL in 
combination with small molecular drugs such as doxorubicin, 5-fluorouracil and 
tunicamycin with reported success in overcoming TRAIL-resistance and enhancing anti-
cancer effects [326-330]. In clinics, studies have been performed by sequential treatment 
with drugs followed by TRAIL or therapeutic antibodies against TRAIL receptors [331, 
332]. Such settings usually give rise to several drawbacks. Some of the foreseeable 
difficulties include patients’ compliance and cost incurred from multiple drug 
administrations. Therapeutic efficacy may also be compromised as a result of 
uncertainties and inadequacies of co-internalization of the therapeutic drugs and TRAIL 
into the same cells.  
In the previous chapter, Pac and TRAIL were co-delivered using cationic micelles 
self-assembled from P(MDS-co-CES) for investigation of anti-cancer effects in non-drug 
resistance human breast cancer cells. For this study, the potential of using these drug 
delivery systems as a solution to tackle the problem drug-resistance is investigated. These 
micelles are used to deliver another anti-cancer drug, doxorubicin (Dox) and TRAIL 
simultaneously into colorectal carcinoma SW480 cells with TRAIL-resistance. The 
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SW480 cell line contains mutations in the p53 gene [323, 333] and is therefore, an 
excellent model to demonstrate the therapeutic efficacy of co-delivery system. Dox was 
physically encapsulated into the micelles and TRAIL was then absorbed onto the surface 
of these cationic micelles. Physical characterization of the nanoparticle/TRAIL and Dox-
loaded nanoparticle/TRAIL complexes was performed with respect to particle size, zeta 
potential, and drug loading as well as release properties. To prove that the cellular uptake 
of Dox-loaded P(MDS-co-CES) nanoparticle/TRAIL complexes occurs through  specific 
interaction between the death receptors and TRAIL present on the nanoparticle surface, 
receptor-blocking studies were performed in SW480 cells using confocal microscopy 
studies. In addition, the cytotoxic selectivity of Dox-loaded nanoparticle/TRAIL 
nanocomplexes towards cancer cells (i.e. SW480) was studied in comparison with a non 
cancer cell line (i.e. WI38, a human lung fibroblast cell line). Moreover, the cytotoxic 
and anti-proliferative effects of co-delivery of Dox and TRAIL using the micellar 
nanoparticles against wild type and TRAIL-resistant SW480 cells were evaluated in 
comparison with free TRAIL, micelle/TRAIL complexes and Dox-loaded micelles. The 
results demonstrated that the co-delivery system can synergistically enhance cytotoxic 
and anti-proliferative effects in both wild type and TRAIL-resistant SW480 cells. 
Therefore, the nanocomplexes containing Dox and TRAIL are a promising therapeutic 
formulation that would facilitate clinical applications by delivering both Dox and TRAIL 
to the same cells and reducing the number of drug administrations. Synergistic cytotoxic 
effects exerted on TRAIL-resistant cancer cells also reveal the potential of using 
nanocomplexes as a solution towards drug-resistance in cancers. 
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5.2 Results and Discussion 
5.2.1 Size and zeta potential of nanocomplexes  
From Figure 5.1, cationic Dox-loaded P(MDS-co-CES) nanoparticles fabricated 
via the dialysis process had an average size of 223 nm and zeta potential of 73 mV. 
Physical encapsulation of Dox in the micelles resulted in an increase in micellar volume 
as compared to blank P(MDS-co-CES) nanoparticles (194nm). Formation of 
nanocomplexes between the nanoparticles and TRAIL resulted in slight changes in size 
(~ 230 nm) and zeta potential (~ 70 mV). In the sodium acetate/acetic acid buffer (pH 
6.0) that was used for complexation, TRAIL is slightly positively charged with a zeta 
potential of 4 mV.  Thereby, the association between TRAIL and nanoparticles would 
most likely be formed through hydrophobic interaction, hydrogen bonding and van der 
Waals forces. Cationicity of P(MDS-co-CES) nanoparticle/TRAIL nanocomplexes is 
desirable for interacting with cell surface membrane and cellular uptake of the 
complexes. Dense assembly of TRAIL molecules on the nanoparticle surfaces may also 
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Figure 5.1 Size and zeta potential properties of doxorubicin-loaded P(MDS-co-CES) nanoparticle/TRAIL 
complexes. Experiments were carried out in triplicates. The standard deviation is presented in error bars. 
Polymer concentration was fixed at 50 µg/mL. All condition was tested in triplicates.  
 
5.2.2 Native protein gel mobility shift assay on Dox-loaded P(MDS-co-CES)/TRAIL  
nanocomplexes 
 
Dox-loaded nanoparticle/TRAIL complexes were first prepared at different mass 
ratios of nanoparticles to TRAIL, and the resulting mixture was then run on a native 
polyacrylamide gel. From the changes in protein mobility during the gel electrophoresis 
process, it is possible to monitor the changes in the binding ability of P(MDS-co-CES) 
nanoparticles to TRAIL at different mass ratios. From Figure 5.2, we observe that 
increasing the nanoparticles to TRAIL mass ratio from 1 to 20 (Lanes 2 to 5) resulted in a 
decrease in the electrophoretic mobility of TRAIL. Complete retardation of TRAIL 
mobility occured at mass ratio of 10. Distinct protein bands on the gel indicate that 
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TRAIL remained in their native confirmation without degradation after complexation 
with P(MDS-co-CES) nanoparticles.  
 
 
     
Figure 5.2 Native protein gel assay of Dox-loaded P(MDS-co-CES) nanoparticle/TRAIL complexes. Lane 
1 – TRAIL (2 μg) alone, Lane 6 – Dox-loaded P(MDS-co-CES) nanoparticles (40 μg) alone, Lanes 2 to 5 – 
nanoparticle to protein mass ratios:  1, 5, 10 and 20 respectively. 
 
 
5.2.3 Drug loading and in vitro release 
The loading level of Dox in P(MDS-co-CES) micellar nanoparticles is defined as 
the ratio of the amount of encapsulated drug to the total mass of the micellar product and 
was determined to be 8.6 ± 2.4%. The in vitro release of Dox from P(MDS-co-CES) 
nanoparticles in the presence or absence of TRAIL was studied for 500 hours at 37oC in 
two different buffered solutions - PBS (pH 7.4) or 20 mM sodium acetate/acetic acid 
buffer (pH 5.6) solution.  As shown in Figure 5.3, in both buffers, typical two-phase-
release profiles are observed, by which, the drug was released at a relatively rapid rate in 
the initial phase followed by a slow and sustained release over a prolonged period of 
time. Under both conditions, there was no significant difference in the cumulative amount 
of Dox released in both the absence and presence of TRAIL.  Comparing the drug release 
profiles at the two pHs shows that the release of Dox from micelles at pH 5.6 was 
significantly faster than that at pH 7.4 with close to 40% higher amount of Dox released. 
This is in consistence with the faster release of DOX in acidic conditions as observed by 
Kataoka and his coworkers [334]. The increase in release rate at the lower pH was likely 
due to the protonation of the amino group of Dox, which led to the increase in aqueous 
1 2 3 4 5 6 
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solubility of the drug. Micellar nanoparticles are usually internalized by the cells via 
endocytosis [335]. Hence, pH-dependent release would enable preferential release of Dox 
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Figure 5.3 Release profiles of Dox from P(MDS-co-CES) micellar nanoparticles in the presence and 
absence of TRAIL in PBS (pH 7.4) and acetate buffer (pH 5.6) at 37°C. Each condition was tested in 
triplicates. The standard deviation is presented in error bars. 
 
5.2.4 Death receptor-mediated endocytosis of the TRAIL nanocomplexes  
Confocal microscopy studies were performed to visualize the cellular localization 
of fluorescent-labeled Dox-loaded nanoparticle/TRAIL nanocomplexes in SW480 cells 
over a 4 hour period (Figure 5.4A). Nuclei were stained blue with DAPI, and cellular 
distribution of Alexa Fluor 647-TRAIL and Dox-loaded P(MDS-co-CES) nanoparticles 
are shown as green and red fluorescence respectively. At 1 hour post-exposure to the 
TRAIL nanocomplexes, clumps of fluorescence appeared in the cytoplasm and strong co-
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localization of Alexa Fluor 647-TRAIL and Dox-loaded P(MDS-co-CES) nanoparticles, 
represented by yellow regions, were observed. This shows that both TRAIL and Dox 
were delivered to the cells with nanoparticles in a concurrent manner. At 4 hours post-
exposure, co-localization of TRAIL and Dox-loaded nanoparticles was reduced as Dox 
was released from the micelles and moved into the nucleus.  However, concurrent uptake 
of TRAIL and Dox into the same cells was observed at neither 1 hour nor 4 hours when 
they were administered in free forms (i.e. without the use of the nanoparticles). 
TRAIL signals apoptosis through binding with death receptors DR4 and DR5, 
expressed on cell surface. To prove that uptake of Dox-loaded P(MDS-co-CES) 
nanoparticle/TRAIL complexes occurs through  specific interaction between TRAIL 
present on the nanoparticle surface and the death receptors, receptor-blocking studies 
were performed. Cells were pre-incubated for 1 hr in the presence (blocked) or absence 
(unblocked) of blocking antibodies against the death receptors before incubation with 
nanocomplexes for an additional 1 or 4 hours. Pre-incubation with the anti-DR4 and -
DR5 antibodies blocked the cellular uptake of the nanocomplexes extensively, thus 
demonstrating that the entry of nanocomplexes was dependent on death receptors 
expressed on cell surface. When the same treatment was performed using free Dox and 
TRAIL formulation, the uptake of TRAIL was prevented, as expected. However, the 
uptake of Dox into the cells was unaffected. This further reveals that the specificity of the 
treatment towards cancer cells expressing death receptors can be conferred by using the 
TRAIL nanocomplexes.  
To elucidate the individual effects of the blocking antibodies on the cellular 
uptake of the nanocomplexes, SW480 cells were pre-incubated for 1 hr with individual 
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blocking antibodies against either of the death receptors (DR4 or DR5) before incubation 
with the TRAIL nanocomplexes for an additional 1 or 4 hours (Figure 5.4B). Confocal 
images showed that both the antibodies were able to block the cellular uptake of the 
nanocomplexes to a similar extent.  
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Figure 5.4 (A) Death receptor (DR4 and DR5)-mediated uptake of TRAIL, Dox-loaded P(MDS-co-CES) 
micelle/TRAIL nanocomplexes or free Dox+TRAIL formulation by SW480 cells. Cells were pre-incubated 
for 1 hour at 37°C in the presence (blocked) or absence (unblocked) of blocking antibodies against the 
death receptors before incubation with TRAIL, Dox-loaded micelle/TRAIL or free Dox+TRAIL 
formulation for an additional 1 or 4 hours. (B) Death receptor (DR4 or DR5)-mediated endocytosis of 
P(MDS-co-CES) micelle/TRAIL nanocomplexes in SW480 cells. Cells were pre-incubated for 1 hour at 37 
°C in the presence (blocked) of antibodies against the death receptors (either DR4 or DR5) before 
incubation with Dox-loaded micelle/TRAIL nanocomplexes for an additional 1 or 4 hours. Nuclei were 
stained blue with DAPI, and cellular distribution of Alexa Fluor 647-TRAIL and Dox-loaded P(MDS-co-
CES) nanoparticle appears as green and red fluorescence respectively. 0.8 mg/l of Alexa Fluor 647-TRAIL 
and 10 mg/l of Dox-loaded P(MDS-co-CES) nanoparticles were used. Dox loading level: 8.6%.  
 
5.2.5 Establishment of TRAIL-resistant cancer cells 
The emergence of drug resistance is a major problem, which results from 
prolonged and repeated treatment with the same drugs. For cancer therapy, such dosage 
cycles are usually inevitable and success of treatment is jeopardized at times due to the 
development of resistance to chemotherapeutic drugs. Therefore, in this study we have 




that are sensitive to TRAIL and those that have acquired resistance to TRAIL. To obtain 
cells resistant to TRAIL, SW480 cells with an IC50 of 100 nM TRAIL, were treated 
repeatedly with subtoxic doses of TRAIL (1 to 20 nM). The selection process is 
associated with only a low level of cell death (~ 20%) each time, thereby giving rise to a 
cell population that is representative of the majority of parental cells. The resultant 
SW480-TR cells were found to be resistant to cytotoxic effects of TRAIL, with even up 
less than 10% cell death at 1000 nM TRAIL (Figure 5.5A). Cell viability studies of these 
TRAIL-resistant cells showed that they have also developed slight cross-resistance to 
Dox-loaded nanoparticles (Figure 5.5B).  This minor cross-resistance might be due to 
some common death signaling intermediates, such as caspases, which were common 
















































Figure 5.5 Viability of parental SW480 and TRAIL-resistant SW480-TR cells after 48 hours incubation 
with varying TRAIL (0.1 to 1000 nM) (A) and DOX-loaded micelle concentrations (1 to 20 mg/l) (B). Dox 
loading level: 8.6%. The standard deviation is shown by error bars that represent the mean ± S.D. (n=3). 
 
5.2.6 Synergistic cytotoxic effect of Dox and TRAIL co-delivery using P(MDS-co-
CES) nanoparticles 
 
Synergism in anti-cancer effects and apoptosis induction of Dox-loaded 
nanoparticle/TRAIL complexes were investigated in both parental SW480 and TRAIL-
A B 
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resistant SW480-TR cells in comparison with individual formulations. As shown in 
Figure 5.6A and B, TRAIL exerted higher cytotoxic effect against SW480 cells when 
delivered by the nanoparticles at all concentrations tested (e.g. cell viability: 62% at 
nanoparticle concentration of 1 mg/l vs. 72% when TRAIL was used alone). However, in 
SW480-TR cells, an enhanced cytotoxic effect was only observed at nanoparticle 
concentration of 10 mg/l. Importantly, the co-delivery of Dox and TRAIL resulted in a 
significant enhancement of cytotoxicity at all nanoparticle concentrations used. 
Comparison between the parental and TRAIL-resistant cell lines showed a similar degree 
of enhancement of cytotoxicity although TRAIL-resistant cells were relatively more 
difficult to kill. For example, after being treated with Dox-loaded nanoparticle/TRAIL 
complexes (TRAIL: 10 nM; 5 mg/l nanoparticles with equivalent Dox concentration of 
0.8 µM), viability of parental SW480 cells was reduced by 40% more than that when 
being treated with TRAIL or Dox-loaded nanoparticles alone. Similarly, viability of 
SW480-TR cells was also reduced by close to 40% after treatment with the 
nanocomplexes as compared to the individual formulations. 
The cytotoxicity of Dox-loaded Micelles was also compared against free Dox in 
the absence and presence of TRAIL (Table 5.1). In parental SW480, Dox-loaded 
nanoparticles were more cytotoxic than free Dox with ~19% lower cell viability after the 
treatment. In SW480-TR cells, Dox-loaded nanoparticles had similar cytotoxicity as 
compared to free Dox. The Dox-loaded nanoparticle/TRAIL complexes and the free 
Dox/TRAIL formulation had similar cytotoxicity against both cell lines. However, in 
normal human lung fibroblasts WI38, Dox-loaded nanoparticles were significantly less 
cytotoxic than free Dox, both in the absence and presence of TRAIL.  
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Increase in subG1 population is considered a marker for apoptotic activities [337]. 
From cell cycle analysis (Figure 5.6 C and D), we observed that the treatment of TRAIL-
sensitive SW480 and TRAIL-resistant SW480-TR with free TRAIL or 
nanoparticle/TRAIL complexes or Dox-loaded nanoparticle/TRAIL complexes (TRAIL 
concentration: 10 nM) resulted in significantly higher subG1 population compared to the 
control without treatment, blank micelles and Dox-loaded micelles, indicating that cell 
death occurred via apoptosis when the TRAIL formulations were applied. In addition, 
treatment with free TRAIL, nanoparticle/TRAIL complexes or Dox-loaded 
nanoparticle/TRAIL complexes resulted in lesser subG1 population in SW480-TR cells 
compared to SW480 cells and this is in agreement with the TRAIL resistance developed 
in SW480-TR. However, the difference in subG1 population between SW480 and 
SW480-TR cell lines was the smallest when Dox-loaded nanoparticle/TRAIL complexes 
were used (47 vs. 17% for free TRAIL; 48 vs. 24% for micelle/TRAIL complexes; 58 vs. 
49% for Dox-loaded nanoparticle/TRAIL complexes). This demonstrates that the co-
delivery formulation is superior to free TRAIL and micelle/TRAIL complex formulations 
SW380-TR. 
To determine if the observed apoptotic activity occurs through caspase-dependent 
mechanisms, SW480 cells were treated with nanoparticles, in the presence or absence of 
the pan-caspase inhibitor, ZVAD-FMK. Cell viability assay revealed that ZVAD-FMK 
indeed inhibits cell death especially resulting from the co-delivery system, indicating that 
the apoptotic activity was based on caspase-dependent mechanisms (Figure 5.7). 
Synergistic cytotoxic effects from the co-delivery of Dox and TRAIL were 
analyzed using the isobologram method on the drug dose to reduce growth rate by half 
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(IC50). Synergy between the two compounds is demonstrated as the combination drug 
dosage falls to the left side of the line of additivity. From Figure 5.6 E and F, the 
combination dose (indicated by the coloured squares) of TRAIL and Dox delivered using 
the nanocomplexes was significantly lower than the individual therapeutics, thus 
demonstrating synergistic cytotoxic effects in both parental SW480 and SW480-TR cell 
lines. The enhancement in therapeutic efficacy by the co-delivery system will enable the 
same level of cancer cell death to be induced using a lower dose of Dox and TRAIL. This 
can reduce the dose-related harmful side effects of the drugs. Such improvements in anti-
cancer effects have also been observed in other studies where the combinations of Dox 
and TRAIL in free-drug formulations were able to induce a much higher level of 
cytotoxicity in prostrate cancer cells at sub-toxic dosages at which the single drugs were 
unable to cause significant amount of cancer cell death [338, 339]. In the current system, 
the co-delivery of Dox and TRAIL using P(MDS-co-CES) nanoparticles will enable 
simultaneous delivery of the two agents in a receptor-mediated manner and thereby 
inducing higher cytotoxicity selectively to cancer cells. The delivery the multiple 
therapeutic agents in a single nanoparticle system will also help to reduce the number of 
drug adminstrations when applied in clinical settings. 
Induction of cell death by TRAIL begins by binding of the ligand to cell surface 
death receptors (DR4 and DR5), followed by a series of death signaling events in the 
apoptosis pathway. From confocal studies, it is observed that TRAIL alone or when 
delivered using P(MDS-co-CES) nanoparticles entered into cells, most likely via 
receptor-mediated endocytosis. This is in agreement with several studies that reported 
cellular internalization of TRAIL subsequent to receptor binding [317, 340, 341]. Thus, 
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Blank Mic Blank Mic + TRAIL Dox-Mic Dox-Mic + TRAIL 
internalization of TRAIL delivered using the nanoparticles did not affect its apoptotic 
signaling functions. This hypothesis is also supported by the successful enhancement of 
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Figure 5.6 Viability of parental SW480 (A) and TRAIL-resistant SW480-TR (B) cells after 48 hours 
incubation with various formulations (TRAIL concentration fixed at 10 nM; Dox-loaded nanoparticle 
concentrations varied from 1 to 10 mg/l; Dox loading level: 8.6%; Free Dox concentrations: 0.086 and 0.43 





mg/l (Equivalent Dox concentration in 1 and 5 mg/l of Dox-loaded nanoparticles) for SW480 and SW480-
TR respectively. The standard deviation is shown by error bars that represent the mean ± S.D. (n=3). Cell 
cycle analysis of parental SW480 (C) and TRAIL-resistant SW480-TR (D) cells after 48 hours incubation. 
For parental SW480, the concentration of P(MDS-co-CES) nanoparticles was 5 mg/l. For TRAIL-resistant 
SW480-TR, a higher concentration of P(MDS-co-CES) nanoparticles (10 mg/l) was used. Dox loading 
level: 8.6%. TRAIL concentration was fixed at 10 nM. All cell culture experiments were performed in 
serum-containing medium. The standard deviation is shown by error bars that represent the mean ± S.D. 
(n=3). Statistical significance in differences was evaluated by Newman–Keuls Multiple Comparison Test 
after analysis of variance (ANOVA). P≤0.05 was considered statistically significant.  An isobologram 
analysis representing the synergy between the two drugs at combination dose (colored squares) of Dox-
loaded nanoparticles (1 mg/l) and TRAIL (10 nM) in parental SW480 (E) and Dox-loaded nanoparticles (5 
mg/l) and TRAIL (10 nM) in TRAIL-resistant SW480-TR (F) cells. 
 
 
Table 5.1 Viability (%) of SW480, SW480-TR and WI38 cells after 48-hour incubation with Dox-loaded 
nanoparticles and free Dox in the presence or absence of TRAIL (10 nM). P(MDS-co-CES) concentration 
was fixed at 5 mg/l for all cell lines (Dox loading level: 8.6%.). Cell culture was performed in serum-
containing medium. The values represent the mean ± S.D. (n=3) 
  DOX-Mic Free DOX Dox-Mic+TRAIL Free DOX+TRAIL 
SW480 57.9 ± 6.3 76.8 ± 4.1 25.1 ± 4.6 22.1 ± 2.2 
SW480-TR 87.2 ± 5.4 80.7 ± 4.6 54.4 ± 2.2 52.2 ± 2.4 






























Figure 5.7 Viability of parental SW480 cells in the presence or absence of pan-caspase inhibitor ZVAD-
FMK pretreatment (50 µM) prior to 48 hour incubation with nanocomplexes. P(MDS-co-CES) and TRAIL 
concentrations were fixed at 5 mg/l and 10 nM respectively. Dox loading level: 8.6%. Cell culture was 
performed in serum-containing medium. The error bars represent the mean ± S.D. (n=3). Statistical 
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5.2.7 Cytotoxic selectivity towards cancer cells 
TRAIL was selected in the current study based on its cytotoxic selectivity towards 
cancer cells. To investigate if there could be any nonspecific cytotoxicity that the Dox-
loaded nanoparticle/TRAIL nanocomplexes may have on normal cells, WI38 was chosen 
as a representative model cell line. Cell viability assay performed on WI38 cells showed 
that TRAIL and nanoparticle/TRAIL complexes did not result in substantial cytotoxicity 
to the cells (Figure 5.8). The viability of the cells after being treated with Dox-loaded 
nanoparticle/TRAIL complexes was estimated to be 76%, which was similar to that when 
being treated with Dox-loaded nanoparticles, indicating that 24% cell death was induced 
by Dox but not TRAIL. As reported in the earlier section, the co-delivery of both 
therapeutic agents to SW480 cells resulted in 75% cell death. Comparison between these 
two cell lines showed that the TRAIL nanocomplexes possess high selectivity towards 
the cancer cells over the normal cells. One of the reasons could be due to the relative 
differences in expression levels of decoy (TRAIL-R3 (DcR1), TRAIL-R4 (DcR2), and 
osteoprotegerin (OPG)) and death receptors (TRAIL-R1 (DR4) and TRAIL-R2 (DR5)) in 
normal versus cancer cells [293, 295]. Decoy receptors compete against death receptors 
for TRAIL binding but do not lead to apoptotic signaling. Other studies have shown that 
the cancer cells express higher levels of DR5 mRNA and protein than normal cells, 
which will in turn contribute to greater susceptibility to apoptosis mediated through 
DR5.[342] More recent findings have also suggested that other factors involved in the 
apoptotic signaling pathway such as death inhibitors (e.g. cellular-FLICE inhibitory protein 
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(c-FLIP), Fas-associated phosphatase-1 (FAP-1) and Inhibitor of Apoptosis (IAP) 
proteins) may also be responsible for different susceptibility to TRAIL [268, 290, 295, 296]. 
The overexpression of cFLIP and IAPs has been reported to play a major role in 
protecting certain human normal cells, such as melanocytes and lung and foreskin 
























Figure 5.8 Viability of WI38 cells after 48 hours incubation with various formulations. Cell culture was 
performed in serum-containing medium. P(MDS-co-CES) (5 mg/l) and TRAIL (10 nM) were used. Dox 
loading level: 8.6%. Free Dox concentration: 0.43 mg/l (Equivalent Dox concentration in 5 mg/l of Dox-
loaded nanoparticles). The standard deviation is shown by error bars that represent the mean ± S.D. (n=3).  
 
 
5.2.8 Long-term survival and proliferation assays 
Anchorage-dependent clonogenic assay is the method of choice to determine cell 
survival and proliferation capacities after exposure to chemotherapeutic agents [344]. 
From Figure 5.9A, treatment with Dox-loaded nanoparticle/TRAIL nanocomplexes 
significantly lowered the survival and proliferative abilities of SW480 and SW480-TR 
cells compared to the individual agents. The absence of cell singlets or small clusters 
remaining in nanocomplexes-treated cultures (Figure 5.9B) indicated that most of the 
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cells underwent senescence or became mitotically arrested after being treated with the co-
delivery formulation. With further culturing, these cells eventually die, resulting in very 
few cells capable of continual survival. Thus, cytotoxic synergism in co-delivery of Dox 
and TRAIL with P(MDS-co-CES) nanoparticles was further demonstrated in impairing 
























































   
 













Figure 5.9 (A) Colony formation at Day 9 and 13 in parental SW480 and TRAIL-resistant SW480-TR cell 
lines respectively subsequent to 48 hours treatment with (1) control, (2) blank nanoparticles, (3) TRAIL, 
(4) blank nanoparticle/TRAIL complexes, (5) Dox-loaded nanoparticles, (6) Dox-loaded 
nanoparticle/TRAIL complexes. Colonies were stained with 0.5% w/v crystal violet. Cell culture was 
performed in serum-containing medium. TRAIL: 10 nM; P(MDS-co-CES): 1 and 3 mg/l for SW480 and 
SW480-TR respectively. Dox loading level: 8.6%. The error bars represent the mean ± S.D. (n=3). 
Statistical significance in differences was evaluated by Newman–Keuls Multiple Comparison Test after 
analysis of variance (ANOVA). P≤0.05 was considered statistically significant. (B) Images of SW480 
colony taken at Day 9 subsequent to 48 hours treatment with (1) control, (2) blank nanoparticles, (3) 
TRAIL, (4) nanoparticle/TRAIL complexes, (5) Dox-loaded nanoparticles and (6) Dox-loaded 
nanoparticle/TRAIL complexes. P(MDS-co-CES) and TRAIL were fixed at 1 mg/l and 10 nM respectively. 




In the previous chapter, P(MDS-co-CES) nanoparticles has shown to be an 
efficient carrier for co-delivering Pac and TRAIL for treatment of human breast cancer 
cells. For this chapter, the efficacy of treatment via co-delivery of Dox and TRAIL 
against TRAIL-resistant colorectal carcinoma cells was investigated. Dox-loaded 
nanoparticles and TRAIL formed stable nanocomplexes with sizes at ~225 nm and zeta 
potential at ~70 mV. Effects of nanocomplexes were tested on both TRAIL-resistant and 
wild type SW480 cells. From confocal imaging, the assemblies of Dox and TRAIL with 
P(MDS-co-CES) nanoparticles were shown to be efficiently delivered to cancer cells. 
Receptor-blocking studies showed that the nanocomplexes entered cells via death 
receptor-mediated endocytosis. Synergism in cell death induction was analysed by the 
isobologram method to study drug interactions. This co-delivery system was significantly 
more effective in eliminating cancer cells and preventing reproliferation after drug 
removal as compared to TRAIL and Dox-loaded nanoparticle formulations. Anti-
proliferative effects of nanocomplexes were retained in remaining cancer cells in long-
term cultures after treatment with the nanocomplexes. Notably, this system exhibited 
high cytotoxic selectivity towards cancer cells over normal cells. Therefore, Dox-loaded 
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nanoparticle/TRAIL nanocomplexes may stand as a potential powerful candidate for 
colorectal cancer therapy. 
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CHAPTER 6  
 
HER2-TARGETED CO-DELIVERY OF HERCEPTIN AND 
PACLITAXEL USING  




One of the widely-accepted methodologies for targeted drug delivery is via 
passive drug targeting based on the enhanced permeability and retention (EPR) effect 
[178, 336, 345], where nanosized drug-loaded micelles can pass through the leaky tumor 
blood vessels and accumulate in the tumor tissue for a prolonged period of time. Active 
targeting can be achieved by incorporating pH and/or temperature-sensitive components 
[346-349] or biological signals such as folic acid [349, 350], galactose [305, 351], LHRH 
[352], RGD [353] and antibody [354, 355] into the micelles. Among these biological 
signals, antibodies are the most promising, and have been used in preclinical and clinical 
applications as anti-cancer agents [355-357]. In particular, Herceptin is a humanized 
monoclonal antibody that recognizes the human epidermal growth factor receptor-2 
(HER2/neu). HER2/neu is overexpressed in 25-30% of invasive human breast tumors and 
has been found to be a worse prognosis than those with HER2-negative tumors as 
measured by significantly lower survival rates [358-360]. Overexpression of HER2/neu 
in breast cancer cells results in higher resistance against anti-cancer drugs such as pac. 
This can be counteracted with the use of Herceptin as it displays tumor inhibitory effect 
through various mechanisms [361, 362], some of which include diminishing signaling 
from the PI3 kinase and MAP kinase pathways, causing cell cycle arrest at the G1 phase, 
promoting apoptosis via antibody-dependent cellular cytotoxicity (ADCC), inhibiting 
 133 
angiogenesis and DNA repair in tumors. Biological implications of the use of Herceptin 
against HER2-overexpressing cells involve the inhibition of HER2-mediated Cdc2-Tyr-
15 phosphorylation and upregulation of p21Cip1. This allows effective p34Cdc2 activation 
and induction of apoptosis upon pac treatment [363]. 
In preclinical studies [363, 364] and in Phase II and III clinical trials [365, 366], 
synergistic chemosensitization effects have been observed with the treatment of subjects 
using Herceptin together with pac. In these clinical formulations, Pac and Herceptin have 
been administered through separate injections into patients. To eliminate the 
inconvenience by reducing the number of injection required for treatment, Herceptin has 
been conjugated with pac. This conjugate has been reported to target pac to breast tumor 
bearing scid mice, which was induced with HER2-positive BT474 mammary tumor cells 
[367]. The co-delivery of Herceptin with pac may not only render the delivery system a 
targeting ability, but may also sensitize aggressive breast cancer cells to pac and achieve 
a synergistic effect in suppressing tumor growth. This conjugation approach confers 
greater advantages over the separate formulations because of the reduction in the number 
of injections with the possibility of achieving synergistic effect through the simultaneous 
delivery of Pac and Herceptin to the same cells. However, one of the major disadvantages 
of this immunoconjugate is the inflexibility of conjugation stoichiometric ratio, which 
may not be beneficial for achieving drug targeting and synergistic effect since their 
therapeutic dosage may not be in comparable ranges. Pac and Herceptin have also been 
reported to be delivered simultaneously to HER2-overexpressing breast cancer cells using 
negatively-charged PLGA nanoparticles [368]. In this formulation, Pac was loaded inside 
PLGA nanoparticles by a solvent evaporation method and Herceptin was adsorbed onto 
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the surface of the nanoparticles via electrostatic interaction. In comparison to chemical 
conjugation, the simultaneous delivery of Pac and Herceptin using nanoparticles 
represents a better approach as the dosage of Pac and Herceptin can be conveniently 
adjusted by altering their initial loading level. 
In the previous chapters, cationic micellar nanoparticles fabricated from 
amphiphilic copolymer P(MDS-co-CES) have been shown to be efficient carriers for 
small molecules drugs and proteins such as TRAIL and Lectin-A, either individually or 
concurrently [313, 369, 370].  For the current study, these micelles are used to co-deliver 
pac and Herceptin simultaneously to HER2-overexpressing cancer cells. Pac was loaded 
into the core of the micelles through a membrane dialysis method, and Herceptin was 
then complexed onto the cationic surface of pac-loaded micelles. Polar groups present in 
the polymer such as esters and tertiary amine groups as well as relatively hydrophobic 
alkyl polymer backbone may interact with amide functional groups, primary and 
secondary amines, carboxylic acid as well as hydrophobic groups in Herceptin through 
hydrogen bonding and/or hydrophobic interaction. Particle size and zeta potential of the 
nanoparticle/Herceptin and Pac-loaded nanoparticle/Herceptin complexes were measured 
in comparison with negatively-charged polystyrene nanoparticle/Herceptin complexes, 
and the stability of Pac-loaded nanoparticle/Herceptin complexes was investigated in a 
serum-containing medium via particle size analysis. Native protein gel assays were 
conducted to evaluate Herceptin binding efficiency of the nanoparticles. Pac loading and 
in vitro release profiles from the nanoparticles with or without Herceptin were studied. 
The intracellular delivery efficiency of Herceptin using these nanoparticles was compared 
against BioPorter (a commercially available lipid-based protein carrier) through confocal 
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microscopy and MTT assays. Cytotoxic effects of co-delivery of pac and Herceptin using 
these nanoparticles was investigated via MTT assays in three different human breast 
cancer cell lines with varying degrees of HER2/neu expression level, namely, MCF7, 
T47D and BT474, and the effect of Herceptin concentration was also explored. Targeting 
ability of this co-delivery system was demonstrated through confocal images and 
cytotoxicity tests of HER2-overexpressing BT474 cells and HER2-negative HEK293 
cells [371] after being treated with nanoparticle/Herceptin complexes. 
 
6.2 Results and Discussion 
6.2.1 Characterization of pac-loaded nanoparticles and pac-loaded 
nanoparticle/Herceptin complexes  
 
As shown in Figure 6.1, cationic pac-loaded P(MDS-co-CES) nanoparticles have 
an average size of 115 ± 6  nm and zeta potential of about 60 ± 3 mV. The drug-loaded 
nanoparticles are larger than blank P(MDS-co-CES) nanoparticles (84 ± 5 nm), showing 
that the presence of pac in the hydrophobic core of the micelles increases micellular 
volume. As the more nanoparticles is added to complex with Herceptin, there is a general 
increase in size and decrease in zeta potential of the complexes, indicating complexation 
between the nanoparticles and Herceptin. From zeta potential measurement, Herceptin 
molecules show a neutral charge in 20 mM sodium acetate/acetic acid buffer (pH 6.0) 
(1.8 ± 0.6 mV). Therefore, the interaction between the antibody and nanoparticles would 
most probably be occurring through hydrogen bonding and/or hydrophobic interaction. 
These nanocomplexes were compared against cationic BioPorter liposomes [277, 286] 
(267 ± 25 nm, 18.9 ± 0.4 mV), which after complexation with Herceptin, aggregates to 
form larger particles (910 ± 46 nm, 12.7 ± 0.6 mV) and (1011 ± 49 nm, 3.7 ± 0.7 mV) at 
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Herceptin concentrations of 200 nM and 2000 nM respectively as used in in vitro 
experiments (as represented in Figure 6.6). 
In comparison, through a similar complex-fabrication method, negatively-charged 
polystyrene beads (-60.8 ± 4.2 mV) form large aggregates of micrometer sizes with large 
polydispersities in the presence of Herceptin. Particles of such large sizes are unfavorable 
because of potential problems associated with aggregation and particle instability.  
The small sizes of P(MDS-co-CES) nanoparticle/Herceptin complexes may 
enable them to prolong circulation in blood and slower elimination by the 
recticuloendothelium system (RES). Herceptin adsorbed on the surface of the 
nanoparticles may target the complexes to the HER2 receptors on HER2-overexpressing 
cell surfaces. Attachment of Herceptin to HER2 receptors and the overall positive charge 
of the complexes may improve their interaction with cell surfaces and increase their 
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Figure 6.1 Size and zeta potential properties of pac (Pac)-loaded P(MDS-co-CES) nanoparticle/Herceptin 
complexes. Experiments were carried out in triplicates. The standard deviation is presented in error bars. 
 
 
6.2.2 Native protein gel mobility shift assay on Pac-loaded P(MDS-co-
CES)/Herceptin  nanocomplexes 
 
Size and zeta potential data of Pac-loaded nanoparticle/Herceptin complexes in 
Section 6.2.1 demonstrate that the Pac-loaded nanoparticles are able to condense and bind 
to Herceptin to form nanocomplexes with cationic surfaces. Native (non-denaturing) 
protein gel shift assay was performed to ensure that Herceptin retains its folded 
confirmation and does not get denatured during the analysis. More importantly, we are 
able to compare the ability of P(MDS-co-CES) nanoparticles to bind Herceptin at 
different mass ratios. The nanoparticle/Herceptin complexes were prepared with 
increasing mass ratio of nanoparticles to Herceptin, and the resulting mixture was then 
applied to a native polyacrylamide gel. Figure 6.2 illustrates the results of this assay, with 
increasing polymer to protein mass ratio from 0.1 to 50 (Lanes 2 to 7). Electrophoretic 
mobility of Herceptin is increasingly reduced as more P(MDS-co-CES) is added for 
Herceptin binding. This shows that stronger nanoparticle/Herceptin interaction occurs 






Figure 6.2  Native protein gel assay of Pac-loaded P(MDS-co-CES) nanoparticle/Herceptin complexes. 
Lane 1 – Herceptin (4 μg) alone, Lane 8 – Pac-loaded P(MDS-co-CES) nanoparticles (200 μg) alone, Lanes 
2 to 7 – nanoparticle to antibody mass ratios:  0.1, 0.5, 1, 5, 10 and 50 respectively.  
 
1 2 3 4 5 6 7 8 
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6.2.3 Drug loading and in vitro release 
Encapsulation efficiency of Pac in P(MDS-co-CES) micellar nanoparticles was 
determined to be 58.1 ± 1.4% and the loading level as 14.3 ± 0.1%. The release profile of 
pac from P(MDS-co-CES) nanoparticles with or without Herceptin was monitored over 
600 hours at 37oC (Figure 6.3). Most of the drug is released within the first 3 days of 
incubation as the nanoparticles show drug release of 54.7% by 59 hours and the total 
release is 69.3%. The presence of Herceptin on the surface of nanoparticles slightly 
reduces the release rate and amount of Pac released (47.3%) over the first 59 hours. 
























Figure 6.3 Release profiles of paclitaxel (Pac) from P(MDS-co-CES) micellar nanoparticles with and 
without Herceptin in PBS (pH 7.4) at 37°C. Each condition was tested in triplicates. The standard deviation 
is presented in error bars. 
 
 




The stability of Pac-loaded P(MDS-co-CES) nanoparticle/Herceptin complexes 
was studied by in vitro simulation of physiological conditions that the complexes might 
be subjected to. Size readings of the complexes were taken at predetermined time 
intervals after incubation in PBS containing 10% FBS at 37oC (Figure 6.4). After 5 
minutes of incubation, the size of the particles increases to 300-350 nm. During this 
period, the cationic complexes may attract the serum proteins, which may cause 
aggregation of the nanoparticles. The adsorbed proteins and aggregation of the 
nanoparticles lead to an increase in particle size. Since the Pac-loaded nanoparticles and 
complexes formed at mass ratio of 50 have higher zeta potential than the complexes 
prepared at mass ratio of 0.1 (Figure 6.1), more proteins may be adsorbed onto the 
nanoparticles and the complexes formed at mass ratio of 50 during the first 5 minutes, 
resulting in bigger particles. However, as time passes, cationic nanoparticles or 
complexes form stronger electrostatic interactions with the serum proteins and compact 
the proteins into tighter structures. Thus, the size of complexes decreases with time. 
Particle size stabilizes at around 200 nm by 4 hours of incubation and remains unchanged 
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Figure 6.4 Stability of pac-loaded P(MDS-co-CES) nanoparticle/Herceptin complexes in PBS containing 




6.2.5 Cellular delivery and uptake of Herceptin 
 
Cellular uptake of Herceptin delivered by the nanoparticles was studied in BT474 
cells via confocal microscopy, in comparison with pure Herceptin and Herceptin 
transported by BioPorter, a commercially available lipid-based protein carrier. As shown 
in Figure 6.5A, without any transport carrier, Herceptin mainly appears on the cell 
membrane with very little uptake into the cells. Similarly, cells treated with BioPorter 
also did not show any increase in cellular uptake (Figure 6.5C) as compared to the cells 
treated with Herceptin alone. This may be due to the encapsulation of Herceptin within 
BioPorter liposomes [372] and entanglement of Herceptin with the Bioporter lipids, 
which prevents the antibody from recognizing HER2 receptors on the cancer cells and 
this in turn reduces the translocation of Herceptin into the cells. Cells treated with 
P(MDS-co-CES) nanoparticle/Herceptin show significantly higher internalization of
 (µg/µg) 
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Herceptin (Figure 6.5B, red regions in the cytosol and purple regions in the nucleus). 
This may be due to smaller size, higher zeta potential, stability and endosomal buffering 
capacity of cationic P(MDS-co-CES) nanoparticle/Herceptin complexes.  
 
     
 
Figure 6.5 Cellular distribution of (A) fluorescence-labeled Herceptin, and (B) nanoparticle/Herceptin 
complexes in comparison with (C) BioPorter/Herceptin complexes. Nuclei were stained blue with DAPI, 
and cellular distribution of Alexa Fluor 647-Herceptin is shown as red fluorescence in the cytosol or purple 
fluorescence in the nucleus. Alexa Fluor 647-Herceptin: 200 nM; P(MDS-co-CES) nanoparticles: 40 ppm. 
 
 Cytotoxicity of Herceptin delivered by the nanoparticles was also compared 
against BioPorter in BT474 cells. The cells treated with BioPorter/Herceptin did not 
show any increase in cytoxicity as compared to the cells treated with Herceptin alone 
because of low cellular uptake of Herceptin (Figure 6.6). In contrast, Herceptin delivered 
by the nanoparticles displays significantly higher cytotoxicity as compared to that 
delivered by BioPorter at both concentrations tested (i.e. 200 and 2000 nM) due to its 
much higher cellular uptake when delivered by the nanoparticles. The association 
between suppression of cell prolifertion and internalization of anti-HER2 antibodies and 
receptors has been reported earlier by Yarden Y. et. al. [373, 374].  


























Figure 6.6 Viability of BT474 cells after being incubated with P(MDS-co-CES) nanoparticles, BioPorter, 
BioPorter/Herceptin and P(MDS-co-CES) nanoparticle/Herceptin complexes at Herceptin concentrations of 
200 and 2000 nM. Concentrations of P(MDS-co-CES) and BioPorter are at 40 ppm and 16 ppm 
respectively. Each condition was tested in eight replicates. The standard deviation is shown by error bars. 
 
6.2.6 Co-delivery of Pac and Herceptin to human breast cancer cell lines 
Cytotoxicity of Pac-loaded nanoparticle/Herceptin complexes was evaluated 
against three different human breast cancer cell lines with varying degrees of HER2/neu 
expression levels in comparison with Pac-loaded nanoparticles, pure Herceptin and 
nanoparticle/Herceptin complexes. HER2/neu is highly expressed in BT474 cells, while 
the expression is moderate in T47D cells and at low level in MCF7 cells [375]. Polymer 
concentrations have been optimized to prevent non-selective cytotoxicity, while at the 
same time, to provide binding for Herceptin to be efficiently delivered. Figure 6.7 shows 
that at 2000 nM, Herceptin alone does have considerable cytotoxicity against BT474 cells 
Herceptin BioPorter/Herceptin  P(MDS-co-CES) nanoparticle/ 
Herceptin nanocomplex 
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with 16% loss of cell viability, but the same does not occur in MCF7 and T47D cells. The 
susceptibility of cells towards Herceptin correlates with their HER2 receptor expression 
level. We also observe that cytotoxicity is slightly decreased when the dosage of 
Herceptin is decreased 10-fold from 2000 nM to 200 nM. Instead, with the use of 
P(MDS-co-CES) as a transport carrier for Herceptin, cytotoxicity is significantly 
increased in all cell lines. In particular, HER2-overexpressing BT474 cells have 22.4% 
higher cytotoxicity at 200 nM Herceptin delivered using P(MDS-co-CES) micelles. 
P(MDS-co-CES) nanoparticles mediate higher cellular uptake of Herceptin, resulting in 
greater cytotoxic effects.  
Cytotoxicity data of Pac-loaded nanoparticle/Herceptin complexes illustrates that 
the effectiveness of treatment is greatly increased with drug and antibody co-delivery 
system as compared to delivering Herceptin alone. This system again shows a 
dependency on the HER2 expression level of the cells as the percentage of the cancer 
cells killed increases with the HER2 expression level. BT474 cells with the highest HER2 
expression level display the greatest susceptibility towards the co-delivery treatment at 
both 200 and 2000 nM Herceptin concentration (Figure 6.7). Cell viability is reduced to 
60.2% after being treated with Pac-loaded nanoparticle/Herceptin complexes (Herceptin: 
200 nM; Pac: 6.7 µM) as compared to 92% with 200 nM Herceptin alone or 83% with 
Pac-loaded nanoparticles, demonstrating a synergistic effect. A similar trend has also 
been observed for the formulations with 2000 nM Herceptin (Figure 7). With this co-
delivery approach, the amount of Pac and Herceptin needed to induce the same level of 
























Figure 6.7 Viability of MCF7, T47D and BT474 cells after being treated with different formulations. Cells 
were treated once with (1) blank nanoparticles, (2) Pac-loaded nanoparticles, (3 and 6) Herceptin at 200 
and 2000 nM, (4 and 7) blank nanoparticle/Herceptin complexes at 200 and 2000 nM Herceptin and (5 and 
8) Pac-loaded nanoparticle/Herceptin complexes at 200 and 2000 nM Herceptin respectively. P(MDS-co-
CES) concentrations were fixed at 20 ppm for MCF7 and T47D cells and 40 ppm for BT474 cells 
respectively. Cell culture was performed in serum-containing medium. Each condition was tested in eight 
replicates. The standard deviation is shown by error bars. Pac concentration: 3.35 µM for both T47D and 
MCF7 and 6.7 µM for BT474. 
 
  Further experiments were carried out with pretreatment of cells with blank 
nanoparticle/Herceptin complexes for 24 hours prior to treatment with Pac-
loaded/Herceptin complexes. Cell death occurs in a significantly greater extent in cells 
that have been pretreated with blank nanoparticle/Herceptin complexes (Figure 6.8). 
Pretreatment results in viability of BT474 cells being almost 1-fold lower than the cells 
without pretreatment at 32.8% and 28.0% at 200nM and 2000nM Herceptin respectively.  
In addition, the pretreated cells were also compared against the cells tested with 
twice-repeated daily treatment of blank nanoparticle/Herceptin complexes without Pac 
encapsulation. This is to find out the extent of cytotoxicity induced by the nanocomplexes 
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without the combined use with Pac. As shown in Figure 6.8, the viability of BT474 cells 
that underwent twice repeated addition of blank nanoparticle/Herceptin complexes is at 
58.8% and 60.1% at 200nM and 2000nM Herceptin respectively, which is a significant 
improvement from single treatment of blank nanoparticle/Herceptin complexes. 
However, the cytotoxicity achieved with twice-repeated daily treatment of blank 
nanoparticle/Herceptin complexes is still much lower as compared to Pac and Herceptin 
co-delivery. This illustrates that co-delivery of Pac and Herceptin using P(MDS-co-CES) 
nanoparticles is advantageous in enhancing the efficiency of chemotherapeutic treatment 























Figure 6.8 Viability of MCF7, T47D and BT474 cells after being treated with different formulations. 
Twice-repeated daily treatment of (1) blank nanoparticles, (2 and 5) Herceptin at 200 and 2000 nM, (3 and 
6) blank nanoparticle/Herceptin complexes at 200 and 2000 nM Herceptin respectively. Cells in (4 and 7) 
were pretreated with (3 and 6) for 24 hours prior to treatment with Pac-loaded nanoparticle/Herceptin 
complexes at 200 and 2000 nM Herceptin respectively. P(MDS-co-CES) concentrations were fixed at 20 
ppm for MCF7 and T47D cells and 40 ppm for BT474 cells respectively. Cell culture was performed in 
serum-containing medium. Each condition was tested in eight replicates. The standard deviation is shown 




6.2.7 Targeted delivery of drug-loaded nanoparticle/Herceptin complexes  
The targeting ability of nanoparticle/Herceptin complexes was evaluated using 
HER2-overexpressing BT474 cells and HER2-negative HEK293 cells via confocal 
microscopy and cytotoxicity studies. Cellular internalization of P(MDS-co-CES) 
micelle/Herceptin complexes was monitored over two hours to verify if the complexes 
can be targeted to BT474 cells but not HEK293 cells. Throughout the course of the study, 
the uptake of the complexes by HEK293 cells is limited and insignificant (Figure 6.9B). 
In sharp contrast, the uptake of the complexes by BT474 cells increases with time. The 
complexes are taken up and distributed to the majority of the cells by 30 minutes of 
incubation (Figure 6.9A). At 2 hours, uptake of complexes continues to increase and 
some of them begin to dissociate as evidenced by the green and red/purple regions in the 
cytosol and nucleus of the cells. The significant increase in Herceptin uptake and 
residence time within BT474 cells as compared to HEK293 cells demonstrates that the 
uptake of the complexes is favored by the HER2-overexpressing BT474 cells as 
compared to HER2-negative HEK293 cells, inferring that Herceptin is able to exert 
HER2-targetting specificity on the complexes. This cellular trafficking study is coherent 
with the cytotoxicity comparison between the two cell lines (Figure 6.10). HEK293 cells 
are irresponsive to the treatment of nanoparticle/Herceptin and no significant cytotoxicity 
is observed with nanoparticle/Herceptin complexes when compared to the blank 
nanoparticles and Herceptin. In contrast, significant cytotoxicity of Herceptin was found 
against BT474 cells when the antibody is delivered using P(MDS-co-CES) nanoparticles. 
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Figure 6.9 Confocal images of cellular internalization of P(MDS-co-CES) nanoparticle/Herceptin 
nanocomplexes in (A) HER2 overexpressing BT474 cells and (B) HER2-negative HEK293 cells at 10 
minutes, 30 minutes and 2 hours. Nuclei were stained blue with DAPI, and cellular distribution of Alexa 
Fluor 647-Herceptin and FITC-loaded P(MDS-co-CES) nanoparticles are shown as red and green 
fluorescence respectively. Yellow regions represent the co-localization of Herceptin and P(MDS-co-CES) 
nanoparticles in cells. In both cell lines, Alexa Fluor 647-Herceptin (200 nM) and 40 ppm of P(MDS-co-



























Figure 6.10 Viability of HER2-negative HEK293 and HER2 overexpressing BT474 cells after being 
treated with different formulations for 48 hours. P(MDS-co-CES) concentrations were fixed at 40 ppm for 
both cell lines. Cell culture was performed in serum-containing medium. Each condition was tested in eight 
replicates. The standard deviation is shown by error bars. 
 
6.3 Conclusion 
We have demonstrated that the cationic micellar nanoparticles self-assembled 
from P(MDS-co-CES) can carry both pacltitaxel and Herceptin simultaneously. The 
nanoparticles provide high capacity for pac loading, and bind with Herceptin more 
efficiently than BioPorter and negatively charged polystyrene beads. Pac-loaded 
nanoparticle/Herceptin complexes are stable over 24 hours under physiologically-
simulating conditions. Compared to BioPorter and pure Herceptin, the uptake of 
Herceptin by HER2 overexpressed BT474 cells are much higher when it is delivered by 
the cationic nanoparticles, leading to greater cytotoxicity. The co-delivery of Herceptin 
increases the cytotoxicity of Pac, and the degree of increment in cytotoxicity depends on 
the level of HER2 expression. The co-delivery of Herceptin yielded greater enhancement 
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in the cytotoxicity of Pac in the cells with a higher HER2 expression level. The 
pretreatment of the cells with blank nanoparticle/Herceptin complexes for 24 hours 
increases the cytotoxicity of Herceptin and enhances the co-delivery efficiency. In 
addition, significantly higher cellular uptake and cytotoxicity of Herceptin in HER2-
overexpressing BT474 as compared to HER2-negative HEK293 demonstrates targeting 
properties of the nanocomplexes. The Pac-loaded nanoparticle/Herceptin complexes 
display great potential to be used as targeted therapeutics against HER2-overexpressing 
breast cancers. 
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CHAPTER 7  
IN VIVO INVESTIGATION OF  
HERCEPTIN AND PACLITAXEL CO-DELIVERY USING  






With the promising data obtained from in vitro investigation of Herceptin and Pac 
co-delivery (Chapter 6), research efforts were further extended to in vivo testing using 
mice tumor models. The initial phase of the study involves the evaluation of 
nanoparticles biodistribution following different routes of injection- tail vein versus 
intratumoral injection. Non-invasive fluorescent imaging at various was performed at 
various times up to 7 days after the mice were then sacrificed at the end of the experiment 
to estimate the distribution of nanoparticles in individual tissues. Next, tumor efficacy 
study was performed by treating BT474-tumor bearing nude mice with Pac-loaded 
nanoparticle/Herceptin complexes, together with the relavant treatmet controls. 
 
7.2 Results and Discussion 
7.2.1 Biodistribution of DiR-loaded nanoparticles  
Comparison between the two modes of injection shows that intratumoral injection 
is more favorable compared to tail vein injection (Figure 7.1A and B). The latter injection 
method resulted in the accumulation of nanoparticles within mainly in the lungs and liver 
but only very low amount of nanoparticles is present in the tumor tissue. This is may be 
due to the aggregation of the cationic nanoparticles in the presence of negatively charged 
serum proteins following intravenous administration. The resultant aggregates could form 
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transient embolism in lung capillaries [376]. Conversely, intratumoral injection results in 
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Figure 7.1  (A) In vivo biodistribution of P(MDS-co-CES) nanoparticles with different injection methods 
(tail-vein vs. intratumoral). (B) Distribution of P(MDS-co-CES) nanoparticles in different tissues 7 days 
post-injection. (Top row, starting from left: heart, tumor and lungs. Bottom row: spleen, liver and kidneys) 
 
 
7.2.2 In vivo anti-tumor efficacy studies of Pac-loaded nanoparticle/Herceptin 
complexes 
 
To understand the therapeutic effects of Pac and Herceptin codelivery, BT474-tumor 
bearing mice were used as the animal model for in vivo experimentation. The treatment 
groups consist of: control treated with actete buffer (20 mM, pH 6.0); Herceptin; blank 
nanoparticles/Herceptin complexes; Pac-loaded nanoparticles and Pac-loaded 
nanoparticles/Herceptin complexes. The concentration of nanoparticles was carefully 
chosen as 8 mg/kg, which is much lower compared to the LD50 of 27.7 mg/kg (Appendix 
I).  As such, all mice survived the entire course of treatment. Measurements of changes in 
tumor size (Fig. 7.2) showed that the growth inhibition resulting from the single modality 
therapies were different. Statistical differences in tumor size at the end of treatment was 
evaluated by analysis of variance (ANOVA) and followed by Tukey Test. P≤0.05 was 
considered statistically significant The mice that were treated with Pac-loaded 
nanoparticles have similar average tumor volume compared to the control group (P = 
Tail vein injection Intratumoral injection 
B 
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0.35). On the other hand, treatment with blank nanoparticles/Herceptin (P < 0.01) 
resulted in tumor reduction of 44% and was not significantly different from Herceptin 
treatment alone. The anti-tumor efficacy is more profound using combination therapy 
with Pac-loaded nanoparticle/ Herceptin nanocomplexes, where there is a growth 
inhibition of 82% versus the control treated mice (P < 0.01). In addition, the codelivery of 
the two therapeutic agents is also statistically superior to Pac-loaded nanoparticles alone 
(P < 0.01). However, there is no statistical difference when compared against blank 
nanoparticles/Herceptin complexes alone (P = 0.13). There may be several contributing 
factors to the insufficient drug synergism. One of the probable reasons could be the 
inadequate release of Pac from the nanoparticles in vivo, which will weaken the 
biological actions of the drug with Herceptin. There could also be limited spread of 
nanoparticles in the tumor tissue as a result of self-aggregation, hindered diffusion due to 
dense cancer cell packing and extracellular matrix and high interstitial fluid pressure 
[377, 378]. Investigation of the spread of nanoparticles within the BT474 tumor tissue 
shows that the nanoparticles self-aggregate within the extracellular space after 
adminstration. As such, the nanoparticles are unable to penetrate or distribute evenly to 





























Figure 7.2 Changes in relative tumor size (%) with time. Statistical significance in tumor size differences 
at the end of treatment was evaluated by Tukey Test after analysis of variance (ANOVA). *P≤0.05 was 
considered statistically significant. 
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Figure 7.3 Distibution of nanocomplexes within tumor tissue 4 hr after intratumoral injection. Nuclei were 
stained blue with DAPI, and cellular distribution of Alexa Fluor 647-Herceptin and FITC-loaded P(MDS-
co-CES) nanoparticles are shown as red and green fluorescence respectively. Yellow regions represent the 




 Non-invasive in vivo imaging demonstrates that delivery of nanoparticles using 
intratumoral injection may be more efficient than tail vein injection as it enables more 
nanoparticles to be accumulated within the tumor tissue compared to other organs. 
Treatment of BT474-tumor bearing nude mice shows that the codelivery of Herceptin and 
Pac shows significantly better anti-tumor efficacy compared to Pac-loaded nanoparticles 
alone. On the other hand, although the mean relative tumor size is lower for mice treated 
with the codelivery nanocomplexes compared to blank nanoparticles/Herceptin 
complexes, no significant difference is observed when assessed using statistical methods. 
The compromised therapeutic efficacy may be due to the self-aggregation of the 
nanoparticles within the tumor tissue, which led to limited penetration and non-uniform 












Over the past few decades, cancer therapy involving two or more therapeutic 
agents in combination has become widely accepted as a more effective treatment regimen 
compared to using single drugs. When chosen appropriately, interactions between 
different drugs can significantly improve the quality of life of patients by enhancing 
therapeutic efficacy and delaying disease progression. Side effects may also be reduced 
as lesser drugs of each kind will be required to achieve similar anti-cancer effects as the 
single drug formulation. Furthermore, based on the postulation that the probability of 
cancer cells developing resistance to a combination of non-cross-resistant drugs varies as 
the product of the probabilities of resistance to each of the individual drug, the use of 
drug combinations may help to lower the chances of developing multi-drug resistance.  
This p.h.D. work has been designed to study the application of nanotechnology 
for advancing cancer treatment, particularly in development of nanoparticles as 
multifunctional vehicles for therapeutic protein and drug delivery. In my research, 
cationic core/shell nanoparticles self-assembled from a biodegradable amphiphilic 
copolymer poly{N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido 
ethyl) methyl bis(ethylene) ammonium bromide] sebacate}P(MDS-co-CES) have been 
fabricated and used for the codelivery of various anti-cancer drugs and therapeutic 
proteins to improve cancer therapy.  
In the initial phase, the P(MDS-co-CES) cationic nanoparticles are investigated 
for their capacity to function as protein carriers. A model protein, Lectin A-chain, Viscum 
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album coloratum (Korean Mistletoe) is used for testing. This protein is unable to enter 
cells alone and its in vitro cytotoxicity is minimal when it is delivered without any 
carrier. Binding assays shows that the polymeric nanoparticles are able to complex with 
Lectin A-chain to form nano-sized complexes. When P(MDS-co-CES) nanoparticles 
were used to deliver Lectin A-chain, the cytotoxicity of the nanocomplexes is 
significantly increased. In addition, when compared to a commercially-available protein 
carrier, BioPorter, P(MDS-co-CES) nanoparticles also performed better with regards to 
particle size and stability as well as the intracellular delivery of the protein.  
Protein-and-drug codelivery capabilities of P(MDS-co-CES) nanoparticles is then 
studied by delivering another therapeutic protein with a similar molecular weight, i.e. 
recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, 
MW: 20 kDa), and an anticancer drug doxorubicin (Dox) simultaneously. TRAIL is a 
promising therapeutic protein as it is selectively toxic to cancer cells and exerts limited 
toxicity to normal tissues when introduced in vivo. Cellular response towards the P(MDS-
co-CES) nanoparticle/TRAIL nanocomplexes has been investigated in both wild type and 
TRAIL-resistant SW480 cells (a human colon adenocarcinoma cell line). Cytotoxicity 
studies have shown that the co-delivery system synergistically enhances cytotoxic and 
anti-proliferative effects in both wild type and TRAIL-resistant SW480 cells. 
Importantly, Dox-loaded nanoparticle/TRAIL nanocomplexes are toxic towards the 
cancer cells, but they do not exhibit significant cytotoxicity against non-cancerous cells 
(i.e. WI38, a human lung fibroblast cell line). In a separate study, TRAIL is codelivered 
with another anti-cancer drug, paclitaxel (Pac) and synergistic anti-cancer effects are 
observed on various human breast cancer cell lines with different TRAIL-sensitivity. 
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Cancer cells that are semi-sensitive to TRAIL responded positively to the combination 
treatment. In vitro cytotoxicity of the codelivery system is significantly higher compared 
to free Pac+TRAIL combination in two out of the three cell lines tested. 
In addition, another important feature that is desirable for an effective drug 
delivery system is target-specificity. A therapeutic antibody, Herceptin (MW: 145 kDa), 
that recognizes human epidermal growth factor receptor-2 (HER2/neu) receptors, is 
loaded onto the surface of P(MDS-co-CES) nanoparticles and codelivered with Pac. The 
binding of herceptin to nanoparticles can confer targeting ability to the nanocomplexes 
and increase delivery of both the antibody and Pac to HER2-overexpressing cancer cells. 
When cell lines with different levels of HER2/neu expression are treated with the 
nanocomplexes, higher therapeutic efficacy is observed in cells with higher expression 
level. Targeting ability of this co-delivery system is demonstrated through confocal 
imaging, which shows significantly higher cellular uptake in HER2-overexpressing 
BT474 cells as compared to HER2-negative HEK293 cells. 
Finally, tumor efficacy studies are performed using the Pac/Herceptin codelivery 
system to treat female athymic mice that bear BT474 tumor xenografts. Mice that are 
treated with Pac-loaded micelles/herceptin nanocomplexes experience significantly 
slower tumor growth compared to those treated with Pac-loaded nanoparticle alone. The 
development of this targeted co-delivery system from self-assembled polymeric 
nanoparticles demonstrates that it is possible to fabricate multifunctional vehicles that can 
be used ubiquitously for the simultaneous delivery of therapeutic agents of different 
chemical nature (i.e. proteins and hydrophobic drugs). Thereby, the realization of this co-
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delivery system represents a comprehensive and effectual contribution towards 
combinational cancer therapy. 
 
8.2 Recommendations 
Enhancing therapeutic efficacy 
The multifunctional nanoparticles developed from self-assembled P(MDS-co-
CES) micelles showed that it can used for the simultaneous delivery of both for many 
therapeutic combinations of anti-cancer drug and proteins. To understand the actual 
therapeutic efficacy of the codelivery systems, Pac/Herceptin codelivery system has been 
selected amongst other in vitro system for tumor efficacy studies in the final phase of this 
p.h.D. work. The results obtained showed that treatment with Pac and Herceptin- 
containing nanocomplexes induced significantly slower tumor growth compared to those 
treated with Pac-loaded nanoparticle alone. However, the tumor growth difference 
between the codelivery system and Herceptin delivered using nanoparticles without Pac 
is not statistically significant. This shows that the in vitro synergistic interaction between 
the therapeutic drug and antibody is not able to translate to similar effects in vivo with the 
current treatment regimen. To improve on this, future studies may be performed by 
varying the treatment schedule to determine the optimal frequency of administrations. 
Alternatively, changing the loading levels of Pac and Herceptin may also influence the 




Understanding potential immunotoxicity 
 When nanoparticles enter the bloodstream, they can stimulate and/or suppression 
of immune responses through binding of proteins in the blood. This is mostly determined 
by the proteins bound on the surface of these nanoparticles that can influence the 
interaction with other blood components and uptake of these particles into cells. In order 
for nanoparticles to enter the mainstream of chemotherapy, it is important to evaluate the 
potential effects they have will have on the immune system. It is known that several 
factors such as size, shape, chemical composition and surface modification of the 
nanoparticles can affect the biocompatibility. However, as the use of nanomaterials is 
considerably new for biomedical applications, there is still a lack of a universal guide for 
understanding of the immunotoxicity for such material. Nonetheless, a series of in vitro 
and in vivo assays can be performed to understand the biological and toxic properties. 
Some of the assays that can be performed include - hemolysis assay to test for the 
potential damage to red blood cells, platelet aggregation and plasma coagulation assays 
as well as pyrogenicity evaluation. By performing this comprehensive evaluation of 
immunotoxicity, this will allow a more extensive assessment of the therapeutic potential 
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 APPENDIX I 
SYNTHESIS AND CHARACTERIZATION OF P(MDS-co-CES) 
The amphiphilic copolymer poly{N-methyldietheneamine sebacate)-co-
[(cholesteryl oxocarbonylamido ethyl) methyl bis(ethylene) ammonium bromide] 
sebacate}P(MDS-co-CES) has been synthesized and characterized with regards to its 
chemical and physical properties [262]. 
 
Synthesis Method of P(MDS-co-CES) 
Synthesis of PMDS 
 N-Methyldiethanolamine (5.958 g, 0.05 mol) and 50.5 g of triethylamine (0.5 mol) were 
added to a 250-mL round-bottom flask with freshly dried 50 mL of THF in a dry ice/  
acetone bath (below -30 °C). Freshly dried THF (40 mL) containing 11.945 g of sebacoyl 
chloride (0.05 mol) was added dropwise to the flask with stirring. The flask was removed 
1 h later, and the reaction was allowed to proceed at room temperature overnight. The 
solvent and residual triethylamine were removed using a rotavapor. The solid was 
washed three times with 300 mL of THF and the solution was collected by filtration. The 
solvent was then removed using the rotavapor. The crude product was semisolid, which 
was put in a vacuum oven overnight to further remove residual solvents. The crude 
product dissolved in 100 mL of toluene was extracted four times with 50 mL of NaCl 
saturated aqueous solution and then was dried with anhydrous NaCO3. It was further 
dialyzed in acetone using a membrane with a molecular weight cutoff of 3.5 kDa. 
Acetone was subsequently removed from the dialysate using the rotavapor, and the final 
product was dried in a vacuum oven for 2 days. 
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Synthesis of Be-chol  
Chloroform (50 mL) dried with a molecular sieve was put into a 100-mL round-bottom 
flask in a dry ice/acetone bath. Cholesteryl chloroformate (4.34 g, 0.0097 mol) and 2.18 g 
of 2-bromoethylamine hydrobromide (0.0106 mol) were then added with stirring. Next, 3 
mL of freshly dried triethylamine was added to the flask. The dry ice/acetone bath was 
removed after 30 min for the reaction to proceed at room temperature for 12 h. The 
organic solution was washed three times with 20 mL of 1 N HCl solution saturated with 
NaCl and once with 30 mL of NaCl saturated aqueous solution to remove residual 
triethylamine. The organic phase was collected and dried with 5 g of anhydrous 
magnesium sulfate. The solution was then filtered and distilled. The crude product was 
recrystallized with anhydrous ethanol once and with anhydrous acetone twice. The final 
product was dried with a vacuum oven for 24 h. 
 
Synthesis of P(MDS-co-CES) 
PMDS (2.85 g, 0.01 mol) and 5.5 g of N-(2-bromoethyl) carbarmoyl cholesterol (0.01 
mol) were dissolved in 50 mL of dry toluene and were refluxed for 2 days under argon. 
Diethyl ether (250 mL) was then added to precipitate the product. To completely remove 
unreacted N-(2-bromoethyl) carbarmoyl cholesterol, the product was washed with diethyl 
ether four more times. 
 
Methods of characterization of P(MDS-co-CES) 
1H NMR Measurements  
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The 1H NMR spectra of polymers dissolved in CDCl3 were recorded on a Bruker 
AVANCE 400 spectrometer (400 MHz). Chemical shifts were expressed in parts per 
million (δ) using tetramethyl silicane in the indicated solvent as the internal standard. 
 
FT-IR Measurements  
The polymers were analyzed using a Fourier transform infrared spectrometer (FT-IR, 
Perkin-Elmer Spectrum 2000, United States). The samples were dissolved in chloroform, 
and the solution was then dropped onto a NaCl crystal. The solvent was allowed to 
evaporate completely prior to the measurements. 
 
Molecular Weight Determination 
  
The molecular weights of polymers were determined using a gel permeation 
chromatography (GPC) (Waters 2690, MA) with a differential refractometer detector 
(Waters 410, MA). The polymer sample (10 mg) was dissolved in 5 mL of THF, and the 
solution was then filtered. The mobile phase was THF at a flow rate of 1 mL/min. Weight 
and number-average molecular weights were calculated from a calibration curve using a 
series of polystyrene standards (Polymer Laboratories Inc., MA, with molecular weight 
ranging from 1300 to 30 000). 
 
CMC Determination 
 The critical micelle concentration (CMC) of the polymer in deionized (DI) water and 
sodium acetate buffer of varying concentration and pH was estimated by fluorescence 
spectroscopy using pyrene as a probe. Fluorescence spectra were recorded on a LS 50B 
luminescence spectrometer (Perkin-Elmer, United States) at room temperature (22 °C). 
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Aliquots of pyrene solution (1.54 x 10-5 M in acetone, 400 µL) were added to containers, 
and the acetone was allowed to evaporate. Polymer solutions (10 mL) at different 
concentrations were then added to the containers. The final pyrene concentration was 
6.17 x 10-7 M. The solutions were kept on a shaker for 20 h at room temperature and 
then at 60 °C for another 4 h to reach the solubilization equilibrium of pyrene into the 
aqueous phase. The emission spectra were scanned from 360 to 410 nm at the excitation 
wavelength of 339 nm while the excitation spectra were scanned from 300 to 360 nm at 
the emission wavelength of 395 nm. Both excitation and emission bandwidths were 4.5 
nm. Fluorescence spectra of pyrene solutions contain a vibrational band exhibiting high 
sensitivity to the polarity of the pyrene environment. The intensity (peak height) ratio 
(I3/I1) of the third band (385 nm, I3) to the first band (374 nm, I1) from the emission 
spectra and I338/I333 ratio from the excitation spectra were analyzed as a function of 
polymer concentration. The CMC value was taken from the intersection of the tangent to 
the curve at the inflection with the horizontal tangent through the points at low 
concentrations. 
 
Transmission Electron Microscopy (TEM) Examinations 
 
The morphology of the micelles was analyzed by TEM (Philips CM300, Holland). One 
drop of the freshly prepared micelle solution containing 0.01% phosphotungstic acid was 
placed onto a copper grid coated with carbon film and was self-dried at room temperature 





Synthesis and characterization of P(MDS-co-CES) 
 
Synthesis and Characterization of PMDS  
Poly(N-methyldiethylamine sebacate) (PMDS) is the main chain of the designed polymer 
(Figure 2.1A). The successful synthesis of PMDS was verified by 1H NMR and FT-IR 
spectra as shown in Figure A1. 1H NMR peaks at δ 2.71-2.73 (signal a), δ 1.62 (signal b), 
and δ 1.32 (signals c and d) were attributed to the protons of four different –CH2- groups 
from the sebacate units (Figure S1A). Peaks at δ 4.17-4.19 (signal e) and δ 2.30- 2.37 
(signals f and g) were due to protons of two different -CH2- groups and the –CH3 group 
linked to the nitrogen atom. FT-IR spectrum also confirmed the polyester formation 
(Figure A1B). The –C=O stretching shifted to a lower wave number (1736 cm-1) 
compared to carbonyl halide (1805 cm-1) because of the inductive effect of halide. The 
peak at 1172 cm-1 was attributed to C-O. 
 
Synthesis and Characterization of Be-chol 
N-(2-Bromoethyl)carbarmoyl cholesterol (Be-chol) has a bromoethyl group that was used 
to quaternize the main chain at the amino group and to produce positive charges at the 
same sites. Bechol was also designed as the randomly dispersed hydrophobic pendent 
chains. It was synthesized by connecting 2-bromoethylamine hydrobromide onto 
cholesteryl chloroformate through an amidation reaction as shown in Figure 2.1. TLC 
analysis showed one point at Rf of 0.68 in the mixture of toluene, hexane, and methanol 
(8:8:1 in volume), indicating that Be-chol was pure. Figure A2 displays the 1H NMR and 
FT-IR spectra of Be-chol. The 1H peak at δ 5.10 (signal HN) was due to the amide groups 
 191 
(CONH) (Figure A2A). δ 3.50 (signal H4) and 3.61 (signal H5) were attributed to the 2-
 
Figure A1. (A) 1H NMR and (B) FT-IR spectra of PMDS. 
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bromoethyl groups. ä 4.52 (H1) and 5.40 (H2) were associated with the cholesterol units. 
The ratio of the H1, H2, HN, H4, and H5 peak areas was determined to be 1:1:1:2:2, 
confirming the successful synthesis of Be-chol. The FT-IR spectrum of Be-chol further 
evidenced its successful synthesis. The IR peak at 3325 cm-1 was due to –NH stretching. 
 
 




Peaks from –C=O stretching and -NH- bending overlapped at 1685 cm-1. The peak at 
1536 cm-1 was attributed to -C-N- stretching. 
 
Synthesis and Characterization of P(MDS-co-CES)  
 
P-(MDS-co-CES) was synthesized by grafting Be-chol onto PMDS through a 
quaternization reaction (Figure 2.1). This reaction needs to be performed at a relatively 
high temperature when alkyl bromide is used as the reagent for quaternization. The 
successful synthesis of P(MDS-co-CES) was verified by 1H NMR and FT-IR spectra as 
shown in Figure A3. The 1H NMR spectrum of P(MDS-co-CES) displays peaks at δ 2.7-
2.8 (signal a), 1.5-1.7 (signal b), 1.2-1.4 (signals c and d), 4.0-4.2 (signal e), and 2.2-2.4 
(signals f and g) because of the protons on the PMDS main chain. Various peaks at δ 0.7-
1.2 were attributed to the cholesterol groups. The peak at δ 5.38 arose from the proton of 
=CH- in the cholesterol groups (signal h). The peak at δ 0.7 was from the methyl group 
directly linked to the cyclic hydrocarbon (signal i). The information provided by the 1H 
NMR spectrum of P(MDS-co-CES) proved that the cholesteryl group was successfully 
grafted onto the PMDS mainchain. IR spectrum of P(MDS-co-CES) showed a peak at 
1252 cm-1 because of C-N stretching of amine. The shift and increased intensity of this 






Figure A3. (A) 1H NMR and (B) FT-IR spectra of P(MDS-co-CES). 
 
 
Molecular Weight and Grafting Degree 
 
 The molecular weight of the polymer was measured by GPC while the grafting degree 
was obtained from 1H NMR spectra. The weight average molecular weight (Mw) of 
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PMDS could reach as high as 18.5kDa while the Mw of P(MDS-co-CES) could be up to 
about 9.1 kDa. The molecular weight of P(MDS-co-CES) was usually lower than the 
PMDS, from which the P(MDS-co-CES) was synthesized. This indicates that the grafting 
reaction at the high temperature might cause the degradation of the main chain, resulting 
in a lower molecular weight. The degree of cholesterol grafting (Rg), defined as the ratio 
of the number of amines quaternized by N-(2-bromoethyl) carbarmoyl cholesterol to the 
total number of amines on the PMDS main chain, can be estimated as follows 
Rg = (ΔApNHm/ΔAmNHp) x 100% 
where ΔAp is the area of the selected peak from the pendent chain, ΔAm is the area of the 
selected peak from the main chain, NHp is the number of hydrogen atoms in the selected 
group from the pendent chain, and NHm is the number of hydrogen atoms in the selected 
group from the main chain. Only suitable protons from the pendent chain and the main 
chain of the polymers were selected in the calculation. The proton signal selected should 
not overlap with signals from other protons. Furthermore, those protons affected by the 
quaternized amines should not be used. For P(MDS-co-CES), the proton of the methylene 
group linked to the carbonyl group of the main chain (signal a), the proton of the 
methylidyne group (-CH=) linked to the double bond (signal h), and the proton of the 
methyl group linked to the hexane and pentane cycles of the pendent chain (signal i) were 
considered suitable for use in the estimation of Rg. On the basis of the peak areas of 
signal a and signal i (Figure S3), Rg for P(MDS-co-CES) was estimated to be about 
27.0% (i.e., Rg = ΔAi x 4 x 100% /3 x ΔAHa ) 2.046 x 4 x 100%/3 x 10.1 = 27.0% . By 
changing the molar ratio of the pendent chain to the PMDS main chain, Rg of the 
cholesterol moiety and the positive charge of P(MDS-co-CES) could be modulated. The 
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cholesteryl grafting degree of P(MDS-co-CES) ranged from 9.4% to 56.2%, depending 
on the purity of PMDS and the amount of Be-chol added. However, the grafting degree 
seldom exceeded 60% even though the molar ratio of Be-chol to PMDS unit increased to 
1.5. This is possibly because the structure of the cholesteryl group provided steric 
hindrance for the reaction. 
 
TEM imaging of the micelles 
Figure A4 shows a TEM image of P(MDS-co-CES) micelles that have been fabricated by 
the membrane dialysis method in DI water. The micelles had a regular shape in nature. 
Particle size of the micelles shown in the TEM image was smaller than that measured by 
dynamic light scattering because the micelles shown in the TEM image were in a dry 
state and the structure shrank after water was removed. 
 
 
Figure A4. A typical TEM image of micelles prepared using P(MDS-co- CES) in DI water with a polymer 
concentration of 2 mg/mL. 
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APPENDIX II 
ACUTE TOXICITY TEST REPORT IN MICE MODEL 
 
This part of the research has been conducted in collaboration with Prof. Fan 
Weiming at Zhejiang University School of Medicine, Department of Cardiology, China. 
The objective of the study was to investigate the dose-related-acute toxicity, animal 
mortality and evaluate the safety of a single intravenous administration of P(MDS-co-
CES) nanoparticles into mice. 
 
Materials and Methods 
40 Imprinting Control Region (ICR) mice were randomly divided into 4 groups (n 
= 10). Each group was given different dosages of the polymeric nanoparticles at 34.6, 
26.3, 20.0 and 15.2 mg/kg respectively. After injection, the mice were observed for 
changes in physiology, behaviour, appetite, defecation, production of abnormal discharge 
from nose, eyes and mouth as well as mortality. The mice were first observed at 0.5 hr 
post-injection and subsequently every 0.5 – 1 hr. After the 1st day, the mice were 
monitored once a day for 7 consecutive days. The acute median lethal dose (LD50) was 
calculated by the Bliss method with 95% confidence limits. SPSS17.0 software was used 
for analyzing the experimental data and statistical analysis between groups was 
conducted with One-Way ANOVA. 
 
Results 
Effects on animal physiology 
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Mice treated with different dosages of nanoparticles experience changes in their 
physiology in different degrees. Those administered with 15.2 mg/kg nanoparticles were 
observed to decrease their movement and experience abdominal breathing 3 min post-
injection, but the symptoms disappeared in 30 min.  Mice injected with 20 mg/kg dose 
experienced immediate symptoms such as sunken eyes, erected haircoat and abdominal 
breathing, but the symptoms ease 1 h after the administration. Within the group, one male 
mouse died and post-mortem examination revealed that cause of death to be lung 
congestion. In the 26.3 mg/kg dose group, the mice to decrease their movement and 
experienced abdominal breathing, hunched posture and trembling immediately after 
administration. A day later, 3 male and 2 female mice died and 1 female mouse died the 
following day. Post-mortem examination revealed large areas of lung congestion, and 
foamy fluid secretion in the nose and mouth. In particular, one of the mice had yellowish-
brown coloration on its kidneys. In the highest dose group 34.6 mg/kg, 5 male and 1 
female mice died within 5 min post-injection and another female mice died 4 hr later. 
Post-mortem examination of the lungs showed large areas of congestion, while the 
kidneys, heart and spleen were of darker color than usual. All mice that survived for 2 
days after the injections were able to return back to normal. 
 
Table A1: Mortality of mice at different post-treatment time points.  
Dose Mortality, Dead 
(mg/kg) <24hr Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Total  (%) 
34.6 7 0 0 0 0 0 0 0 7 (70%) 
26.3 5 1 0 0 0 0 0 0 6 (60%) 
20 1 0 0 0 0 0 0 0 1 (10%) 




Determining the median lethal dose LD50 
Tail vein injection of the tested mice resulted in 70%, 60%, 10% and 0% mortality in the 
34.6, 26.3, 20.0 and 15.2 mg/kg dose groups respectively (Table A1). The median lethal 
dose, LD50, determined by Bliss method, was 27.7 mg/kg with 95 % confidence interval 
of 23.9 ~ 32.1 mg/kg.  
 
Effect on body weight 
 
After treatment, the body weights of the tested mice were monitored on Day 1, 3 and 7. 
The mean body weight of the 34.6 mg/kg dose group was found to be slightly lower 
compared to other groups. However, no statistically significant difference was found with 
when One-Way ANOVA analysis was conducted (P> 0.05).  
Table A3: Mean body weight of mice after treatment. 
Mean Body Weight（g） Dose (mg/kg) 
Day 1 Day 3 Day 7 
34.6 19.8 ± 0.97 25.0 ± 1.06 26.6 ± 1.74 
26.3 19.7 ± 1.15 26.0 ± 1.94 27.2 ± 2.56 
20 19.9 ± 1.35 27.3 ± 1.93 28.9 ± 2.70 
15.2 19.9 ± 1.24 26.9 ±2.52 28.7 ± 3.34 
 
